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Abstract 
Respiratory Syncytial Virus (RSV) is the major cause of acute lower tract infection in 
early childhood. Annual epidemics occur which are well documented in developed 
countries during winter months, placing considerable pressure on the provision of 
health care. Little is known about the epidemiology of RSV infection in the Middle 
East and other desert climate regions of the world. 
The aim of this project was to study the specificity of the immune response to RSV B 
in children, and to relate this to the infecting RSV strain, with particular emphasis on 
antibody response to RSV attachment (G) protein. 
RSV is an important cause of hospital admission in children (54%) during winter 
months in Qatar. 63% of these infections are due to RSV A. A case study involving 
analysis of RSV strains from hospitalized children was carried out in Qatar over 2 
winter seasons (1999-2000 and 2000-2(01). RSV incidence was found to correlate 
with high relative humidity and low temperature. A comparison of enzyme immuno 
assay (EIA) and polymerase chain reaction (peR) for the detection of RSV in clinical 
samples demonstrated that peR was more sensitive than EIA. All positive RSV 
samples obtained during the study period were classified as belonging to RSV A and 
B subtypes using Multiplex peR. 
In this project, primer sets were designed and optimized to amplify the whole of the 
G gene of RSV A and B strains. Derived sequence analysis allowed deduction of the 
molecular epidemiology of RSV G gene for RSV A and B strains in Qatar and 
elsewhere. Sequence data of the G gene from Qatar RSV A&B isolates confirmed the 
variability of this protein and showed that variability occurs among group B RSV 
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viruses isolated in Qatar (0.8%), although to a lesser extent than among the group A 
viruses (5%) from same location. However, the group B viruses isolated in Qatar were 
highly variable in G gene sequences compared to the prototype strain RSVB N2 
(13%) and to strain world-wide (10%) at the nucleotide level. 
In order to produce an epitope map of the RSVB G protein, synthetic peptides 
representing linear B-cell epitopes of a representative Qatar RSV B isolate 
(B/Q/28/00) were used. The reactivity of human sera with the synthetic peptides was 
studied using sera from young children from whom RSV had been isolated. The sera 
from these children had variable peptide binding responses against different regions 
of the G protein of RSV B and the responses were focused on the conserved region. 
The results indicated that peptide 14 (a. a 150-165) of the G protein, in the conserved 
region of the protein, is a major antigenic site. This peptide sequence was recognized 
by a majority of the tested sera (93% sera). 
To examine the relationship between neutralization antibody titre and reactivity to the 
synthetic peptides in children's sera, a modified micro-neutralization method was 
used. There was no significant correlation between the peptide binding activity in the 
sera and the neutralization titre of these sera. Sera from children infected with RSV A 
bound to peptides from the G protein of RSV B strain. However, children infected 
with RSV B had greater neutralizing antibody titre to RSV B strain than to the two 
RSV A strains. There was no difference in the neutralization antibody titre in sera to 
RSV A when assessed with prototype strains isolated many years ago (RSV A2), and 
with the recently-isolated strain AlQ/IO/OO. 
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1. Chapter 1: General Introduction 
Virology 
1.1 Background 
Respiratory disease is a common cause of morbidity and mortality in the general population, 
although the most severe illness is often seen among infants and the elderly. Several viruses can 
cause respiratory illnesses, the resulting symptoms of which include fever, coryza, otitis media, 
laryngitis and bronchiolitis. It is difficult to distinguish between different causal agents since similar 
symptoms are often seen, so to be certain laboratory diagnosis is necessary. The most common viral 
respiratory pathogens causing lower and upper respiratory tract infections are influenza and 
respiratory syncytial virus (RSV). 
Human respiratory syncytial virus (HRSV) causes respiratory tract infections particularly in infants 
and young children. There is also increasing evidence that points to RSV causing significant disease 
in the elderly (Falsey et aI., 1995). The infection can vary in severity ranging from a mild infection, 
similar to a common cold, to severe pneumonitis or bronchiolitis in susceptible individuals. RSV 
infection is estimated to cause 90,000 hospitalizations and 4,500 deaths per annum in the USA in 
children and huge economic implications, costing an estimated $300 million in the USA (Meissner, 
1994). Approximately 18,000 children annually (predominantly infants) are admitted to hospital 
with diagnosis of bronchiolitis in the UK, with 80% caused by RSV infection (Crowcroft et al., 
1999). In urban areas of Britain, 2% of infants need hospitalization as aresult of RSV infections 
(Sims et al., 1976) 
Little is known about the epidemiology of RSV infection in developing and Middle Eastern 
countries. In most studies, RSV was found to be the predominant viral cause of acute lower 
respiratory tract infections (ALRI) in childhood, being responsible for 27-96% (mean 65%) of 
hospitalized cases in which a virus was found in the Gambia (Weber et aI., 1998a). RSV infection is 
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seasonal in most countries (Stott & Taylor, 1985). Very little information is available about the 
incidence and mortality of children infected with RSV or strain variation of circulating strains. 
Further studies on RSV should address these questions in more detail. The availability of 
information on the molecular epidemiology and seasonality of these infections from this part of the 
world would be important in planning vaccination and treatment strategies. 
1.2 History of RSV 
RSV was first isolated in 1956 from a laboratory chimpanzee with respiratory symptoms (Blount et 
al., 1956). Soon after, the virus was isolated from a child with pneumonia in Baltimore and the 
characteristic syncytial cytopathic effect was observed, hence its name (Chanock & Finberg, 1957). 
RSV was soon recognized as an important cause of respiratory illness across the globe (Anderson et 
al., 1991). 
1.3 Taxonomy 
RSV is classified in the order Mononegavirales, which consists of four families designated by the 
International Committee of Taxonomy of Viruses. The family Mononegavirales also includes the 
Rhabdoviridae, Filoviridae, the Bornaviridae and the Paramyxoviridae. Mononegavirales is 
derived from the Greek word monos meaning single, nega from negative and virales (from the Latin 
meaning viruses). All members have a linear negative stranded monopartite genome with a similar 
genome arrangement (3' non-translated region-env-pol-5' non-translated region). They also have a 
helical nucleocapsid, initiation of translation by a virion associated RNA dependent RNA 
polymerase from a single 3' promoter (Murphy, 1995) RSV is a member of the Paramyxoviridae, 
which is divided into two sub-families; the Paramyxovirinae and the Pneumovirinae All members 
of the family possess an envelope, are large in diameter, approximately 150 nm and are 
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pleiomorphic. They have a non-rigid helical nucleocapsid that is negative sense. The virion has a 
lipid bi-Iayer derived from the host and has 2-3 glycoprotein projections, 13-18nm long, spaced 7-10 
nm apart, depending on the genus. 
The Paramyxoviridae possess three nucleocapsid-associated proteins, RNA binding protein (N or 
NP), a phosphoprotein (P) and a large polymerase protein (L). The Land P proteins form the viral 
polymerase. They also have three membrane-associated proteins, non-glycosylated envelope protein 
(M) and two glycosylated proteins, the fusion (F) and the attachment protein (G, H or I-IN). The 
pneumoviruses, including RSV, are in their own sub-family because they do not have the same gene 
order and are not related antigenically to members ofthe Paramyxovirinae (Fig. 1.1). 
1.4 Viral genome 
The RSV genome is 15,222 bp in the prototype strain A2 in length consisting of 10 genes encoding 
11 major proteins (Fig 1.2) There are three transmembrane proteins, F, G and SH, two matrix 
proteins, MI and M2. There are also structural proteins, N, P and L and three non-structural 
proteins, NS 1, NS2 and M2-2. There are intergenic regions consisting of a few nucleotides that are 
scanned by the polymerase, but not transcribed. 
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Figure 1.1: Taxonomic Tree of Respiratory Syncytial virus 
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Figure 1.2 (a): RSV gene order. 
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NS1532, NS2 503, N 1203, P 914, M 958, SH 410, G 923, F 1903, M2 961, L 6578. 
Figure 1.2 (b): Diagrammatic representation of RSV virion. 
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1.5 Viral proteins 
1.5.1 Non-structural proteins 
Separate mRNAs encode the two non-structural proteins NS 1 and NS2. The function of the proteins 
is not known, but it is believed that NS 1 has an inhibitory effect on RNA transcription and 
replication (Atreya et al., 1998). The proteins may be involved in the regulation of the other RSV 
genes or aid transportation of viral proteins to the cell membrane (Teng & Collins, 1999). 
Recently, a key genetic component detennining the ability of highly virulent viruses (e.g. influenza 
type H5Nl) to resist the inhibitory effects of host cytokines such as interferon and tumor necrosis 
factor ex, seems to be the non-structural protein of the virus, NS 1. Although small, this protein 
already has many assigned functions and has been pinpointed as the major tool that influenza uses 
to avoid switching on host innate immunity (Zambon & Barclay, 2002; Seo et al., 2002; Garcia-
Sastre et al., 1998). 
Seo et al (2002) found that a single amino acid change in the NS 1 protein was sufficient to confer 
cytokine resistance in their animal model system. Poole et al (2002). Found that the NS 1 of 
paramyxoviruses may play a role on limiting the yield of IFN-)( during infection as a general 
property of paramyxoviruses. This indicates that NS 1 protein can play a role in the balance between 
viral replication and the host immune response (Poole et al., 2002). 
1.5.2 Structural proteins 
The N gene encodes the nucleocapsid protein, which encapsulates the genomic RNA to fonn the 
nucleocapsid template, and is involved in RNA replication, with the P and L genes (Grosfeld et al., 
1995). The N gene binds tightly to genomic and anti genomic RNA to form the ribonucleoprotein 
template. The N gene is highly conserved within sUbtypes (John son & Collins, 1989) and therefore 
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is the target for study of the classification and sub-typing of strains of RSV (Cane & Pringle, 1991). 
The P gene encodes the major phosphoprotein which has two functions, first as a transcription 
factor and second as a polymerase cofactor (Barik et al., 1995). 
The L gene product is the polymerase. The M2 and the L genes overlap by 68 nucleotides. The L 
protein is never found free in the infected cell, but forms a complex with P to constitute the viral 
polymerase (Hamaguchi et aI., 1983). 
1.5.3 Matrix proteins 
There are two matrix proteins, both of which are non-glycosylated. The predominant matrix protein, 
MI is the most abundant in the virion and its function is to transcriptionally inactivate the 
nucleocapsid. A second function is to assist in the interaction of the nucleocapsid and the envelope 
(Ulloa et al., 1998). 
The second matrix protein, M2 is only present in the Pneumovirinae. This protein is important in 
virus transcription and balances RNA replication and transcription (Bermingham & Collins, 1999). 
M2 is a processivity factor for mRNA transcription that enhances transcription readthrough at 
intergenic regions and is a transcriptional antiterminator (Hardy & Wertz, 1998). 
1.5.4 Surface glycoproteins 
The F gene encodes a transmembrane surface glycoprotein necessary for fusion of the virus to cell 
surface membranes and mediates virus penetration. It is also responsible for the formation of 
syncytia from infected cells. The F protein is more conserved than the G protein, and is a major 
antigenic protein. It consists of two subunits, the Fl and F2 linked by a disulphide bridge (Lopez et 
al., 1998). 
The G gene is 923 nucleotides in length and encodes the attachment protein (inferred because 
antibodies specific for G inhibit virus binding to receptor (Levine et al., 1987). It is a type n 
glycoprotein of 289-299 amino acids with a single hydrophobic domain and an N terminal single 
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transmembrane region. The G protein precursor is 33 Kd, which is subjected to post translational 
modification by the addition of N and 0 linked carbohydrate side chains to produce a mature 
protein. The protein has a very high serine, threonine and proline content which is analogous to 
mucin proteins. 
The protein consists of three regions, the intracellular, transmembrane and extracellular. The 
extracellular region is separated into two variable regions separated by a conserved region (Cane, 
1993) (Fig 1.3). The conserved region is thought to be involved in cell receptor binding, as it is 
believed to be conserved between subgroups and genotypes. 
More recently a highly conserved domain of G has been shown to bear homology to the chemokine 
fractalkine (CX3CL). In vitro interaction of G and the fractalkine receptor (CX3CRl) has been 
demonstrated, and pre-treatment of cells with fractalkine has been shown to inhibit viral plaque 
formation. Virtual abolition of viral plaque formation is achieved by pre-treatment of cells with 
both heparin and fractalkine (Tripp et al., 2(01). Interestingly, it has long been known that RSV 
infected cells produce a secreted form of G, and it was previously believed that this was essentially 
a decoy for anti-G protein antibody. The homology with CX3CL raises the possibility of G having a 
role in immune subversion, by mimicking CX3CL. 
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c) 
Figure 1.3: G protein structure 
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Linear representation of G protein. a) Amino acid number. b) The protein is shown as the dark bar, 
with N and C terminal indicated. The white box is the transmembrane domain. Cysteine residues 
are marked with black dots. The black box indicates the strictly conserved 13 amino acid central 
region. Red dotted lines represent the position of synthetic peptides recognized by human 
convalescent sera, numbers corresponding to amino acid 1=229-243,2=247-258,3=262-276 and 
4=280-294 respectively. The smaJl blue bars represent the epitopes, which afford maximal 
neutralization. The G soluble protein is shown with the green dash dot line and the initiation codon 
of this segment with AUG. c) the variable and conserved regions of G protein. 
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These data suggest the importance of the putative heparin binding domain and the CX3C-like 
domain. In addition, Tripp et al., (2003) have shown that RSV G glycoprotein reduces respiratory 
rates associated with the induction of G glycoprotein-CX3CRl interaction, an effect that is inhibited 
by treatment with anti-G glycoprotein or anti-CX3CRl monoclonal antibodies. These data suggest 
new approaches for treating some aspects of RSV disease. Teng & Collins (2002) have reported that 
deletion of both the heparin binding domain and the CX3CL like domain has little effect the virus 
attachment and replication. Also, a virus expressing solely the secreted form of G is almost as 
efficient as wild type virus at replication in vitro and in mice (Teng et al., 2(01). 
After testing the reactivity of monoclonal antibodies and escape mutants with different virus strains, 
three types of epitopes have been identified. The first type is conserved; the second is group-
specific shared by all viruses of the same anti genic group. The third is strain specific/variable and is 
present in certain isolates of the same antigenic group (Martinez et aI., 1997). The conserved region 
is located between positions 164-176 that includes 4 conserved cysteine residues at positions 173, 
176, 182 and 186. The conserved region has a subgroup-specific immunodominant site at 174-188. 
The studies showed within the amino acid sequence 174-187 are the sub-group specific protective 
epitopes. 
A synthetic peptide from the same regIon containing a Cys-Ser substitution at position 186 
completely protects immunized mice against group A RSV infection (Simard et al., 1997). This 
study also showed that amino acids 125-203 of subgroup A glycoproteins represent a domain which 
is fully protective and completely prevents replication of RSV A in mice. 
Within G gene sequence variation of approximately 47% between the A and B subgroups has been 
shown and the most extensive amino acid sequence differences between groups are found on the G 
gene (Johnson et al., 1987). 
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The SH gene encodes a small hydrophobic glycosylated protein with unknown function (Bukreyev 
et al., 1997). 
Separating the genes are conserved intergenic regions, which are not copied into the mRNA and 
they vary between 1-56 nucleotides in length. 
1.6 Replication cycle 
The viral attachment receptor is unknown at present. However, the conserved 13 amino acid 
segment in the middle of the G protein ectodomain (amino acids 164-176) is believed to include the 
putative receptor binding site (John son et al., 1987). Pre-incubation of RSV with heparin inhibits 
infection of cultured cells and the RSV attachment protein G was able to bind specifically to 
heparin (Krusat & Streckert, 1997). This study showed that heparin or other cell surface 
glycosaminoglycans (GAGS) are involved in RSV binding to cells through glycoprotein G. 
A recent study by Melero and Martinez (2000) confirmed previous findings using flow cytometry to 
measure binding of RSV to cultured cells. It was shown that cell surface proteoglycans are 
important for RSV binding and that removal or destruction of GAG inhibits binding. However, 
there are other possible methods of attachment and entry to cells with different cell types. This has 
been shown by the competent replication of a mutant virus lacking the G gene in Vero cells, 
although impairment of growth occurred in vivo and in other cell lines. It is therefore thought that 
the interaction of RSV with the cell surface GAGs promotes attachment of the G gene to an 
unidentified receptor through a central conserved region (Karron et al., 1997). In vivo ciliated 
epithelium cells are peripherally infected. Therefore, it is possible that there is more than one 
mechanism of entry. 
Virus entry occurs by fusion of the virus envelope with the cell surface membrane at pH7 and the 
protein involved is the fusion (F) glycoprotein. F is formed from a precursor Fo that becomes 
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activated after cleavage by a host protease to form virion disulphide linked FI and F2 sub-units. The 
viral envelope becomes incorporated in to the host cell surface and the nucleocapsid is released in to 
the cytoplasm (Karron et al., 1997; Lopez et al., 1998). 
The mechanism of replication has not been completely elucidated, but it is believed that the 
polymerase molecule binds to the 3' end of the RNA. The polymerase transcribes the RNA until it 
meets a gene end signal, then falls off and binds again at the next gene downstream. It has been 
shown that RSV has read through transcription (Hardy & Wertz, 1998). Here, the RNA polymerase 
does not fall off the RNA at a gene end signal, but carries on to the next gene, therefore enhancing 
production of genes further downstream. Replication involves the synthesis of a full length, positive 
sense copy (antigenome). This is found only in nucleocapsid form and is the template for synthesis 
of progeny genome. 
Viral replication occurs in the cytoplasm and progeny virions form when nucleocapsids bud through 
the plasma membrane acquiring a lipid envelope containing virally encoded transmembrane 
proteins. RSV buds through the apical 
surface that may contribute to the localisation of the virus to the respiratory tract as the virus buds 
into the tract (Roberts et al., 1994). The cytopathic effect induced by the virus causes syncytia 
formation, which leads to cell death. 
1.7 Strain analysis 
Strain analysis is important because it provides information about epidemiology and transmission of 
RSV (Anderson et al., 1991). On the basis of monoclonal antibody studies, RSV has been classified 
into two major groups A and B, and within these groups, antigenic subtypes of RSV have also been 
identified, differences between RSV strains have been observed with monoclonal antibodies 
specific for the nucleoprotein (NP) component, matrix protein (M), large glycoprotein (G) and 
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fusion protein (F) (Mufson et aI., 1985). Sequence studies of the nucleoprotein (N), phosphoprotein 
(P), small hydrophobic (SH) protein and attachment (G) protein gene have confinned the division 
of RSV into two groups and also identified numerous variants or lineages within each group (Peret 
et al., 1998). The RSV groups A and B circulate indepented in the population with group A being 
somewhat more prevalent (Cane et al., 1992). 
Most molecular studies involving variation have concentrated on the N, P and SH genes using 
restriction enzyme analysis of PCR amplicons (Cane & Pringle, 1991). Six lineages or genotypes 
based on restriction fragment length polymorphism (RFLP) analysis of the SH gene have been 
identified for subgroup A (Cane et al., 1994). Subgroup B has been divided into two lineages using 
the Nand P region of the genome and into six lineages using the G gene (Peret et aI., 1998). RSV 
strain variation occurs because of the variation seen within the G gene and this variation probably 
results in the ability of RSV to re-infect individuals. The G protein is involved in neutralization and 
protective antibody responses. There are a high percentage of nucleotide changes resulting in amino 
acid changes, which could cause a selective advantage to G protein changes (Cane & Pringle, 
1995b). There is variation of approximately 47% within the G gene between the two subgroups 
(Jobnson et al., 1987) and intrasubgroup variation is approximately 20% for group A strains (Cane 
& Pringle, 1995b) and 9% within group B (Sullender et al., 1991; Cane &Pringle, 1995; Sullender 
et al., 1998). A more recent study has suggested that variation in the G protein does not correlate 
with severity of infection (Brandenburg et al., 2000b). 
Genetically similar strains cluster temporally rather than by geographical location, suggesting 
immunological pressure may determine the genetic variation and evolution of RSV from the same 
antigenic group. However, this infonnation is limited and requires further analysis by anti genic 
characterization of clinical isolates and sequence infonnation (Cristina et al., 1991). Knowledge of 
humoral responses to known genotypes will enable strain variation to be understood more clearly. 
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Multiple strains circulate simultaneously in the same community and different strains circulate in 
different communities during the same year. A study by Cane between 1988 and 1993 in 
Birmingham showed yearly variation in the predominating circulating RSV strain, and it was 
suggested that G gene variation confers an advantage to the virus allowing re-infection (Cane et aI., 
1994), this study showed some lineages of subgroup A increased in number over several years and 
then decline possibly because of increased resistance in the community to a particular genotype. 
A study based in the Gambia assessed the prevalence of RSV over four epidemics (Cane et aI., 
1999). This study also showed that variation in the predominating sub-types was observed between 
seasons. This was considered likely to represent evolutionary changes within the virus (Cane et aI., 
1994; Garcia et al., 1994 ). Studies in Korea also showed that multiple genotypes co-circulate in 
each epidemic and a shift occurred in the predominant genotypes of G gene for subgroup A viruses 
over 9 consecutive epidemics (Choi & Lee, 2(00). Another study done over two seasons in several 
states in USA showed that RSV strains co-circulate (Anderson et al., 1991). In this study, however, 
differences in the predominant subgroup were seen between the different States in the same 
epidemic, which suggested that the same predominant strains were not circulating throughout the 
country at the same time. 
A study in Denmark over three epidemics showed a pattern of predominance in the circulating 
strains. Other studies performed over a five year period in the Urgway showed a pattern of 
predominance of certain strains with no one strain predominating more than once in five years 
(Cristina et al., 1991). Speculation has arisen that variation in the predominant strain was because 
the novel strain can evade the immune system and therefore circulate freely. However, as most 
research has been based on a small sample number and only on hospitalized infants, it is difficult to 
understand the basis of the circulating strains in the whole community. 
There is little information available about the burden of disease in developing countries. A study in 
Mozambique showed a higher prevalence of sub-group B viruses. Most of the strains circulating in 
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a single outbreak isolated in very distant places in different years were more genetically linked than 
strains co-circulating in the same group isolated during the same outbreak in the same geographical 
region. However, there was one cluster more genetically distant from previous isolates found in 
other regions (Roca et al., 200 1). 
One possible model, which has been elucidated to explain antigenic variation, is that immunological 
pressure in a community forces positive selection towards new antigenic variants of RSV and 
therefore accounts for the ability to re-infect. This is supported by antigenic changes in the G 
protein and amino acid changes, which accumulate progressively. Evidence of co-circulating strains 
present in the community in low frequency may proceed a season of dominance (Cane et aI., 1994). 
The disappearance of a strain may be due partly to increased herd immunity to that particular strain 
or because of increased resistance to a particular genotype (Johansen et aI., 1997). There are a 
variety of possible mechanisms, which could cause changes within the G gene sequence. One 
mechanism is frame shifting which occurs by the deletion of a base resulting in a change of reading 
frames, which alters the production of the amino acids (Garcia-Barreno et aI., 1990). It is likely that 
frame shifting occurs because of an error by the polymerase, which allows the virus to escape 
neutralization by monoclonal antibodies (Cane, 1993). Other mechanisms could include premature 
stop codons, substitutions and hyper-mutations (Sullender & Edwards, 1999). 
RSV associated disease. 
1.8 RSV epidemiology 
RSV is a global disease that is highly infectious. A single exposure to an RSV outbreak gives a 50 -
100% risk of contracting disease, dependent on the setting. RSV is the most common microbial 
cause of pneumonia and bronchiolitis in children under one year of age, with one in one hundred 
children in the USA being hospitalised as a result of RSV infection. In one thirteen year study of 
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hospital admissions in Washington D.e., 43% of all infant bronchiolitis and 25% of infant 
pneumonia were caused by RSV. Although the death rate from RSV in developed countries has 
been falling, due largely to better intensive care treatment and not to any effective anti-viral 
therapy, it is estimated that between 0.3 and 1 % of those admitted to hospital with RSV related 
disease will die. Risk factors for hospitalisation include low socio-economic status and living in 
heavily industrialised areas. Morbidity and mortality rates are highest in those with 
bronchopulmonary dysplasia or congenital heart disease, and those who are immunosuppressed in 
some way. As there are a number of agents that can cause RSV-like symptoms, the epidemiology of 
the virus in the developing world is more obscure (Brandt et al., 1973; Kim et aI., 1973; Parrott et 
aI., 1973; Collins, 2(01). 
Identification of two virus groups (RSV -A and -B) has led to studies to investigate the relationship 
between strain and disease severity. Several studies have found RSV-A to be more severe and 
others have shown no difference. Only two studies have shown RSV-B to cause more severe 
disease. These two groups co-circulate and the immune responses to each are mostly cross-reactive 
(Hall et aI., 1990; Brandenburg et al., 2(01). In areas of temperate climate, an 'RSV season' occurs. 
This lasts from late autumn, peaks in mid-winter, and ends in early spring. Although the timing of 
the outbreak is predictable, its severity is not (Hall et al., 1990; Brandenburg et al., 2(01). 
As no long-term protection immunity to RSV develops, it is increasingly recognized as an 
important disease in the elderly, causing approximately a quarter of acute respiratory illness in this 
group. It has been suggested that this group alone represent sufficient economic justification for the 
development ofa vaccine (Falsey, 1998; Han et al., 1999). 
1.9 Reinfection with RSV 
Repeated infection with RSV throughout the life of an individual is common, even in the presence 
of moderate levels of RSV specific antibody (Hall et al., 1991). At two years of age, 50% of 
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children show signs of having had more than one RSV infection. Symptoms upon re-infection in 
both children and adults tend to be less severe. This may be due to protective immune mechanisms 
and/or the fact that re-infection must occur at a later age which will itself improve the outcome of 
infection. 
Other respiratory viruses, such as influenza, re-infect but this is facilitated by anti genic change. 
How RSV reinfects so readily is yet to be defined but a number of factors are thought to be 
important. RSV is readily transmissible and replicates rapidly at site of infection. 
This rapid replication is likely to outpace the generation of secondary immune responses especially 
CD8lymphocytes. The secretory IgA response protecting the respiratory surface is short lived, 
while serum IgG has limited protective effect. These factors are probably important in allowing re-
infection, but are shared with influenza virus. RSV's unique G protein may be important. It has an 
unusual non-globular structure, with multiple glycosylations, that may induce poor quality 
neutralising antibody and limited CD8 T-cell responses. G-protein is secreted by RSV infected cells 
during natural infection and may act as an antibody decoy and/or a CX3CL chemokine mimic hence 
subverting the immune response (Collins & Pollard, 2(02). 
Other possibilities of multiple infections with RSV occur through an individual's life because of the 
highly infectious nature of the virus (Blydt-Hansen et aI., 1999). This is probably due to selection 
pressure and the virus escaping the immune system by changing anti genic regions and glycosylation 
sites. It is probable that the G gene shows extensive variability for this reason. Cytoplasmic and 
transmembrane regions are followed by a sharply defined hypervariable domain between amino 
acid 101 and 133. There is a more extended variable region in the carboxy terminal third made of 
three smaller variable regions. There are two major variable regions separated by highly conserved 
domains between 147 and 207. As most of the nucleotide changes in parts of the gene coding for 
the variable area result in coding changes, there may be immunological pressure for change in 
certain areas of the G protein and this may account for the ability of the virus to re-infect repeatedly 
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(Cane et al., 1991; Melero et al., 1997). A study by Sullender et al (1998) showed isolation of two 
strains of RSV A with 15% amino acid variation from sequential infections in children. 
The other possible reason that re-infection can occur is because the immune response upon infection 
is not protective. Re-infection could occur with a different virus, which is not recognized by the 
immune system. Studies have already shown that infection with one subtype does not confer 
immunity against another subtype or the same subtype (Mufson et al., 1987). 
Re-infections may occur because of antigenic diversity and less effective, short lived immunity at 
mucosal site of replication. RSV is also resistant to effective neutralizing antibodies possibly 
mediated by the unique structure of the G gene, decreased immune response following RSV 
infection in the neonatal period due to immunological immaturity and immunosuppression mediated 
by maternally-acquired antibodies (Collins et al., 1999b). 
1.10 Pathogenesis 
Transmission of RSV occurs either directly by aerosols or fomites. After initial infection with RSV, 
the incubation period is approximately three to five days (Domachowske & Rosenberg, 1999). 
Virus replication commences in the nasopharynx, and then travels to the cells in the respiratory 
epithelium. RSV spreads to other uninfected cells by causing syncytia formation. 
RSV causes a spectrum of disease symptoms and pathologies that are generally divided up 
according to which parts of the respiratory tract are infected- the most common symptoms due to 
RSV infection are simply the common cold. When only the upper respiratory tract is significantly 
infected, the patient gets rhinitis with a blocked and runny nose, and is generally irritable. This lasts 
a short time, days to a week, and requires no specialist treatment. 
If infection occurs further down the respiratory tract in the bronchioles, the disease is more serious. 
It starts with common cold symptoms, and progresses 3 to 5 days later, to produce fever and 
symptoms due to difficulties in getting air out of the lungs; deep cough, breathlessness, rapid 
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breathing, expiratory wheezing and possibly cyanosis. In advanced cases the chest may become 
expanded due to increasing amounts of dead air space in the lung. 
When infection occurs lower down the respiratory tract pneumonia occurs. The symptoms are 
similar to those mentioned above, but the expiratory wheeze is lessened because of obstruction of 
air coming from the alveoli due to narrowed bronchioles. Effective hospital care, possibly including 
supplementary oxygen, has reduced mortality rates to < 1 % in developed countries. Death if it 
occurs, is usually due to blockage of the airways via a number of mechanisms. Inflammation of the 
mucosa around the airways; copious mucus secretions in the lung lumen, the clearance of which is 
often impaired due to a breakdown in ciliary transport, caused by direct viral killing of mucosal 
cells, and the deposition of necrotic cells into the lumen of the lung. In RSV pneumonia, breathing 
is impaired by thickening of the alveolar walls, due to mononuclear cell infiltration, and a filling up 
of the alveolar lumen with copious amounts of mucus (Pu et al., 200 1). The main reason for the 
increased susceptibility of babies to severe RSV -related disease is thought to be mechanical with 
their narrower airways being more susceptible to blockage. Although much of RSV pathology is 
caused by inflammatory mechanisms, anti-inflammatory drugs such as corticosteroids are not an 
effective therapy (Brandenburg et al., 2(01). 
1.11 RSV and Asthma 
Correlation of severe RSV associated disease and asthma has been conclusively demonstrated (Bont 
et al., 2000; Bont et al, 2001; Sigurs et al., 2000). Studies in a mouse model ofRSV and asthma 
have demonstrated that airway hyper-responsiveness to either dust mite faecal antigen or ovalbumin 
can be induced by prior RSV infection, and that this allergic airway sensitization may be transferred 
by T lymphocytes. Schwarze et al demonstrated that both CDB cells and IL-5 were necessary for the 
development of this hyper responsiveness in mice. These data suggest that severe RSV infection in 
humans may have a causal effect in the development of asthma in later life (Schwarze et al., 1999 a; 
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Schwarze et al., 1999 b). Therefore, if this causative link is true, prevention of severe RSV disease 
in infants, using a vaccine, should have a beneficial effect on subsequent asthma rates. 
1.12 RSV subgroups and their clinical importance 
RSV is divided into two subgroups A and B based on studies using monoclonal antibodies 
(Anderson et al., 1985; Belshe et al., 1982b) . RSV A seems to be more prevalent than RSV B. 
Infection with one subtype does not prevent future infection with the other sUbtype. It is thought 
that RSV A causes a more severe disease (McConnochie et al., 1990; Walsh et al., 1997) . 
However, in another study RSV B was found to cause a more severe disease using clinical and 
immunological markers (Hornsleth et al., 1998). A study in Argentina over seven consecutive 
epidemics showed that both strains co-circulated and that sub group A occurred at least eight times 
more often in six out of the seven years. Subgroup A was more common with bronchiolitis and 
subgroup B was more common with pneumonia (Carballal et al., 2000; McConnochie et al., 1990). 
However, as most studies have involved small numbers of predominantly hospitalized infants, there 
is little information relating to the severity in RSV infection in populations as a whole. 
1.13 Laboratory Investigations 
The clinical presentation of RSV is often similar to other respiratory tract infections and therefore 
the only method of a definitive diagnosis is the use of laboratory tests. Wheezing is a common 
indication of RSV infection in young children. Samples often include nose and throat swabs and 
nasopharygeal aspirates (NP A) and RSV can be detected by cell culture, using Hep 2 cells, which 
results in characteristic cytopathic effects (cpe) of syncytia if a sample is positive. However, 
problems with this method include difficulties in growing the virus and lack of cpe (especially seen 
with RSV B). Also, RSV is a labile virus and therefore needs to be stored at -800 C to maintain 
viability. Other detection methods include EIA and immunofluorescence, which are specific, 
38 
sensitive and rapid. 
Commercial kits are also available for diagnosis of RSV, including the Becton Dickinson 
Directigen rapid antigen test, which showed a sensitivity of 83% and a specificity of 90% when 
NPA samples were tested. The advantage of these kits is they produce results extremely quickly 
(within approximately 15 minutes). They are very easy to use, not requiring any special equipment, 
are read by eye and hence can be used within the hospital ward as a bedside kit (Kok et aI., 1990). 
However, the tests are not widely used, as there is a dispute over sensitivity and specificity. Another 
kit also based on enzyme immunoassay methodology, Abbott Diagnostics Testpack, has 
independently been evaluated in conjunction with Directigen. The study showed that Directigen had 
a sensitivity of 76% whereas Testpack had a higher sensitivity of 92% (Rothbarth et aI., 1991). A 
further study performed in Edinburgh showed the Directigen had a sensitivity of 79% and a 
specificity of 97% in comparison with direct immunofluorescence. Results showed that a positive 
result is trustworthy, not requiring laboratory confirmation, but a negative result does need 
confirmation (Mackenzie et al., 1999). The results of the study showed that it was necessary for the 
sensitivity of the commercial tests to be increased before they can be used routinely, but when 
sensitivity is improved they will be extremely useful in hospitals when choosing treatment or 
preventative measures (Borriello, 1999). 
As a result of the advent of molecular methods for the detection of a variety of virus genomes, 
diagnosis can be achieved more quickly and is more sensitive. The advantage of molecular 
technology is that sequence information can also be obtained. Polymerase chain reaction (PCR) 
tests are often performed routinely on clinical samples and results can be obtained within 48 hours. 
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Host Response to RSV 
1.14 Virus tropism 
RSV enters the body via the respiratory tract and infection is restricted to the respiratory tract, 
affecting mainly the epithelial cell layer. The receptors for the virus include CX3CR (the fractalkine 
receptor), via the G-protein; extracellular sugars via with both G and F; and ICAM-I which has 
been shown to bind to RSV F protein (Arnold & Konig, 1996; Behera et aI., 200 I). None of the 
known receptors satisfactorily explain the limited RSV cell tropism. 
RT-PCR studies have shown RSV RNA to be present in peripheral blood mononuclear cells 
(PBMCs), although there is no evidence for RSV replication outside of the respiratory tract in 
immunocompetent individuals. In immunocompromised patients, the duration of disease increases 
and in some cases RSV spreads to other areas of the body (Milner et al., 1985). 
A combination of cellular and humoral immunity is involved in combating RSV infection. Humoral 
immunity probably controls RSV infection. An infant may be protected by maternal antibody for 
only a couple of months. Breast fed infants may however, be protected for longer because of 
receiving antibody in colostrum (Mito et al., 1984). Cellular immunity is important in viral 
clearance and a recent study shows characterization of a novel HLA B7 restricted memory RSV 
specific CTL epitope in humans. The epitope lies within the NP gene, although strong RSV -specific 
CTL responses directed towards epitopes within SH, F, M and NS 1 in human RSV specific CTL 
activity have also been seen. Once dominant RSV specific CTL epitopes have been identified it will 
be possible to concentrate on the role of RSV specific CTLs in controlling disease in pediatric 
infection (Goulder et al., 2(00). 
Different proteins in the virus generate different immune responses. Immunity to F protein is cross-
reactive, whereas immunity to G is usually group specific. The F protein activates a CD4 Th 1 
response, causing production of IL-12 and interferon gamma. The G gene however, produces a Th 2 
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response, with production of IL-4 and 5, hence causing extensive eosinophilia. Recently, the region 
of the G gene responsible for this elevated production of eosionphils has been mapped to a region 
between amino acid 193-203 in the second variable region of the G gene (Sparer et al., 1998). There 
is also another region believed to be important in generating the humoral response. In one study 
they showed that if CD4+ cells were deleted in Balb/c mice prior to administration of peptide from 
amino acid 184 to 198, eosinophilia did not occur, whereas the elimination of CD8+ cells had no 
effect. 
The CD8+ cells are believed to regulate the CD4+ response. In a study performed by Hussel using 
Balb/ c mice, which produce a CD4+ response to RSV G protein (Hussell et aI., 1997), severe lung 
pathology due to acute eosinophilia was observed. When CD8+ cells were administered the disease 
was less severe, possibly shifting the immune response away from being Th2 mediated. Another 
study showed similar results with the probability that CD8+ cells down regulate Th2 cytokine 
production and hence eosinophilia (Srikiatkhachom & Braciale, 1997a). RSV infection may induce 
lung inflammation via early production of inflammatory chemokines. The presence of histamine, 
eosinophilic cationic protein and major basic protein in NP A and tracheobronchial aspirates show 
RSV infection triggers migration to the airways and activation of basophils and eosinophils. In the 
mouse model, the pathogenesis of RSV induced lower airway disease is similar to that in humans. 
In Balb/c mice, RSV rapidly replicates in lungs after intranasal inoculation and induces 
mononuclear cell infiltration. These changes correlate with the amount of viral inoculum. In human 
RSV, a more severe disease occurs in children who have higher concentration of RSV in their 
secretions. Chemokines are involved in RSV mediated lung inflammation and chemokines and 
MIPl are involved in the pathogenesis of lung inflammation in mice experimentally infected with 
RSV (Haeberle et al., 2(01). 
Cytokines secreted during RSV infection include interleukin 8, which is a chemotactic chemokine, 
IL-6, lL-lO and RANTES, which are also thought to regulate RSV infection (Sheeran et al., 1999). 
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Lung surfacant protein A increases attachment of RSV and therefore subsequently enhances entry 
into host cells (Hickling et al., 2(00). 
1.lS Cellular immune response 
In vivo and in vitro RSV infection of respiratory epithelial cells leads to production and release of 
chemokines, notably RANTES, MCP-I, MIP-Ia and ll....-8 (Olszewska et al., 2000; Thomas et al., 
2000~ Casola et al., 2001; Haeberle et al., 2001). This response leads to an inflammatory influx 
which, when measured in broncioalveolar lavage (BAL) fluids from infants with RSV bronchiolitis, 
is made up ofneutrophils (-75%), monocytes (-10%) lymphocytes (-10%). 
Monocytes recognise RSV as a pathogen using the pattern recognition receptors TLR-4 and CD 14, 
In vitro, RSV activates these receptors, causing cytokine release; in vivo prevention of the RSV 
TLR-4 interaction has been shown to reduce monocyte and NK cell trafficking into infected mouse 
lungs (Kurt-Jones et al., 2000; Haynes et al., 2(01). 
The T-lymphocyte response is critical to the successful resolution of infection. Children with 
deficient T-cell function, are unable to clear the virus for prolonged periods (Milner et al., 1985). 
Also severely immunocompromised adults (e.g. those receiving bone marrow transplants) have a 
high incidence of RSV infection leading to serious disease, even death (Collins, 200 I). 
In Balb/c mice infected with RSV, passive transfer of RSV specific T -cells is able to reduce lung 
virus titre. However the severity of disease, as assessed by lung pathology or weight loss is 
increased. Th! CD4 T -cells were able to augment disease but in these experiments, IL-4 secreting 
Th2 CD4 T -cells were more potent both at increasing disease and reducing viral load. CD8 T -cells 
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have been shown both to be more and less potent at augmenting disease than CD4 T -cells 
depending on the experimental system (Graham et al., 1991; Alwan et al., 1992; Alwan et a., 1994). 
There are conflicting data as to the Th phenotype of cells generated by RSV infection. Analysis of 
BAL washes from Balb/c mice infected with RSV showed both Thl and Th2 T-cells, although the 
major producers of IFN-gamma were NK cells, early in infection, and CD8 T-cells later in infection 
(Hussell et al., 1996; Srikiatkhachom & Braciale, 1997b; Hussell & Openshaw, 1998). In humans, 
serum levels of Thl or 2 cytokines are not correlated with disease severity. In vitro stimulation of 
PBMC from RSV patiants with RSV antigen gave high levels of IFN-gamma and low levels of IL-4 
and 1 L-l 0 (Brandenburg et al., 2000a). Memory responses to RSV have been shown to be 
predominately of the Thl phenotype (Anderson et al., 1994). 
Th2 responses to RSV were found when PBMCs were cultured with live RSV but not with UV 
inactivated RSV. Several groups have observed that the immune response to G protein is Th2 
directed (Jackson & Scott, 1996; Srikiatkhachom & Braciale, 1997a). A piece of evidence 
suggesting that a Th2 response may not be beneficial is that higher type 2 cytokines levels were 
found in the PBMCs of children with RSV bronchiolitis than in healthy donor children. It is 
interesting to note that CD8 T -cells were the predominant IL-4 secreting cell in this study (Bendelja 
et al., 2(00). Also there is a correlation between Th2 cytokines and an early experience of RSV. 
Early exposure to RSV is predictive of a poor disease outcome (Roman et al., 1997). 
A mouse model was developed to investigate the reasons for the failure of a formalin inactivated 
RSV vaccine. This not only failed to protect from disease for a prolonged period, but also caused 
enhanced disease in vaccinated children who subsequently were infected with RSV. This disease, 
which was fatal in two cases, was characterised by an intense lung inflammatory infiltrate including 
eosinophilia (see section 1.5.2) (Chin et al., 1969; Kapikian et al., 1969; Kim et al., 1969). Similar 
immunopathology can be induced in Balb/c mice (and other animal models e.g. cotton rats) by 
priming with RSV G-protein or formalin inactivated RSV, and later challenging with live RSV 
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(Openshaw et al., 1992; Woolums et al., 1999; Ponnuraj et al., 2001; Prince et aI., 2(01). This 
disease is also characterised by an eosinophil influx to the lung and by the induction oITh2 
phenotype T-cell responses (although high levels ofIFN-y from other sources may still be present) 
(Spender et al., 1998). Blocking of Th2 responses using anti IL-4 and IL-lO monoclonal antibodies 
or Th2 cell depleting antibody prevents immunopathology (Connors et al., 1994; Walzl et al., 
2(01). The initial priming event does not induce C08 cell activity. Hussell and colleagues 
demonstrated that C57BU6 mice that do not develop immunopathology when primed with G and 
later challenged with RSV generated CD8 T-cell responses to G whereas Balb/c mice did not. 
Moreover when C57BU6 mice were rendered unable to generate CD8 T -cell responses, by 
knocking out their O2 microglobulin gene, they developed immunopathology (Hussell et aI., 1997; 
Hussell et al., 1998). More recently, it has been shown that activated IFN-gamma secreting NK 
cells are able to protect from vaccine enhanced disease in the Balb/c mouse model (Hussell & 
Openshaw, 2(00). 
The relevance of this sensitisation and challenge model to RSV bronchiolitis in naturally infected 
children is limited as severe disease in humans normally occurs upon first exposure to RSV. It does 
however provide information as to the role of C08 cells in regulating other cell types during the 
clearance of a natural infection. 
C08 T-cells recognise cytosolically derived antigen in the context ofMHC class 1 molecules. 
Because of this ability to detect intracellular infection they are believed to be key cells in the 
clearance of viral infections. N, SH, M, M2, and NS2 specific C08 T-cells have been found in the 
blood of RSV exposed humans (Cherrie et al., 1992). In children these cells appear within 10 days 
of infection and increase in number throughout the infection peaking at the time of disease 
resolution (Collins, 2(01). Passive transfer experiments in mouse models of RSV infection have 
demonstrated the ability of C08 cells to clear virus, but also implicated them in 
immunopathogenesis (see above). The presence ofCTL (which were not definitively characterised 
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as CD8 T-cells) was associated with decreased severity of clinical disease in humans (Isaacs et al., 
1987; Domachowske & Rosenberg, 1999; Rosenberg & Domachowske, 200 I). However others 
have suggested that rapid development of CTL responses leads to wheezing and/or bronchiolitis, 
whereas gradual development of this response leads to less severe illness. In both humans and mice, 
the presence of RSV specific CD8 cells after the resolution of disease has been shown to be 
predictive of later wheezing (Openshaw et al., 2001). 
Collectively, these data indicate that both Thl and Th2 CD4 T-cells are induced by RSV infection 
of humans, although the predominant cytokine in the lung is IFN-y secreted by CD8 T -cells, 
monocytes and probably NK cells. Which Th phenotype, if any, is best at preventing severe disease 
is unclear, although the balance of evidence points towards Th 1. The CD8 T -cell response is 
concomitant with virus clearance, and is also extremely important in avoiding CD4 T -cell mediated 
immunopathology upon re-infection. CD8 T-cell activation has both beneficial effects but may also 
cause immunopathology when generated in excess. 
1.16 Humoral response 
Infection with RSV elicits an antibody response to all of the viral structural proteins. The antibodies 
directed towards the F and G proteins are the most important for protection (Hall et al., 1991). 
There are a number of strands of evidence that show that antibody has the ability to protect from 
RSV infection. There is a brief period of 5 to 6 weeks after birth when maternal antibody titres are 
highest and RSV infection is rare. Also the levels of antibody in cord blood have been shown to be 
inversely correlated with severity of subsequent RSV disease (Holberg et al., 1991). There is an 
inverse correlation between virus neutralising antibody level in the respiratory tract and ability to 
experimentally infect animals or adult humans (Mills et al, 1971; Hall et al., 1991; Grahamet al., 
1993). 
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Hypotheses to explain the relative susceptibility of young infants to RSV is that titres of anti F and 
G glycoprotein antibodies (both serum and sIgA) induced in young infants are significantly less 
than that in older individuals. The limited quantity of antibody that infants make shows little 
neutralising activity (McIntosh et al., 1978; Murphy et al., 1986). 
The formalin-inactivated vaccine that was tested in the late 1960's induced an immunopathological 
response in some children upon subsequent infection with live RSV. This induced antibody 
response, was directed mainly at the F protein, and with low neutralizing activity. Until recently this 
aberrant antibody response had been hypothesized to induce immunopathology. Better 
understanding of the cellular immune response has implicated unbalanced T -cell responses in the 
vaccine-induced disease. With the possible exception that high serum IgE levels after infection and 
severe disease are correlated, (more probably a by-product of a harmful Th2 response, rather than 
evidence for IgE mediated immunopathology) there is little evidence of antibody driven 
immunopathology. Given the current view of the protective and benign effects of antibody in RSV 
infection, administration of RSV -F specific monoclonal antibody is now successfully used as an 
immuno-prophylactic in high-risk infants (Groothuis et al., 1995; Groothuis et al., 1998). This also 
has a marginally beneficial effect when given to already infected infants (Malley et aI., 1998). 
Although anti-viral antibody levels may mediate protection from disease they are not necessary for 
successful recovery from disease as evidenced by the clearance of virus from 
hypogammaglobulinaemic and agammaglobulinaemic patients. Moreover, Graham et al. (1991) 
demonstrated that antibody was not necessary for the clearance of RSV infection in mice. 
Repeated infection with RSV throughout the duration of life is the norm, and although antibody has 
some protective effect, re-infection can occur in the presence of relatively high levels of RSV-
specific immunoglobulins. 
Vaccination 
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There is no vaccine currently available for RSV, but given the high rate of re-infection with RSV it 
is unlikely that any vaccine will induce life-long sterile immunity. 
The minimum requirements for a successful vaccine in infants would be to protect the child from 
lower respiratory tract infection for it's first or possibly two RSV seasons. This is the period when 
infection is most dangerous. This essentially is the role of the current prophylactic treatment, 
passive transfer of RSV specific antibody, but a vaccine would be cheaper and hence more widely 
available. A successful RSV vaccine for the elderly needs to be at least analogous to the current 
once yearly influenza vaccine, providing protection for at least one RSV season. 
1.17 Live attenuated vaccines 
A live attenuated vaccine must strike a balance between immunogenicity and pathogenicity. Over 
successive decades this balance has proved difficult to achieve for RSV. When tested in adult 
volunteers or infants trial vaccines have been found to be either over-attenuated and showing no 
protective effect, under-attenuated and demonstrating a pathogenic effect or genetically unstable 
and showing a propensity to revert to wild type (Kim et al., 1973 ; Belshe et al., 1982; Wright et al., 
1982). 
In the last ten years Murphy and his co-workers have developed a new generation of genetically 
defined live attenuated vaccine candidates (Crowe, 1995; Whitehead et al., 1999; Wright et al., 
2(00). The viruses were attenuated using a combination of cold passaging, selecting for temperature 
sensitive mutants (cpts), and chemical mutagenesis. The new viruses were then genetically 
sequenced both to discover the mechanism of attenuation and to allow identification of reversion 
mutants. One of these candidates provided protection in chimpanzees, even when they were infused 
with anti-RSV antibody prior to immunisation. This suggests that this vaccination may be able to 
overcome the problem of maternal immunity. A development of this candidate vaccine, called; cpts-
248/404 went through phase 1 clinical trials and was found to be genetically stable and 
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immunogenic. However in very young infants the virus was found to be pathogenic (Wright et aI., 
2(00). 
Other approaches have been to delete whole genes from the RSV genome. A NS 1 and M2-2 
negative mutant has been shown to be immunogenic and safe in a chimpanzee model. Human trials 
have not yet been attempted (Teng et al., 2(00). 
Given that RSV itself does not induce lasting protective immunity this would not seem a logical 
route to take. If it was shown that the reduced severity of RSV re-infection was due to immune 
mechanisms as opposed to age related factors, protection from severe disease may be possible. 
1.18 Inactivated RSV vaccines 
An RSV inactivated vaccine, consisting of formalin-inactivated virus in alum, was developed. In 
clinical trails it produced neutralising and complement fixing antibodies in serum. Despite this, the 
number of vaccine recipients who developed lower respiratory tract complications upon subsequent 
RSV infection was greatly increased, with 80% of the vaccinees requiring hospitalisation. Sadly, 
two infants died. Post-mortem examination of these infants and studies of the other vaccine 
recipients showed a large mononuclear cell and eosinophil infiltrate in the lungs suggesting an 
immunopathological cause for the disease (Chin et al., 1969; Kapikian et aI., 1969; Kim et aI., 
1969). Inactivated vaccines induced antibody responses that were different from those after natural 
infection. Formalin inactivation also adversely affected the antigenicity of RSV F-protein. 
Inactivated RSV also failed to induce anti-G protein antibody. RSV antigen was shown to induce an 
exaggerated proliferative response in vaccinated children (Openshaw et aI., 2001). 
Hypotheses proposed to account for vaccine-enhanced disease initially centered on differences in 
antibody production between inactivated vaccine and natural infection. However in the RSV 
system, it has become increasingly clear that the T-Iymphocyte response induced by inactivated 
vaccine is inappropriate. The formalin-inactivated virus in alum is unable to produce IFN-y 
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producing CD8 T-cells (Graham et al. 1993), which are necessary to prevent immunopathology in 
mice (Tang & Graham, 1997). The current view is that protection from RSV requires a balanced 
immune response and that domination of one T cell phenotype over the others leads to 
immunopathology (Openshaw et al., 2(01). 
1.19 Subunit vaccines based on RSV proteins 
RSV vaccines using purified or recombinant viral proteins have also been tested. Immunisation with 
the F and/or G proteins has been shown to be induce antibody and T-cell responses that reduce the 
level of virus replication in lungs of mice (Trudel et al., 1989; Tebbey et aI., 2(00) and cotton rats 
(Walsh et al., 1987). A number of studies have linked the reduction in lung virus titre with enhanced 
lung immunopathology, probably because of the paucity of CTL and Thl responses generated by 
these non-replicating immunogens (Connors et al., 1992a). Successful clinical trails immunising 
with purified fusion protein (PFP-2) in alum have been carried out in seropositive children with 
RSV predisposing conditions (eg. bronchopulmonary dysplasia) and in adults. As these individuals 
have already been exposed to RSV, the possibility of priming for vaccine-enhanced disease is 
removed, making this a suitable vaccine candidate in these populations. 
Replicating recombinant vaccina virus expressing RSV F protein and/or G protein have been 
constructed. These provide protection from disease (largely mediated by antibody) without priming 
for immunopathology in rodent models. A vaccinia M2 protein construct also protects from disease 
but its action is mediated by CD8 CTLs (Connors et al., 1992a; Connors et aI., 1992b; Wyatt et aI., 
1999). 
1.20 Vaccines based on the G gene 
There have been several vaccines based on the G gene because of its importance in provoking 
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immune responses. There is a vaccine, BBG2Na, in Phase 1 and 2 clinical trials that incorporates 
the conserved region of the RSV G protein and the first variable and second variable regions joined 
to albumin binding region of streptococcal protein G to increase its half-life when expressed in E. 
Coli. The fusion of the two proteins produced a strong antibody response in mice (Libon et al., 
1999). The adsorption to alum makes the vaccine candidate BBG2Na more immunogenic and has 
proved promising in animal models (Power et al., 1997). When tested in neonatal mice, adequate 
protection was provided, showing that the vaccine is efficient in the presence of maternal antibody 
and when the immune responses are immature. Also, the vaccine managed to induce balanced Th 1 
and Th2 responses (Siegrist et al., 1999). A further study in 2000 showed that BBG2Na increases 
protective efficacy of serum antibodies in RSV seropositive mice. These results show that the 
vaccine could be used in the seropositive population providing protection from subsequent RSV 
infections (Goestch et al., 2(00). Two different plasmid vectors encoding cytoplasmic or secreted 
forms of BBG2Na when immunized in mice produced protective immune responses (Andersson et 
al., 2(00). 
Another vaccine candidate was produced from a cDNA clone containing all the genes of the A2 
long strain of RSV plus the G gene of RSV B inserted at the A2 FIM2 intergenic regions (Jin et aI., 
1998). The addition of plasmids encoding the N, P and L genes were needed to recover infectious 
virus, which showed stable expression of chimeric DNA. Another study showed that efficient 
recovery of cloned virus needed the M2-1 protein as a separate plasmid (Collins et aI., 1999a). This 
chimeric vaccine expressing the G protein of RSV A and B may prove to be useful. 
Anti-peptide antibodies have been shown to neutralize RSV infection in vitro and reduce lung titers 
and lung pathology. The short central conserved region ID the G 
gene may be used for designing a peptide antibody response, which has cross reactivity between 
types (Walsh et al., 1998). 
Vaccination with plasmid vectors encoding fulllengthlsecreted G protein (DNAG) elicits balanced 
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systemic and pulmonary Th 1 and Th2 cytokine responses in mice and not atypical pulmonary 
inflammatory reaction post RSV challenge in cotton rats. Therefore pulmonary Th2 cytokine 
responses and enhanced lung pathology are not intrinsic properties of RSV G protein. DNAG 
conferred evident neutralizing antibody responses and protection in mice and cotton rats (Li et al., 
2(00). 
The lack of enhanced lung disease may relate to the animal model. The G protein has not been 
reported to induce eosinophilia in cotton rats therefore the mouse model may not be as good the 
cotton rat model. 
Plasmid DNA vectors deliver RSV G in the absence of other antigen /adjuvant. Also, they induce 
balanced Thl!fh2 responses, regardless of the route of administration same as seen as with 
intranasal infection. In contrast immunization with formalin inactivated RSV for G protein always 
elicited Th2 response. 
Increased production of IL-5 and increased lung pathology is more specifically linked to response to 
secreted form of G protein in mice. Priming with secreted glycoprotein G of RSV antigens enhances 
IL-5 production and tissue eosinophilia after RSV challenge. Therefore, RSV secreted G may be 
important in evading the host immune system and a determinant of disease pathogenesis (John son et 
al., 1998). The amino acids 193-203 are responsible for enhanced pathology including pulmonary 
eosinophilia in mice (Sparer et al., 1998). 
Experimental systems, however, might cause problems such as the effect of adjuvant and/or carrier. 
Recombinant vaccinia viruses may modulate the immune response to the G protein because the 
proteins expressed are involved directly in evasion of the host immune defence and may alter the 
immune response to other antigens (Smith et al., 1997). 
However, the G protein has also been shown to cause immunopathological effects producing 
pulmonary eosinophilia upon subsequent challenge (Hancock et al., 1996). 
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The variation seen within the G gene suggests there is an immune or selective pressure on this 
region. Therefore any vaccine produced needs to create the correct immune response, to protect 
against re-infection and to prevent enhanced illness upon natural infection. 
1.21 Treatment and control 
There are no effective antivirals used in RSV infection on a routine basis. However, 
immunoglobulin is often given to prevent RSV infection in certain circumstances. 
RSV-IG is produced by screening plasma donors for high titres of RSV neutralizing antibodies and 
purification follows. This treatment commonly known as Respigram is licensed in the United 
States. A blind, randomized trial conducted by the PREVENT group on premature infants with and 
without bronchopulmonary dysplasia showed a reduction in hospitalizations as a result of RSV 
associated illness, and a decrease in time spent in hospital and decrease in symptoms (Smith et aI., 
1997). Another trial involving infants and children with congenital cardiac disease showed that 
RSV disease was prevented in infants less than six months old (Groothuis et al., 1993). However, 
after the trial, children with cyanotic congenital disease were recommended not to receive RSV-IG. 
Disadvantages of the treatment include intravenous doses administered monthly during the RSV 
season and treatment is expensive. Also, it has been shown that once lower respiratory symptoms of 
RSV infection have started the passive administration of RSV IG had no beneficial effects. 
Monoclonal antibodies are also used to treat and prevent RSV infection. Antibodies to the fusion 
protein are often used because it is highly conserved between sUbtypes. It is possible that the 
monoclonal antibody will be administered intramuscularly or perhaps nasally. Trials are being 
performed to assess efficacy (Weltzin et al., 1996). The main advantages of this type of treatment is 
that it is less expensive and also there is more viral neutralizing ability per gram, which may reduce 
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the volume needed for protection. 
Humanized mouse antibodies are also being evaluated at present. A study performed by Meissner in 
1999 used an antibody against the F protein, but the results were not favorable as no differences 
between placebo and treated were observed (Meissner et al., 1999). Another humanized antibody 
(MEDI-493) palivizumab was successful in clinical trials, shown by a reduction in hospitalizations 
(Subramanian et al., 1998). It has now been licensed and is used as prevention for RSV infections. 
Ribavirin is a broad-spectrum antiviral and has been used in treatment of measles, parainfluenza 
and hepatitis viruses. Ribavirin has many toxic qualities including the reduction of red blood cells 
(Fume et al., 2003). The Food and Drug Administration (FDA) has licensed aerosolised ribavirin 
for treating infants with RSV, but it has not been licensed for adults. It probably is not worth using 
as an antiviral because it is very expensive, difficult to administer and only slightly decreases viral 
load. However, ribavirin is known to decrease the length of hospitalization for patients with severe 
RSV related LRTI (Levin, 1994). 
Probably one of the most effective methods of preventing RSV transmission is isolating infected 
individuals. In order to reduce infections there should be avoidance of infected adults, and frequent 
hand washing. Day-care facilities are also often associated with RSV infections presumably because 
of potential for viral transfer and spread. Improved patient management results in fewer nosocomial 
infections by early identification of RSV infection (Karanfil et al., 1999). 
1.22 Aims of this project: 
1. There is little available published information concerning the molecular epidemiology of RSV 
in the Middle East, especially the Gulf region. Accordingly, it was proposed: 
a) to document the incidence of RSV infection in Qatar in children younger than 2 years of age; 
and 
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b) to use retrospective data to determine the effect of temperature, rainfall, humidity etc. on the 
incidence of RSV infection over a five year period (1994-1998). The results of this work are 
given in chapter 3. 
2. It has been hypothesised that the C-terminal region of the RSV G protein includes epitopes 
important for virus neutralisation and that loss or masking of the terminal amino acids can allow the 
virus to escape from antibody neutralisation. It was therefore proposed to investigate strain diversity 
of RSV G protein (especially RSV B) by: 
(a) analysing the distribution of RSV strains of A and B subtypes by Multiplex PCR of the NIP 
gene; 
(b) performing sequence analysis of the complete RSV G gene from representative isolates as 
well as clinical material from Qatar; and 
(c) comparing sequences from Qatar isolates with those from elsewhere. The results of this 
work are presented in Chapter 4. 
3. Finally, it was proposed to investigate the immunological responses to RSV B strain by: 
(a) synthesising overlapping peptides of the C-terminal region of the RSV B G protein and to 
perform epitope mapping with these peptides; 
(b) evaluating the reactivity to these peptides in acute, convalescent and sequential sera from the 
same individuals; and 
(c) determining any correlation between RSV neutralising antibody titre with anti-peptide 
reactivity in the same samples. The results of this work are given in Chapters 5 and 6. 
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2 Chapter 2: Materials and Methods 
Variation in RSV detection with season of the year 
2.1 Setting and Medical Care 
2.1.1 QATAR 
The state of Qatar lies half way along the western coast of the Arabian Gulf, with an area of 11,437 
sq. km. It has a moderate desert climate with long hot summer and short winter with little rain. The 
native population is about 500,000, most of whom live in the capital city (Doha), males 
predominate over females and the number of foreign expatriates exceeds the number Qatari 
nationals, most of whom come from the Indian subcontinent (HMC, 1994). 
2.1.2 HMC 
Hamad Medical Corporation (HMC) comprises three major hospitals, which are the main hospitals 
in the state of Qatar with a total capacity of 1292 beds. They are; Hamad General Hospital (660 
beds) encompassing the Departments of Medicine, Surgery, Paediatrics, in addition to specialised 
intensive care units and Cardiology and Dialysis units; the Women's Hospital (288 beds) with 
Obstetrics and Gynaecology and a Neonatal Care unit; and Rumailah Hospital, which provides care 
to the elderly and disabled people in Qatar. Thus all paediatric hospital attendance occurs at one 
hospital (HMC, 1994). 
2.1.3 Meteorological data collection 
The weather and climate data are recorded at Doha International Airport. The observatory is 
operated and maintained by the Department of Civil Aviation and Meteorology of the Ministry of 
Communication and Transport, State of Qatar (Long period Means and Extremes of 
Climatologically Element 1962-1998). The mean values of monthly temperature, evaporation, 
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relative humidity, total rainfall and wind speed were calculated from the data base for the study 
years (1994 - 1998). 
2.2 Study population and data collection 
The study population was all children presenting or admitted to HMC between November 1999 and 
April 2000 (a six-month period) and meeting the following population case definition: 
Lower respiratory infection (LRI) or acute bronchiolitis, presenting within five days of onset of the 
illness (Wright, 1996). 
Data analysis used Microsoft Excel. The data on admission, discharge and RSV incidence were 
obtained from Health Infonnation System (HIS) department at HMC. 
Parents and Ethical Committee agreement had been obtained before sample collection for this Qatar 
study project (Appendix 1). 
2.3 Sample collection 
Nasopharyngeal aspirates (NPA) were obtained from children presenting to HMC and meeting 
case definition on each working day during the study period. Wherever possible additional 
respiratory samples were collected from children found to be RSV Ag positive. Paired sera were 
also collected from previously healthy children in accordance with the Study protocol. NP A and 
serum samples were stored at -70°C until required. 
2.4 EIA (RSV Abbott Test Pack - Screening test) 
A method for the detection of respiratory syncytial virus that utilizes a solid phase enzyme 
immunoassay to detect viral antigen present in nasopharyngeal aspirates, washes and swabs was 
used. This was perfonned in accordance with the manufactures instructions for all samples received 
from the serology laboratory at HMC and for all NPA samples. 
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2.5 PCR (Multiplex PCR - Confirmatory test) 
A nested Multiplex Rt-PCR containing primers for detection of Influenza A (HIN!, H3N2), 
Influenza B and RSV A and B (nucleor protein), which has been developed for detection of these 
viruses in respiratory samples at CPHL, was used to analyse the samples assayed positive by the 
ABBOTf Test Pack and also to assay negative samples (Ellis et al., 1997). 
All PCR work was carried out in conditions designed to prevent the occurrence of carry-over 
contamination. Nucleic acid extraction, PCR reaction mixes set-up, thermo cycling and gel analyses 
were all conducted in separate rooms. Transfer of primary product to the secondary reaction mix 
was done at a PCR workstation, which was equipped with UV light. Each room had dedicated 
equipment and clothing, and all pipette tips used were plugged to prevent any possibility of 
contamination. All work was carried forwards from RNA extraction through gel analysis of the 
final peR amplicon. Each run consisted of 24 samples with negative controls after the sixth sample. 
Runs were validated when all the negative controls were negative and all the positive controls were 
positive, with products of the correct size. 
Nucleic acid extraction 
RNA was extracted from a l001l1 volume of each sample (clinical specimens) by the guanidinium 
thiocyanate-silica binding method (Boom et al., 1990). The clinical specimen was added to a tube 
containing 835 III oflysis buffer (120g guanidinium thiocyanate, l00ml 0.1 M Tris-HCI, pH6.4, 22 
ml 0.2 M EDTA pH 8.0, 2.6 g Triton X-I (0) and 15 Jll of silica suspension, mixed, incubated for 10 
min at room temperature. The RNA bound to the silica was washed twice with 1 ml buffer L 2 
(120g GuSCN, 100 ml 0.1 M Tris-HCI pH6.4), twice with 1 ml of 70% (vol./vol.) ethanol, once 
with 1 ml acetone and then dried at 56°C for 10 min. RNA was then eluted with 30 III of RNAse 
free water and 1Jll ofRNasin enzyme and converted into cDNA by RT-PCR. For reverse 
transcription, 22.2 III of RNA were added to a reaction mixture (17.8 Jll) containing 20 mM Tris-
HCI (pH 8.4), 50 mM KCI, 7.5 mM MgCI2, 1.5mM of each dNTP, 25 ng of random primer pdN6 
57 
(Pharmacia), 1.6 ,.11 of RNasin (Promega) and 200 U Moloney murine leukemia virus reverse 
transcriptase (Gibco BRL). The reaction was incubated at room temperature for 10 min, 37°C for 45 
min, 95°C for 5 min and quenched on ice (Boom, 1990; Gibson, 1993). 
The primary primers used were (AH 1 A and AHI PIl for FLU HI, AH3 A and AH3 OIl for FLU 
H3, BHA A and BHA OIl for FLU B, RSV 548 and RSV 1366 for RSV A and B) (Stockton et al., 
1998). 
The secondary primers used were (AHl Band AHI Ell for FLU HI, AH3 Band AH3 CIl for FLU 
H3, BHA B and BHA CIl for FLU B, RSV 783 and RSV 1117 for RSV A and RSV 783 and RSV 
966 for RSV B (Stockton et al., 1998). Each primer pair was used at 5pmol in the primary 
amplification and 2.5 pmol in the secondary amplification reaction. For the primary PCR, 20 J.ll of 
cDNA was added to 80 Jll of reaction mix containing lO-mM Tris-HCI pH8.8, 3.5 mM MgCh, and 
2.5mM KCI and 1.5 JlI Taq polymerase. Amplification, using a DNA Engine thermocycler (T3 
from Biometra), consisted of 1 cycle at 94°C for 2 min, followed by 35 cycles of 94°C for 1 min, 
50°C for lmin, and 72°C for 1 min. Two Jll of primary product were transferred into 48 ul of 
secondary amplification mix (as above with 0.2 mM each dNTP) 'The samples were then incubated 
for one cycle 94°C for 2 min, then 35 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min. 
Agarose gel electrophoresis 
For multiplex PCR amplicon analysis, 15 Jll of PCR product were mixed with 2 1-'1 Orange G 
loading buffer (0.25% Orange G + [10% Ficoll in TE (10 mM Tris, pH 7.4, I mM EDTA]) and run 
on a 1.2 % agarose gel (S B Fine agarose gel, from Seven Biotech LID) in Ix TBE (89-mM boric 
acid, 2 mM EDTA, pH8.4). The amplicons were visualized using ethidium bromide staining and 
photographed using a Polaroid camera. 
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G gene sequencing 
2.6 RSV G primer designs 
Primers were designed both by eye and using OLlGO 6-primer design software. The sources of 
sequences which were used to design these primers were those deposited in GENEBANK (RSV A2 
strain, isolated 1968, assigned accession number AF035(06), (Whitehead et al., 1998), and also 
described in the following publications: (Wertz et al., 1985); (Cane & Pringle, 1991)for RSV A and 
(Roca, 2001 ; Taylor, 2001) for RSV B. Primers were designed to amplify and sequence the 
complete G gene for both RSV strains Aand B. Different sets of primers were designed to be as 
similar as possible in their physical and chemical characteristics. They were around 20 bases in 
length, with a 50% G+C content and annealing temperature 45°C - 60°C. 
2.7 RSVGPCR 
At the beginning, nested amplification was performed with concentrations of 5 pmol of primers in 
the primary reaction and 2.5 pmol in the secondary round reactions. In the primary PCR, 20 J..lI of 
serial dilution cDNA of QatarlRSV Al2000/10 were amplified in a 100 J..lI final volume containing 
PCR buffer (20 mM Tris-HCI pH 8.4, 50 mM KCI, 1.5 mM MgC}z) 0.2 mM each dNTP and 1.5 J..lI 
Taq. For the second round reaction, 2 J..Ll of the primary product were transferred into 48 J..lI of the 
above mix with 0.3 J..lI of Taq. Cycling conditions consisted of 2 min at 94°C, then 35 cycles of 
94°C for 1 min, 50°C for 1 min, 72°C for 1 min, for both rounds of amplification. 
2.8 Optimization of the RSV G PCR 
2.8.1 Biochemistry optimization 
AlQIlO/OO which gave a strong band at dilution of (11100) was used to test 12 different Stratagen 
Optiprime buffers (see Appendix 2 for composition of buffer). 
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2.8.2 Annealing temperature optimization 
Starting from the best buffer result, the annealing temperature (Ta) for primer length around 20 
bases was calculated by using the following equation 
Ta= 4(G+C) + 2(A+T) (Dieffenbach, 1993) 
2.9 Gel purification 
PCR products were excised from the agarose gel using a clean scalpel and purified from the 
agarose using QIAquick gel extraction columns (QIAGEN) according to the manufacturers 
instructions and stored at -20°C. 
2.10 Sequencing 
RSV A and B PCR amplicons were sequenced using the secondary primers with 3.2 pmol 
concentrations. Sequencing was performed using dye deoxy terminator chemistry and cycle 
sequencing (Perkin Elmer) according to the manufacture recommendations Samples were run on an 
Applied Biosystems 373 A sequencer (ABI sequencer). The sequencing gel was 40% Acrylamide 
gel (25 g of urea (from Sigma), Ig of Resin AG 501-x8 (D) (from Bio RAD) and 7.5 of acrylamide 
(fromBio-Rad laboratories) made up to 45 ml with distilled water, which was then filtered by using 
50mm filter unit (from Nalgene), finally 250 ~l of 10% ammonium persulphate (ASP from 
Amresco) and 22.5 III of TEMED (from Sigma) were added to the gel solution. Gently and evenly 
the gel was squirted along edges of ABI sequencer avoiding air bubbles. Sequencer plates (after 
proper cleaning by water, dionised water and 100% ethanol to dry) were fixed by clips (heating 
block was adjusted to 95°C). After 2 hours the clips were removed and lxTBE (Tris Boric acid 
EDTA) buffer were added to the machine. To prepare samples for loading, each sample (including 
PCR sequencer controls) was mixed with 5:1 deionized formamide: EDTA (125 III deionized 
formamide to 25 III EDTA 50mM!De tran Blue 50mglml) and incubated for 2 minutes at 95°C, 
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then placed on ice for one minute, then spun briefly before loading into the sequencer. The type of 
run was a full scan that took 14 hours. 
2.11 Sequence analysis 
Output files from the 373 A sequencer were imported into SeqED (Applied Biosystems) for 
comparison of forward and reverse sequence. 
Unreliable data were removed from the beginning and end of the sequence. Edited files were 
transferred to the EditSeq programme (Lasergene, DNA Star). From this format the sequences were 
exported into MegAlign (Lasergene, DNAStar) where they were placed in frame and aligned using 
the Clustal method. The Clustal method groups sequences into clusters by examining sequences 
between pairs. The clusters are aligned as pairs, then collectively as sequence groups to the overall 
alignment. After the multiple alignments are completed, a neighbour joining method is employed to 
construct phylogeny. Sequences were trimmed to be of the same length for each sequence product. 
Sequences which were aligned in MegAlign (Lasergene, DNAStar) were exported in a Paup format 
and converted into a Phylip format using the program Readseq. The output files were used to 
perform the Bootstrap test by two methods,Parsimony and distance for each phylogeny tree in an 
attempt to see how stable the internal nodes of these trees are by deleting random positions in the 
alignment and duplicating others to keep the total number of positions the same. The best tree was 
then recalculated. This was repeated many times (usually> 100) and the number of times a specific 
cluster was seen was counted. Dr. Graham Clark at the London School of Hygiene and Tropical 
Medicine kindly assisted with the bootstrap analysis. 
2.12 Peptide synthesis 
Fifteen overlapping synthetic peptides (1-15) representing amino acid sequence 149-299, of the G 
protein of RSV (B/Q/28/00). This sequence includes the C-terminal region with two variable 
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regions separated by the most conserved region in both sUbtypes A and B and excludes the 
transmembrane region. The peptides were numbered 1 through 15 starting from the COOH-
terminus of the sequence. Peptide 16 represents the most conserved region only and peptide 17 
contains the amino acid sequence that has a 4 cysteine noose. Peptides (13, 14, 15, 16, 17) were 
synthesized by a Pioneer Peptide Synthesis System (Perceptive Bio systems) at LSHTM and the 
remaining commercially by Peptron Ltd (Seoul, Korea) using same system. 
2.12.1 Reagents 
All synthesis solvents were of analytical grade. Fmoc-protected amino acids, the polyethylene 
glycol graft polystyrene (PEG-PS) and HA TU were purchased from Novabiochem. 
Dimethylformamide (DMF) was purchased from Rathbum Chemicals. Piperidine, N, N-
diisopropylethylamine (DIPEA) from Fluka and triisopropylsilane were purchased from Fluka. 
DMF was stored over type 4A molecular sieves (BDH) overnight before use and checking for 
acidity by mixing a few drops of DMF with Bromophenol blue (200mg/2ml of DMF), which should 
stay yellow. 
2.12.2 Peptide assembly: 
Synthesis was performed on polyethylene glycol polystyrene grafts (PEG-PS) resin cartridge. The 
required amount of resin was first allowed to swell by adding 20ml of DMF and then packed in the 
cartridge where the peptide was to be assembled. The synthesis proceeds from the carboxyl 
terminus to the amino terminus of the peptide. Converting it to its ester form with DIPEAlHATU 
prior to coupling with the N-amino group of the preceding amino acid activates the carboxyl moiety 
of each incoming amino acid. The temporally protecting group of the N-amino moiety was removed 
at the beginning of the next synthesis cycle by flushing 20% (v/v) of piperidine in DMF through the 
column. Excess piperidine was washed out with 12-column volumes of DMF. The machine then 
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prepared the activated amino acids and introduced them into the sample loop at the correct time. 
The amino acids were dissolved in the activator solution in sufficient quantity, as calculated by the 
standard scale program to yield 0.059mmol of amino acid solution. This was achieved by 
reweighing 0.8mmol amino acids containing RA TU to provide the required four-fold excess of 
amino acids. This generated the maximum possible yield and highest quality of the final product. 
The washing step was carried out after each step of Fmoc removal or coupling of each amino acid. 
In addition, reactive side chains on the amino acids were protected with permanent protecting 
groups. Repeating the synthesis cycle until the last amino acid was assembled extended the peptide 
chain. At the end of the synthesis, the peptide was assembled in association with the resin. The 
peptide-resin was transferred to a sintered funnel and then subjected to successive washing steps 
with Propan-2-01 and scavengers in the presence of KOR, followed by a drying step using a water 
vacuum. At the end of the synthesis, the side chain-protecting groups were removed. 
2.12.3 Peptide-resin cleavage 
Peptide was cleaved and side chains deprotected by rocking in 95% Trifluoroacetic acid (TFA from 
Romil) and 5% scavengers depending upon the amino acid sequence, for approximately 2 hours at 
room temperature. Water was use as a general scavenger, but for Methionine and Cysteine 
containing peptides ethanedithiol was used. The resin was then filtered, washed well with cleaving 
solution and rotator evaporated to oily residues. The peptides were precipitated by the addition of 
cold diethyl ether (30-40 ml). After 3 washing times with diethyl ether, the peptide was dried and 
the white powder was collected and stored at -20°C for further use. Peptides for which special 
chemicals were used as scavengers were dissolved in distilled water/acetic acid and extracted with 
ether twice, the organic phase was back-washed with water and the aqueous phases, which 
contained peptide, were collected and lyophilised. 
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2.13 Peptide Characterizations: 
2.13.1 High performance liquid chromatography (HPLC): 
The purity of the peptides was assessed by HPLC to exclude contamination with deletion products 
and to ensure the presence of a single peak of the major product. Using a Shimadzu system witha 
perfusion reverse phase column (Poros 4.6mmx 10 cm: PerSeptive Biosystems). The column was 
previously washed with 100% HPLC grade methanol (Rathburns, Scotland) then equilibrated with 
initial buffer: 5% buffer B in buffer A. [Buffer A = 0.1% TFNHPLC grade H201 acetic acid. 100 III 
of this was injected on to the HPLC column and eluted with a 5- 70% B gradient over 15 minutes at 
a flow rate of 9 ml/minute detected by UV 214 nm. I thank Dr Patrick Corran at LSHTM for help in 
making these purifications. 
2.13.2 Mass spectrometry: 
The molecular weights of all synthetic peptides were determined by mass spectrometry performed 
by Peptron Ltd (Seoul, Korea) using an HP 1100 series LCIMSD spectrometer. 
2.14 Optimization of solid-Phase ELISA 
Two human serum samples (one from a recent RSV infection (confirmed by PCR» with high RSV 
antibody titres and peptide 11 from RSV F protein, which was highly reactive with human serum, 
were used to standardize the ELISA technique. 
Four different plates (IMMULON 1, IMMULON 2, IMMULON 4 and NUNC) were coated 
overnight at 4°C with SOil I per well of a 51lglml solution of peptide in 0.1 M carbonate- bicarbonate 
buffer (pH 9.6). The plates were blocked with 4 different blocking reagents (1 % gelatin, 5% milk 
solution, 1 % bovine serum albumin/phosphate buffered saline (BSA-PBS) and 1 % fetal calf serum 
(FCS». Serial twofold dilutions of serum in 0.05% Tween 20 of corresponding blocking solution 
(final volume SOil I) were added to the plates, which were incubated at 37°C for 1 hr and then 
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washed. Fifty microliters of a 111 ()()() dilution of peroxidase ~onjugated goat anti- human IgG 
(DAKO) was added to each well and the plates were incubated for 1 hr at 37°C. Unbound 
conjugate was removed by washing and SOil I of 0.04% o-phenylenediamine-hydrogen peroxidase in 
citrate/phosphate buffer was added to detect bound enzyme. The reaction was stopped after 10 
minutes by the addition of 25 ~l of 2 M sulphuric acid per well and absorbance (A492) was 
determined in an automatic plate reader (Dynex MRX). 
2.1S Peptide screening assay 
Different samples were used to test peptide reactivity. Qatar study sera collected before and after 
the infection during 2 seasons (35 samples), neonatal sera (mainly maternal antibodies, 20 samples) 
and adult serum (6 samples). 
IMMULON4 plates were coated with peptides (1-17) [5J.1g/ml in O.lM carbonatelbicarbonate buffer 
pH 9.6] 50 J.11 per well and incubated overnight at 4°C. The following day, the plates were blocked 
with 1 % BSA-PBS solution, serial twofold dilutions of serum in 0.05% Tween 20 in blocking 
solution (final volume SOil I) were added to the plates, which were incubated at 37°C for 1 hr and 
then washed. The rest of work was as described in the above section. 
2.16 Inhibition assay 
Further investigations were carried out using peptide 14 that was recognized by the majority of sera 
to find out if this part of the RSV B G protein was bound with high affinity by these sera, which 
might suggest that it is immunogenic. 
Sera from Qatar children (Q20, 28 and 37) before and after infection with RSV were used. Sera 
from all these children showed increasing levels of neutralizing antibodies after infection. 
The experiment discussed here was designed to determine if there was an increase in affinity of 
binding to peptide 14 (affinity maturation) following an infection. The inhibition assay (Rath et al., 
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1988) was used. The inhibition of binding to RSV Ag in the presence of peptide 14 was measured. 
Peptide 9 (non-reactive peptide) was used as a negative control and RSV antigen as a positive 
control (RSV Ag is a long strain of RSV grown on a monolayer of MA (Meth A) cells) from 
Biogenesis). The free peptide concentration of peptides 14 and 9 as well as the concentration of 
RSV Ag and the serum dilution that would be used in this assay were previously determined for this 
experiment. 
The serum dilutions to be used had been determined using RSV Ag (at 31lg/ml)- coated plates at the 
dilution that gave an OD reading of 0.7 (i.e. dilutions 1140 and 1120 were used for sera Q20 before 
and after, respectively, dilutions 1120 and 1/320 were used for sera Q28 before and after 
respectively and dilutions 1120 and 11160 were used for sera Q37 before and after, respectively). 
Three IMMULON4 plates were coated with RSV Ag 31lg/ml in O.IM carbonatelbicarbonate buffer 
pH 9.6, 50 III per well and incubated overnight at 4°C. The following day, plates were blocked with 
1 %BSA-PBS solution for 2hours at 37°C, and washed 5 times with tap water. 21 III of diluent 
(1 %BSAlPBS/0.05% Tween 20) were placed in each well. Three inhibitor concentration were used 
[10111 of Img/ml of pep tides 14 and 9 or 61lg/ml ofRSV Ag +21 !J.l of diluent] were added to 
appropriate 8 wells and were titrated across the plate using half log dilutions. 25 III of the 
representative serum dilution were added to appropriate wells. The remaining steps were similar to 
the Solid Phase ELISA assay described in section 2.15. 
From the inhibition assay the log concentration of peptides (14 and 9) and RSV antigen, which 
required to inhibit 50% of the maximum binding as an index of affinity was obtained. 
2.17 Virus isolation 
2.17.1 Cells 
Hep-2 cells were obtained from the European Tissue Culture collection (ETCC). Cells were grown 
in growth medium (minimal essential medium (MEM)(Gibco-BRL) supplemented with 10% FeS at 
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37°C in a 5% C02 incubator. Cell counts were performed and cells were seeded at 5 x 104 cells/ml 
to give 80-90% confluence the next day. 
2.17.2 Virus growth 
2.17.2.1 Control RSV strains 
Four RSV strains were used in the development of RSV enzyme immunoassays, neutralization 
tests and for PCR controls (RSV A long and A2 strains from American Tissue Culture Collection 
(ATCC), RSVB VS 907 and RSVB VS 1039 95-9085. (Kindly supplied by Dr. Pat Cane of 
Birmingham University) and RSV B N2 (from ATCC). Prior to infection with RSV, 5x104 Hep-2 
cells were grown overnight to 80% confluence and medium removed prior to inoculation. Virus 
containing medium was gently dispersed over the whole cell sheet and the culture was incubated at 
37°C for 2 hours. Every 30 minutes, the flask was gently rocked to disperse the medium and then 
rotated in the incubator for even distribution of virus over the cell sheet. A control flask was set up 
in the same way with 2 ml of MEM 2% FCS. After 2 hours incubation, excess virus stock was 
removed from the flask and replaced with 20 ml 2%medium. The flasks were then incubated at 
37°C in an atmosphere of 5%C02 in air and examined daily for the presence of a typical CPE and 
the formation of syncytia. When 75% of the cell sheet was affected (2-4 days for RSV A and 3-4 
days for RSV B post infection) the contents of the flask were harvested using a cell scraper to 
remove the cell sheet from the flask. The contents of the flask were then pooled and gently 
dispersed prior to aliquoting into suitable amounts on ice and stored at -70°C for subsequent use. 
2.17.2.2 Field strains Isolated from Qatar samples: 
RSV positive NPA samples from Qatar were inoculated onto 80% confluent monolayers of Hep-2 
cells and incubated at 37°C, and monitored daily. The infected cells were passaged when the viral 
CPE showed 60-70% of cells infected. Qatar isolates were named with an initial letter indicating 
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sub type (either RSV A or B). The next number indicates the year that the sample was collected (99 
or 2(00), the following number indicates the study sample number (e.g. Qatar/ RSV Al2000/1 0). 
2.17.2.3 Preparation of isolate for electron microscopy: 
The isolate was grown as previously described, the supematant was removed and the cells were 
covered with 3% phosphate buffered glutaraldehyde (12ml of 25% glutaraldehyde and 88ml of 
Modified Millonigs Phosphate buffer [18.76g sodium dihydrogen phosphate, 4.28g sodium 
hydroxide and 11itre of H20]) overnight at room temperature. Mr.Bart Wagner from the Northern 
General Hospital performed the electron microscopy. 
2.18 Virus titration 
A checkerboard design was used to determine the optimal virus dilution of the control strains and 
isolate of RSV and the optimal primary and secondary antibody dilutions. Hep-2 cells were seeded 
at 5x104 cells/ml in minimal essential medium (MEM) (Gibco-BRL) containing 2% foetal calf 
serum in 96 well microtitre plates (Greiner Labortechnik) and incubated overnight at 3TC in an 
atmosphere of 5% C02 in air. 100 J.11 of each virus dilution were added in duplicate to wells 
containing cell monolayers. The plates were sealed and centrifuged by Sorval Refi Centrifuge at 
1,500 rpm for 45 min at 37°C and incubated at 37°C for 1 hour 15 min. Samples were aspirated 
from the wells and replaced with MEM medium containing 2% foetal calf serum and further 
incubated for 3 days at 37°C in 5% C02. The medium was removed from the plates and the cells 
washed with cold phosphate buffered saline (PBS) prior to fixation for 20min with absolute 
methanol contains 2% (voVvol) hydrogen peroxide. 100 J.11 of 5% milk solution (Marvell: dried 
skimme milk) in PBS were added to each well for 30 min. 
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Virus infected cells were detected by the addition of polyclonal goat anti-RSV antibody (Chemicon 
Inc. USA) diluted 1: 1000 in 5% milk for 1 hour at room temperature. Wells were washed with 5% 
milk solution in PBS for 30 min. 
Rabbit anti-goat horseradish peroxidase (HRP) conjugate (Chemicon Inc. USA) diluted 1: 2000 in 
5% milk was added to each plate, incubated for a further hour at 37°C. After washing four times 
with PBS using a Denley washer, WOllI of 3,3' diaminobenzidine (DAB Wmg/ml), PBS 40 ml and 
30% H202 13.3 ml) substrate was added to each well and incubated at room temperature for 30 
minutes. The substrate was removed and wells were washed 2 times with sterile water. Wells were 
examined under the microscope. Each plaque appeared as a brown cell/syncytia. Infectious foci 
were counted in each well of each serial dilution. The serial dilution of virus that gave 100 (or the 
maximum) number of plaque per well was used to calculate the number of infectious foci per ml 
(pfu) for each strain (Chapter 6, section 6.5 Final RSV micro neutralizing assay). 
2.19 Evaluation and standardisation of cell based foci forming unit assay of RSV using DAB 
2.19.1 Monoclonal antibodies: 
Selection of both commercial and non-commercial monoclonal and polyclonal antibodies was 
achieved using a cell - based ELISA with DAB substrate as previously described. The best 
conditions were selected for use in the neutralization assay (described below). 
2.19.2 Incubation periods: 
Different incubation periods were tested for virus growth (I, 2,3,4,5 or 6 days). 
2.19.3 Fixation methods: 
Two types of fixation reagent were tested, absolute methanol containing 2% (vollvol) hydrogen 
peroxide or absolute methanol containing 50% (vollvol) acetone. 
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2.20 Preparation of neutralizing rabbit anti sera 
To prepare crude culture supernatant 2 RSV strains (RSV-A (strain long) and RSV-B (strain Vs 
1039» were grown in Hep-2 cells as previously described and then harvested (supernatant and 
cells) into 20 ml universal plastic tubes. They were centrifuged in a bench centrifuge (MSE 
centrifuge; 2000 rpml20 minutes) and the supernatant was removed from the pellet. The pellet was 
resuspended in 2-3 ml of normal saline, centrifuged for 1 hour, finally the supernatant was removed, 
and the pellet was dried and resuspended in 200JlI of saline. The supernatant from the first 
centrifugation step was transferred into Ultra-Clean centrifuge tubes. The tubes were centrifuged at 
28000 rpm at 4°C for 2 hours (BECKMAN ultra centrifuge SW27 rotor). The supematant was 
removed and the tubes were inverted for 10 minutes to dry. lOOJlI of saline was added to the whitish 
pellet layer and it was sonicated for 30 minutesin a Grant ultrasonic bath. This crude culture 
supernatant of HRSV-A (long strain) and RSV-B (strain Vs 1039) was used to immunise two 
rabbits. Blood samples were taken before and at 2 weeks after immunisation. 
2.21 Evaluation of different dilutions of serum 
Two human serum samples were used to determine the best serum dilutions to use in the 
neutralization assay (2-fold and 4- fold). 
2.22 Micro neutralization test 
Neutralization antibodies were determined by a modification of the micro neutralization method of 
Anderson et al.(1985). RSV A and B virus stock was diluted lO-fold in MEM medium. Twofold 
dilutions (starting at 1:5) of test sera were incubated with 100 50% tissue culture infective doses of 
RSV A (A2 andAlQ/lO/OO) and B N2 strains for 2 hours at 37°C in 5% CO2 of 96-well plate. The 
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Hep-2 cell monolyers were fixed after 3 days of incubation and cell based ELISA assays were 
performed. Plaques (representing syncytia) and cytopathic effects were to a dilution of 10-3 with 
RSV A and up to a dilution 10-2 for RSV B. The mean plaque count was 80 for strain A and 40 for 
strain B. Therefore, the titre of the virus stock was estimated as: 
Number of plaques x reciprocal of the dilution x 1/ vol. of inoculum, viz. 
RSV A pfu/ml = 80 x 103 x 1/0.2 = 4 x 105 
RSV B pfu/ml = 40 x 102 x 1/0.2 = 2 x 104 
The expression of viral antigen on the Hep-2 cells was detected by the cell-based foci forming unit 
assay for RSV using DAB substrate as previously described with a primary antibody to a mixture of 
3 RSV proteins F, G and P (MAB858-4 from Chemicon) for RSV A strains and RSV G protein 
(MAB858-2 from Chemicon) for RSV B strains and anti-mouse horseradish proxidase (from Dako). 
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3 Chapter 3: The seasonality of RSV infection in Qatar 
3.1 Introduction: 
RSV is a well-recognized cause of acute lower respiratory tract infection (ALRI) in early childhood 
and accurate estimates of invasive RSV diseases have been obtained in several industrialized 
countries (Weber et al., 1998b). However, little is known about RSV infection in tropical and 
developing countries. 
RSV spreads via infected respiratory secretions and transmission occurs mainly through direct close 
contact with infected individuals or contact with surfaces contaminated with respiratory secretions. 
RSV can survive on clothes for about 30 minutes and on smooth surfaces like countertops and 
stethoscopes for several hours (Blydt-Hansen et al., 1999). RSV can cause respiratory tract 
infections of patients in any age. Clinically severe RSV infections are mainly found in the very 
young, presumably at their first infection. Reinfection with RSV is common with a milder clinical 
course and the infection usually remains limited to the upper respiratory tract. Frequent reinfections 
enable RSV to remain highly prevalent in the population. At least 50% of children are infected 
during their first winter. By two years of age, almost all children will have been infected at least 
once and over 50% will have been infected twice (Henderson et al., 1979). RSV infection is 
seasonal in most countries, outbreaks occur most frequently in the cold season in areas with 
temperate and Mediterranean climates and in the wet season in tropical countries with seasonal 
rainfall (Weber et al., 1998a; Weber et al, 1998b). RSV infection is also now well documented as a 
cause of yearly winter epidemic of acute lower respiratory tract diseases (ALRI), including 
bronchiolitis and pneumonia. 
In developing countries there are few population-based estimates of the incidence of RSV disease, 
where RSV infections may follow a different pattern (Videla et al., 1998). Viral infections have 
been found to cause a median of 37% of LRI. Among viral etiologies, RSV is the most frequent, 
causing a median of 18% of LRI. Applying this proportion to the incidence of etiological agents of 
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LRI, the estimated incidence of RSV -associated LRI is 97 to 180 episodes per 1000 children / year 
(Wright, 1996). 
Generally, the proportion of those infected world-wide that do not develop symptoms is unknown, 
however, in industrial areas of Britain, studies of urban population have estimated that 25/ I 000 
infants would develop severe RSV bronchitis and require hospital admission and about 3% of these 
develop respiratory failure and require ventilation (Smyth et al., 1997; Stott & Taylor, 1985). 
Factors, which may influence the incidence and severity of RSV -associated disease in developing 
countries, are passive smoking, malnutrition, asthma, HIV infection, and over crowding (Wright, 
1996). 
Other epidemiological factors that could explain the reported variation in disease severity are 
environmental factors such as air quality, which may exert an influence on RSV infection by 
modulation of the infant's capacity to respond to pulmonary disease by compensatory 
hyperventilation. Parental smoking also increases the risk and severity of RSV infection. It is 
important to define the role of air humidity or temperature, either indoors or outdoors, of industrial 
air pollution, as this may contribute to excess cardiovascular deaths among adults or elderly 
patients, and could affect the capacity of young infants to cope with respiratory infection 
(Brandenburg et al., 1997). 
Asthma is another factor that may relate to RSV infection. Asthma is a lung disease with the 
following characteristics: airway obstruction that is reversible, spontaneously or with treatment, 
airway inflammation, and increased bronchial responsiveness to a variety of stimuli (Dawod & 
Hussain, 1995). Little is known about the link between RSV infection in infancy and subsequent 
asthma in developing countries (Weinberger, 2(03). Two studies from the Gambia (Weber et al., 
1998a) and Qatar (Dawod & Hussain, 1995) noted frequent wheezing episodes in children after 
RSV infection. A possible explanation is the release into the airways of leukotrienes, which usually 
induce airway obstruction (van Schaik et al., 2000). 
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The aim of this part of the work was to document the incidence and seasonality of RSV in Qatar 
among previously healthy children under 2 years of age. The following methods were used in an 
attempt to achieve the aims: 
Collection and analysis of weather statistics; 
Comparison of two RSV detection methods (EIA and reverse transcriptase (RT) -PCR) for 
screening; and 
Retrospective analysis of viral detection data; 
Prospective analysis of clinical samples from children admitted with a clinical case detection 
compatible with acute respiratory infection; 
Correlation of prospective, retrospective and viral detection data with weather statistics to 
determine the relationship of some weather parameters to RSV incidence in a 5 year period; and 
Setting up a PCR laboratory at HMC, during 2 RSV seasons of the study period, for the 
identification of RSV subtypes by RT-PCR. 
3.2 Results: 
3.2.1 Epidemiological and clinical results: 
As described in the Materials and Methods, all hospital admissions in Qatar took place through a 
single hospital. The total number of admissions to the Pediatric department of HMC over the 6 
month period, from November 1999 to April 2000 was 10,435. These included emergency and 
elective admissions. The main causes of hospital admission, compiled from the health information 
system of the hospital episode statistics and based on primary admission diagnosis are shown in 
Figure 3.108. The sex distribution for admissions of all children under 14 years was 64% male. 
Diseases of the respiratory system accounted for the majority of admissions (53%) in this age 
group, with bronchitis and pneumonitis as the primary diagnoses. The most common secondary 
admission diagnosis was bronchiolitis as shown in Figure 3.t.h. Enteric infectious disease 
accounted for only 7% of admissions in this age group. 
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Figure 3.1: Distribution of the main (a) & secondary (b) causes of hospitalization among 
children in the Pediatric Department at HMC with total number 10,435 (November 1999 to 
April 2000). 
17% 
5% 
7% 
• Enteric infectious & parasitic Diseases . 
• Disease of respiratory system. 
Diseases of circulatory system. 
o Diseases of genitourinary System . 
• Injury and poisoning 
53% 
(a) Diseases of the respiratory system were the main reasons for the admiss ion of 
children. 
Bronchiolitis • Pneumonia . Asthma • Sepsis Acute tonsillitis Unknown 
(b) Bronchiolitis was the main respiratory disease causes children admission. 
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3.2.2 Seasonal distribution of RSV in Qatar 
An estimate of the seasonal variation of RSV in Qatar was prepared using retrospective data 
collected from the HMC hospital microbiology/serology diagnostic laboratory over a 5year period 
(1994-1998). The respiratory samples analysed by the hospital laboratory were primarily 
nasopharyngeal aspirates (NP As) obtained from children of all ages admitted for diseases of the 
respiratory system. Detection was performed using a rapid antigen detection test (EIA Abbott Test 
Pack) (Chapter 2 section 2.5). It is clear that there was a marked seasonal distribution of RSV 
detection (Table 3.1 and Figure 3.2). 
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Table 3.1(a&b): Seasonal distribution of distribution of RSV detection 
Total Number of RSV pos. by EIA 
Month samples (%) 
January 595 200 (33.6) 
February 316 88 (27.8) 
March 185 37 (20) 
April 125 19 (15.2) 
May 93 12 (12.9) 
June 93 17 (18.3) 
July 71 14 (19.7) 
August 71 18 (25.3) 
Se~tember 79 40 (30.6) 
October 131 40 (30.6) 
November 295 159 (53.9) 
December 470 221 (47) 
(a) Total number of NPA samples and incidence of RSV during the 5 year period (1994 - 1998). 
Correlation of RSVI some 
weather elements Coefficient values R P-values 
Monthly mean temperature - 0.7384 0.006 
Mean relative humidity 0.7628 0.0039 
(b) Statistical analysis of the correlation between the incidence of RSV and some weather elements 
by Chi-Sequared test. There is a highly positive correlation between RSV detection and the mean 
relative humidity with a significant P-value, while there is a negative correlation between RSV 
detection and the monthly mean temperature with a significant P-value 
77 
Figure 3.2: Monthly distribution of RSV positive cases shown with meteorological data over a 5 year period 1994-1998 
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78 
RSV detection from April to September over a 5-year period was low. The incidence 
of RSV gradually increased from October to March peaking in November. 
Meteorological indices accumulated over the same 5-year period are also displayed in 
Figure 3.2. The monthly mean temperature was highest (25-35 QC) during the 
summer months (April to October) and fell to a low in January and February (17-
20QC). The total rainfall occured during the winter months only, between October and 
March. However, an unusually high rainfall in March 1997 distorted the average 
figures for rainfall in March. The average annual range of mean relative humidity 
remained fairly constant over the year with slight peaks in December and January The 
mean evaporation was highest during the summer months (April to September) and 
fell to a low in January and February. The peak of mean relative humidity 
significantly coincided with the peak of RSV incidence (with P-value and correlation 
value (R) respectively 0.0039 and 0.7682), and there was a significant inverse 
correlation between the monthly mean temperature (P = 0.0061 and R = -0.7384) and 
RSV infection. 
3.2.3 Samples 
NPA samples were collected during two seasons. In the first season 1999-2000 
samples were collected from November - April and the second season 2000-2001 
samples were collected from December - April. 
Age distribution of RSV infection 
A total of 418 NPAs were taken from children under 2 years of age (58% male) as 
part of routine diagnostic procedures at admission over this period of time (first 
season: November 1999 to April 2(00). The rate of RSV detection decreased with 
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increasing age of the children sampled (Figure 3.3), with 62% of positive RSV 
detection in males, reflecting the admission and sampling bias. 
3.2.4 Comparison of detection methods for RSV 
418 NPA samples were taken from 418 pediatric patients admitted with respiratory 
tract infections over the study period. 148 NPA samples (35%) were positive for RSV 
by EIA and multiplex peR and 182 samples (43.5%) were negative by both tests. Of 
the remainder, 79 samples were RSV positive by peR but negative by EIA and 9 
samples were positive by EIA but negative by peR (Table 3.2). 
Using peR detection as a gold standard, the sensitivity of the RSV EIA was 
calculated to be 74%, and the specificity 95.5%. These data therefore confirm the 
validity of using the EIA results to determine seasonality of RSV in Qatar, but 
indicate that it will underestimate the total number of RSV cases. A typical gel of the 
results of peR is shown in Figure 3.4 with sub type A giving an amplicon size of 
344 bp and subtype B giving an amplicon size of 138 bp. 
3.2.5 Screening samples 
A total of80! NPA samples were collected during two RSV seasons (Tables 
3.3.a&b). There was no mortality among the RSV positive children during the two 
seasons. 
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Figure 3.3: RSV positive detection (by EIA and PCR) among children of different 
ages during time for first season. RSV detection significantly decreased with 
increased age. 
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Table 3.2: Comparison of EIA and peR for RSV detection in clinical samples during 
first season of the study. 
EIA (+) EIA (-) Total 
PCR (+) 148 79 227 
PCR (-) 9 182 191 
Total 157 261 418 
Although, 79 samples were positive by RT-PCR and negative by EIA, EIA sensitivity 
and specificity comparing to the RT-PCR were 74% and 95.5% respectively. 
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Figure 3.4: Typical gel image of RT-PCR result obtained. 
Fragment sizes are RSV A = 344 bp, RSV B=138bp, Flu HI (influenza A (HINI)) = 
944 bp, Flu H3 (Influenza A (H3N2)) = 591 bp and FLU B (Influenza B) = 767 bp. 
(N) Negative controls were placed after every 6 specimens and the positive controls at 
the end of each run. RSV A positive specimens are seen in lane 
1,2,3,4,5,10,11,15, 16,17 and 19. RSV B positive specimen seen in lane 8,9,12,13 and 
18. Dual infection (A&B positive) specimen can be seen in lane 6. M is marker with 
base pair sizes indicated by arrows. 
82 
Table 3.3 (a & b): Relationship between age of child at admission with RSV 
subtyping. 
(a) 
Age group RSV Dual infection NPA PCRor EIA RSVA RSVB RSVA&B (Months) 
+Ve or (RSV & Flul 
0·3 158 92 57 24 8 
3·6 83 57 31 20 1 
6·9 75 35 24 5 3 
9·12 37 17 l3 0 3 & (1) 
12·24 23 19 l3 4 1 
>24 42 6 4 1 0 
226 142 54 16 
Total 418 (54%) (67%) (25.5%) (7.5%) 
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Table 3.4 (a & b): Relationship between age of child at admission with RSV 
sUbtyping. 
(b) 
Age group RSV Dual infection 
*NPA EIA+Ve RSVA RSVB (Months) Only RSVA&B 
0·3 112 36 24 11 1 
3·6 97 17 7 8 2 
6·9 35 6 4 2 -
9·12 26 6 5 1 -
12·24 4 4 3 1 -
>24 9 3 2 1 -
78 49 28 3 
Total 383 (20%) (61%) (35%) (4%) 
*NPA: Nasopharyngeal aspirates 
The total number of NPA samples during study period (first season (Table a) and second 
season (Table b) 801 was samples and the total positive RSV samples was 304 (38%) 
with predominance of strain A. There were insufficient NP A samples from remaining 22 
samples to allow further investigation. 
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Analysis of RSV subtype distribution showed that RSV A was the predominant subtype 
throughout the study. Of the 418 RSV positive samples 142 (67%) and 54(25.5%) were 
RSV A and RSV B positive, respectively, in the first season and 45(62.5%) and 24(35%) 
were RSV A and RSV B positive, respectively, in the second season, including some dual 
infections (16 (7.5%) and 3 (4%) samples for first and second season). The RSV A and B 
seasons started simultaneously, with the appearance of RSV B detection being higher in 
the second season. 
3.2.6 Qatar study samples 
A total of 60 children were eligible to participate in the study, after agreement by parents 
and the Ethical Committee, but only 36/60 children were recruited (Figure 3.5). The 
most frequent reasons for non-recruitment included parental refusal and unavailability of 
parents. The recruited children were followed up during two RSV seasons and both NP A 
and sequential serum samples were collected as often as possible (by asking the parent to 
bring their children to the hospital whenever they had any flu like symptoms) as 
summarized in Appendix 3. Four sequential sera were available (acute, after 1 month, 
after 1 year and after 1 year and 1 month) for four children, three sequential sera were 
available (acute, after I month and after 1 year) for fifteen children and the rest of Qatar 
study children 2 sequential sera only were available (acute and after 1 month). 
Unfortunately no reinfection episode or isolate was detected among the Qatar study 
population (Figure 3.6). 
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Figure 3.5: The plan of laboratory work using the clinical samples. 
Blood convalescent & sequential 
Neutralization test 
Epitope Mapping 
, 
, 
I 
I 
I 
Patient recruitment 
Respiratory samples 
NPA 
Antigen detection 
EIA I--------.-! 
Strain variation + 
Sequencing (G gene) 
L ................................................................................................................................ , ............................................................................................................................. i 
86 
ovember 
1999 
Figure 3.6: Schematic diagram indicating of the start and end of each season during 
the study period. 
December I January 1 February I 
April 
March I ~ 2000 
AlQ/lOOO AlQ/21/00 B/Q/31/00 
B/Q/ll/OO AlQ/26/00 B/Q/33/00 
AlQ114/00 AlQ/27/00 
B/Q/28/00 
December 
April 2000 I January 1 February I March I ~ 2001 
AlQ/39/01 
AlQ/37/01 
AlQ/41/01 
5 RSV A isolates were obtained during the first season (NQIl 0, 14,21, 26, 27/00) and 3 
from the second season (NQ/37,39,41/01), while all RSV B isolates were obtained from 
the first season (B/Qlll ,28,3 1 ,33/00). Note that there is no reinfection. Blue and red 
colours indicate the availability of RSV A and B isolates. 
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3.2.7 Neonatal samples 
In order to validate the Qatar sample sera 20 Qatar sera were collected at random from 
children admitted to HMC with non-respiratory symptoms during the same study period, 
most of them were less than one month of age (Q44-Q54 from the first season & Q55-
Q64 from the second season) Appendix 4 
3.3 Discussion: 
This is the first study from Qatar to examine the role of RSV infection as the etiological 
agent of respiratory disease in children less than 2 years of age. A total of 801 (418 first 
season and 383 second season) NPA samples were obtained from children younger than 2 
years admitted to HMC with respiratory disease symptoms, between November and April 
1999/2000 (for first season) and between December and April 2000/2001 (for second 
season). Of these (38%) had laboratory evidence of RSV infection, (54 % were detected 
by EIA and RT-PCR in the first season and 20% were detect by EIA only, in the second 
season). EIA was less sensitive than RT-PCR and sample collection was started one 
month later in the second season. This finding indicates that RSV infection was the major 
infectious cause of hospitalisation of children with respiratory symptoms during the study 
period in Qatar. This finding is similar to reports from Europe (Whitehead et al., 1999), 
the United States (Halstead & Jenkins, 1998) and some developing countries (Weber et 
al., 1998; Maitreyi et al., 2000). The detection rate (per cent) ofRSV infection in the 
Arabian Gulf and other countries (summarized in Table 3.4), as assayed by ELlS A or 
culture detection methods, varied from 29% in the United Arab Emirates (Uduman et al., 
1996), 40% in Kuwait (Hijazi et al., 1995) and 79% in Saudia Arabia (Bakir et al., 1998). 
Recently RSV was found to be a major pathogen causing acute lower respiratory tract 
infections in India, being detected in 24.5% of children by RT-PCR (Rajala et al., 2003), 
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and a large proportion (45%) ofRSV cases associated with pneumonia in Native Alaskan 
children (Bulkow et al., 2(02). One study from Mozambique indicated that RSV 
infection was present in 8.6% of study infants in the outpatient department and 10.6% of 
admitted children with LRTI (Loscertales et al., 2(02). 
It can be seen from Table 3.4 that there is a big variation in the percentage of RSV 
detection. This variation may be due to the age of the children who were tested. The 
frequency of RSV detection would also depend on the sensitivity of the method used, the 
type of sample (NP A or nasal swab) tested, the timing of sample collection after the onset 
of infection or whether there is any other infection present in the sample which might 
interfere with RSV detection. It is interesting that infectious enteric disease appears to be 
a minor cause of hospital admission in this study, despite the fact that Qatar is considered 
a developing country where diseases due to enteric infection usually are a major cause of 
admission of children to hospital (Wright 1996). A possible explanation is that Qatar is 
relatively affluent compared with many other developing countries and has good health 
facilities. 
Several studies have found a predominance of male patients suffering respiratory illness, 
which corresponds generally to the higher incidence of ALRI of any aetiology in boys 
(Weber et al., 1998; Hijazi et al., 1995; Dawod & Hussain, 1995). 
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Table 3.5: The detection rate (%) of RSV infection in the Arabian Gulf and other 
countries. 
Country Method of % Positive Type of 
detection (N) Specimen 
UAE * EIMFA 29% +NPW 
(252) 
Kuwait ** IFA 40% ++NPS 
(523) 
Saudi a IFA 79% +++NPA 
(1429) 
India *** Rt-PCR 24.5 % NPA 
(200) 
Mozambique EIA (ABBOT) 10.6% NPA 
(4589) 
Alaska Native Tissue culture 45% NPA 
children orEIA (431) 
Jordan IFA 25.46 % NPW 
(271) 
Argentina **** IIF 36.3% NPA 
(168) 
Hong Kong Tissue culture 13.9% NPA 
orEIA (1340) 
Iraq EIA (ABBOT) 37.6% NPA 
(57) 
Qatar EIA(ABBOT) 38% NPA 
&RT-PCR (801) 
(N) Total study number 
* Enzyme immuno membrane filter assay (EIMFA) 
** Immuno fluorescence antibody (IFA) 
*** Reverse transcription - PCR 
**** Indirect Immuno fluorescence antibody (IIF) 
+ Nasopharyngeal washing 
++ Nasopharyngeal swap 
+ ++Nasopharyngeal aspirate 
Age group Reference 
< 3 years (Uduman et aI., 1996) 
< 13 years (Hijazi et aI., 1995) 
<5 years (Bakir et aI., 1998) 
7 -60 (Rajala et aI., 2003) 
months 
< 5 years (Roca et aI., 2001) 
< 3 Years (Bulkow et aI., 2002) 
< 2 years (Bdour, 200 1 ) 
< 2 years (Videla et aI., 1998) 
< 5 years (Chan et al., 1999) 
< 5 years (Albargish & Hasony, 
1999) 
< 2 Years 199912000 & 
200012001 
Comparisons between RSV incidences, detection method used and age in work published 
from various developing countries. The detection methods have some effect on the 
percentage of RSV detection. 
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Although asthma was present in a few cases at HMC (S.9 % as secondary classification), 
a previously published study (Dawod & Hussain, 1995), which examined childhood 
asthma in Qatar, found that viral respiratory infections were the most common (95%) 
precipitating factors for asthma, and 44% of children with RSV bronchitis had further 
episodes of wheezing over the next two years. In addition, in the current study, RSV 
detection was highest among the youngest children (0-3 months). Therefore, during the 
months of the October to March, RSV is an important pathogen in infants and young 
children in the state of Qatar, highlighting the need for the development of effective 
vaccines (Wahab et al., 2001). 
In most published studies, RSV has been a highly seasonal infection and peaks during 
winter with an annual peak in November, December and January in temperate climates 
and during the rainy season in warmer climates (Weber et al., 1995b). This information it 
important for healthcare provision and implementation of RSV prevention (Chan et aI., 
2002). In Qatar, a desert country, the pattern of RSV infection showed a clear seasonality 
during winter months despite the fact that winter is mild with little rain. A similar pattern 
was observed in other Arabian Gulf countries (Uduman et aI., 1996; Hijazi et aI., 1995; 
Bakir et aI., 1995; Wahab et al., 2001). Moreover RSV incidence was found to correlate 
with high relative humidity and low temperature (Figure 3.2). A possible explanation is 
that these conditions allow the optimum survival of RSV in this environment. These 
results are consistent with those obtained by Chan in Hong Kong (Chan et al., 1999). 
However similar studies in Singapore (Chew et al., 1995) do not show a relationship with 
humidity. Despite the fact that humidity in the summer in Qatar is usually at 
approximately the same high level or higher than in winter, the temperature is also very 
high (- 45°C). It is interesting that a phenomenon of increasing virus yield in vitro with 
lower temperatures has been recorded using different cell lines and detection methods 
91 
e.g. virus growth on Hep2 detected by immunolocalization of infected cells (Razinkov et 
al., 2(02) and the virus growth on human airway epithelial cells detected by an 
immunofluorescence assay (Zbang et al., 2(02). Ambient temperature in Qatar may be 
sufficiently high to inactivate virus. Parental smoking and the use of wood burning stoves 
have been shown to increase the risk and severity of RSV infections. It is important to 
define the role of air humidity or temperature, either indoors or outdoors, or of industrial 
pollution, which could also affect the capacity of young infants to cope with respiratory 
infections (Brandenburg et al., 1997). 
The success of detection of respiratory viruses depends on the type of specimen collected, 
transport of specimen and method of virus isolation. In this study NP A specimens were 
chosen for virus isolation. NPA yields a greater number of cells for virus isolation 
(Maitreyi et al., 2(00) and collection is also a less traumatic procedure for young 
children. A study in Glasgow tested the sensitivity of perinasal swabs in comparison with 
NPAs and reported 93% and 99% sensitivity, respectively (Mackie et al., 1991). By 
comparing nasal swabs (NS) with NPA or nasal wash, previous studies from developing 
countries (Stensballe et al., 2(02), found between 9 and 65% reduction in sensitivity. 
Also, in anothr developing country, using a nasal swab was associated with a 27 - 31 % 
reduction in sensitivity compared with a NPA (Stensballe et al., 2(02). Therefore, NPA 
appears to be the ideal specimen for RSV detection. However, collecting NPA specimens 
is costly and requires a vacuum system, a suction catheter, a mucus trap and transport 
medium. NS collection only needs a swab and a transport medium and it might be 
preferable in epidemiological studies, where a large number of samples are reqiuered. 
In the work described here, multiplex PCR has been shown to be a more reliable tool for 
the diagnosis of RSV infection than antigen detection methods, especially in young 
children. The 9 samples positive by EIA test, which were negative by multiplex PCR, 
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could be explained by either a false positive result in the EIA or viral genome 
degradation before PCR, as sample analysis was performed several months after 
collection. In addition, antigen detection cannot be used for RSV sub typing analysis. A 
further advantage of using the PCR method is for the detection of dual infections, of 
which there were minorities in each season (16 in the first season and 3 in the second 
season and one RSV A and Flu B in the first season). It is not known to what extent the 
two viral genomes (mixed infection) detected contributed to the disease symptoms of the 
patients (Lina et al., 1996; Drews et al., 1997). The RT-PCR technique is a very sensitive 
method, which may be capable of detecting viral genomes for a period of time after 
symptoms have abated. This finding draws attention to the primary cause of illness and to 
the potential of one respiratory illness to predispose to another. There is very little 
information about RSV A and B dual infections because most studies do not subtype 
RSV strains. However, Drew et al (Drews et al., 1997) noticed that RSV was associated 
with most dual infections with other viruses, a finding confirmed by this present work 
where the majority of dual infections were associated with RSV A and B. 
Another important seasonal viral infection, which was detected in the study population 
during first season, was influenza virus that could be detected and sub typed in the 
multiplex peR that was used for RSV detection. The finding of low influenza infection 
among children under two years of age during the study period agreed with other studies 
(Sugaya et al., 2000; Maitreyi et al., 2000). This could be explained because infants may 
be protected from influenza virus infection by passive maternal antibodies, whereas high 
RSV incidence in infants indicates that RSV infection can occur despite the presence of 
maternal antibodies (Glezen et al., 1981). 
Rapid diagnosis of respiratory viruses is essential for initiating immediate appropriate 
therapy (e.g. antiviral drug), reduces the use of unnecessary antibiotics and is important 
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in the hospital management of the patient (Maitreyi et al., 2000; Savon et al., 2(00). The 
EIA used here showed a reasonable sensitivity (74%) and specificity (95.5%) as has been 
found by others (Dayan et al., 2(02). It appears that the Abbott Testpack® is a useful tool 
in the detection of RSV in febrile infants but it has limitations. During months typically 
associated with RSV disease, a positive RSV Testpack® indicates a high likelihood of 
illness, but clinicians should be wary of false negatives. 
The current work defined the incidence of RSV infection (38%) among 801 children 
under 2 years of age admitted to HMC with respiratory disease symptoms. Systemic 
analysis of specimens for pathogens other than this virus was not undertaken and 
therefore the possibility of an important contribution of other respiratory viruses in the 
remaining negative samples (62%) cannot be ruled out nor can their possible contribution 
to dual infections among RSV positive samples (38%). The significance of RSV infection 
in other age groups or in other infections with other respiratory viruses, which are 
common cause of morbidity, mortality, and loss of productivity, also needs to be 
determined. 
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4 Chapter4: Molecular analysis of the diversity of the G protein 
gene from Qatar RSV isolates 
4.1 Introduction: 
All Pneumoviruses encode two major surface glycoproteins (G and F), which are 
incorporated into the virus particle. The G protein has been shown to be the most 
divergent gene, which distinguishes between sUbtypes A and B and also between 
genotypes within these subtypes. There is 67% similarity at the nucleotide level and 53% 
similarity at the deduced amino acid level between group A and B strains (Peret et aI., 
1998). This protein is responsible for the attachment of virus particles to the cell receptor. 
It is a type II glycoprotein with a single hydrophobic domain between residues 38 and 66 
that serves as a transmembrane anchor. The G protein precursor is synthesized as a 32-
Kda single peptide, which is modified by the addition of O-linked and N-linked sugar 
moieties to give the mature form with a molecular mass of 80 to 90 Kda. The protein 
ectodomain contains four cysteine residues (codons 173, 176, 182, and 186), which are 
conserved in all RSV isolates and a short segment (residues 164 to 176) of exact 
sequence identity between the two antigenic subgroups (Garcia et aI., 1994) or in all 
group A isolates (amino acids 163- 189) (Martinez et al., 1997). In addition, the G protein 
is produced in two forms, anchored G protein and soluble G protein, which are produced 
by translation and processing from different start codon (AVG) (Anderson et al., 1995). 
Three types of epitope have been identified in the G protein by testing the reactivity of 
monoclonal antibodies with a large panel of viral strains: (1) conserved epitopes that are 
present in all RSV isolates, (2) group specific epitopes shared by all RSV strains of the 
same antigenic group, and (3) strain-specific or variable epitopes that are present in 
certain isolates of the same antigenic group (Melero et al., 1997). The strain-specific 
epitopes have been mapped within the hypervariable C-terminal third of the G protein 
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ectodomain. It has been shown that the C-tenninal region of the RSV G protein includes 
epitopes important for the neutralization of the virus and that loss of the terminal amino 
acid can allow escape from antibody neutralization(Cane et al., 1992). Epitopes of the 
other two types have been tentatively located near the four-cysteine cluster of the protein 
ectodomain (Garcia et al., 1994; Cane & Pringle, 1991) have shown that the amino acid 
variability is not evenly distributed over the G protein; in the extracellular part of the 
protein there is a sharply defined hypervariable domain separated from a more extended 
variable domain by a highly conserved region. 
The genetic variability of RSV has been best characterized for group A strains. Up to 
20% diversity have been shown at the deduced amino acid level among group A strains 
and 9% within group B (Cane et al., 1996). There is an additional G protein variability 
within anti genic groups with amino acid differences of as great as 20% in a single 
epidemic period. This exceeds the 10% differences among the heamagglutanin (HA) 
protein of drift strains of influenza A virus. G-protein mutations are due to frame shifts, 
premature stop codons, substitutions, and hypermutation (Sullender & Edwards, 1999). 
The reason for this diversity is not completely clear. 
It has been demonstrated that genetically similar strains seem to cluster temporally rather 
than by geographical location (Cane & Pringle, 1991). These studies suggest that 
immunological pressure may direct RSV evolution. Although such studies have provided 
important insights into the epidemiology of RSV strains, the circulation pattern of distinct 
strains in a single community and simultaneously in different communities have still not 
been fully characterized (Peret et al., 1998). Limited strain diversity studies are available 
from the developing world. 
RNA viruses (for example RSV or Influenza A and B) show a high level of genetic 
divergence. This can be observed by the emergence of variant strains in the population. 
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The level of genetic divergence among the G glycoproteins of RSV virus is the highest 
reported for an RNA virus gene product (Garcia et al., 1994). It is possible that RSV 
follows the evolutionary patterns of influenza A & B viruses. It remains to be determined 
whether or not immune selection is a factor determining genetic variation and evolution 
of RSV from the same anti genic subgroup. To clarify this point both the antigenic 
characterization of clinical isolates and sequence analysis of the relevant genome 
segments should be carried out (Cristina et al., 1991; Akerlind et al., 1988). If this is 
coupled to evaluation of antibody responses to known genotypes, particularly in primary 
infection, it is a powerful tool for dissection of RSV strain variation and the forces 
driving it. 
The aim of the work described in this chapter was to evaluate the genetic diversity of 
both group A and B RSV strains by sequencing the G protein gene of isolates from young 
children collected during two seasons in a single community in Qatar. In this way it was 
hoped to obtain a series of RNA sequences of Qatari strains to compare with available 
RNA sequences of RSV in GenBank. The aim was also to provide information about the 
diversity of the RSV B strain and the selection of the RSV B strain for use in epitope 
mapping. 
4.2 Results: 
4.2.1 Strain variation: 
Multiplex peR detection allowed differentiation of RSV into RSV A and RSV B 
subtypes as shown in Figure 3.4. RSV A strain was detected in more than 60% of all 
RSV infections in all age groups sampled for 2 seasons, a small proportion of dual 
infections with RSV A and B were also detected in all age groups. The PCR detection 
strategy for RSV is based on amplification of the N and P region of the genome; this was 
selected because it is highly conserved between strains and also allows subtyping of RSV 
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into A and B subtypes (Stockton et al., 1998). However, to derive sequence analysis ofG 
gene, which is highly variable, required a different PCR detection strategy. Accordingly, 
clinical material that was found to be positive for RSV by PCR and EIA, was used as 
source material to attempt to isolate RSV and derive sequences, in accordance with the 
flow chart shown in Figure 3.5. Cases for whom paired sera, as well as an NPA sample 
were available, were used to isolate RSV. Using this approach, a total of 36 NPAs, 
known to contain RSV by peR and EIA, were inoculated into Hep 2 cells. A total of 12 
RSV isolates (8 of strain A and 4 of strain B) were prepared and their subtype properties 
were defined (Appendix 3 and Figure 4.1). 
4.2.2 Amplification of the G gene: 
4.2.2.1 G gene peR optimization: 
There were many problems with amplification of the G gene directly from clinical 
material, including the high degree of variability of the gene making it difficult to design 
primers. There are also a limited number of published sequences especially for RSV B 
therefore enhancing problems for primer design. 
The overall strategy involved designing primers which would amplify the whole G gene 
(923 nucleotides) in a single reaction, including a small amount of additional upstream 
sequence from the SH gene (SH 136 Forward) and downstream sequence from the F 
(FIReverse) gene. This primary product could be used to generate secondary 
overlapping fragments, which could be used in sequencing reactions. 
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Figure 4.1: Flow chart of sequencing materials, both NPA and cell culture grown 
virus from Qatar children group were used to generate RNA sequences of Qatar 
strains. 
samples 60 
children 
strains B 
5 complete sequences of RSV A were obtained from viral isolates (AlQ/lO,14,27/00 and 
AlQ/39, 41101) and 5 were obtained from NPA samples (AlQ/13,16,17,19,29/00). 3 
complete sequences of RSV B were obtained from viral isolates (B/Q/ll, 28, 33/(0) and 
2 were obtained from NPA samples (B/Q/5, 18/(0). 
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Sources of sequence which were used to design primers which could amplify the whole 
of the G gene were those described in the following publications: (Wertz et aI., 1985; 
Cane & Pringle, 1991) for RSV A and (Roca et al., 2001; Sullender & Edwards, 1999; 
Taylor et al., 2001) for RSV B. There were limited numbers of sequences available to 
choose conserved regions. 
Primers designed to amplify the smaller internal overlapping fragments were chosen in a 
similar way. The primer sets were designed to be as similar as possible in their physical 
and chemical characteristics, around 20 bases in length, with a 50% G+C content (Table 
4.1.). 
Primers were designed to sequence the whole Human RSV G gene (923 nucleotides), in 
overlapping segments each between 300 -500 base pairs long as described in the 
materials and methods (section 2.7 & 2.8). The primer mapping positions are 
demonstrated in Figure 4.2 and which primer sites yielded product of the expected size is 
detailed in Table 4.2. 
Systematic testing of primers was performed because it was not possible to amplify the 
complete regions of RSV G gene and to give the expected product size was performed 
using AlQatarlRSV Al2000/1O for RSV A & RSV B control (N2) for RSV B strains. 
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Primer 
name 
Fl R 
SH l36F 
G2F 
G152 F 
G178 F 
G508 R 
G618R 
G645R 
F95 R 
G618 F 
G645F 
G508F 
SH237 F 
0178 R 
0248F 
G152 F 
G178 F 
G618R 
G645R 
* G1F 
* G390 R 
* G390 F 
G510F 
* G600R 
* G600 F 
* B080l R 
Table 4.1: List of the designed primers used in the amplification of the RSV G gene. 
Sequence Annealing Temp GC content 
5'···3' Co. % 
CAA CTC CAT TGT TAT TIG CC 40 40 
CATCCA TAACAATAGAATTC 30 30 
GGG CAA ATG CAA ACA TGT CCA AAA 41.7 43.5 
TTG CAA TGA TAA TCT CAAC 31.6 31.5 
ATA A TT GCA GCC A TC ATA TIC 33.3 33.3 
AAG TIG AAC ACT TCA AA 29.4 30 
TTT GTG GGC TTG GTG GTG 55.6 55.5 
TTT TTT GGT TGT CTT G 31.2 3 1.2 
T AA AA T TCT TCA GTG AT 23.5 23 .5 
CAC CAC CAA GCC CAC AAA 55.6 47.6 
CAA GAC AAC CAA AAA A 31.2 31.2 
TTT GAA GTG TIC AAC TI 29.4 29.4 
A TI CCA TAA CAA AAC CTT 27.8 27.8 
GAA TAT GAT GGC TGC AAT TAT 33.3 33.3 
CTI GAT CTG GCT TGT TGC ATC 47.6 47.6 
ATA ATI GCA GCC ATC ATA TTC 41.7 33.3 
AAG TTG AAC ACT TCA AA 31.6 33 
TTT TTT GGT TGT CTT G 29.4 31.2 
TAA AATTCTTCA GTG AT 55.6 23.5 
GGG GCA AAT GCA ACC ATG TCC AAA 72 50 
GTT TGT GCT GTT GTA TGG TGT GTI 68 41.6 
AAC ACA CCA TAC AAC AGC ACA AAC 68 41.6 
ACT TIG AAG TGT TCA AC 45 35.2 
TGT GGG TTT GAT GGT TGG TTT TTT 66 37.5 
AAA AAA CCA ACC ATC AAA CCC ACA 66 37.5 
AAG TIC AAC ACT TCA AA 44 29.5 
*: These primers were designed for the current study. 
The red primers were used in the generation of the primary product, while blue primers, 
were used in the secondary reactions. 
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Figure 4.2 &Table 4.2: Schematic diagram and tables of primer sets used to 
amplify and sequence the G gene. 
SH 
410 
SH 136 F 
GI F 
r.? F 
G 
923 bp 
Primary product 
1292 bp 
Secondary produc~ 
G390R 
FIR 
G508R 
F 
1903 
I r.'iIOF I F IR 
------------------------------------------------------------------------
r.I'i ? r.fi4'iR 
GI 52F G6 18R 
G390F G600R 
G600F FIR 
G618F BG80 lR 
G6 18F FIR 
G645F FIR 
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Table 4.l: primer sets used to amplify and sequence the G gene. 
Primer Fragment Start Finish Seq. 
length (bp) 
G2F& G508R 506 4644 5150 Y 
G 152F & G618R 466 4794 5260 Only G152F 
G510F & FIR 465 5152 5617 Y 
G618F & BG801R 183 5160 5443 None 
G645F & FIR 122 5287 5617 None 
G 152F & G645R 493 4794 5287 Y 
G618 & FIR 305 5260 5617 Only FIR (400bp) 
GIF & G390R 390 4643 5032 None 
G390F & G600R 210 5032 5242 None 
G600F & FIR 301 5242 5617 Only FIR (400bp) 
Y: The primer set works and gives the expected fragment with sequence. 
None: No data obtained (no fragment). 
Red primers are those that were finally used to amplify and sequence the G gene 
103 
Some primers sets were excluded for inability to amplify a fragment of the expected size. 
The reasons for this failure were not fully investigated. Once it had been determined that 
each primer set yielded a fragment of the expected size, optimization of the reaction 
conditions was performed, to improve the sensitivity of detection. Biochemical 
optimization using a range of buffers and pH conditions and annealing temperatures was 
undertaken. This was done to ensure that the primer sets chosen eventually for sequence 
analysis would amplify directly from clinical material, which might contain a low copy 
number of template. Initial approaches to this included comparing the sensitivity of 
detection of RSV with the multiplex PCR primers with the newly selected G gene primer 
sets. This optimization was performed using AlQatarlRSV Al2000/1O virus. 
It appeared that the RSV G gene based primers were less sensitive than the NP primers 
by 10 to 100 fold in their detection of RSV (Figure 4.3). However, biochemical 
optimisation using different buffer compositions indicated that the sensitivity for 
detection of RSV could be improved for some of the primer sets (Figure 4.3). This figure 
shows those multiplex PCR primers more sensitive than G gene primers. 
4.2.2.2 G gene peR: 
G gene nested PCR conditions were modified from the RT-PCR conditions and the final 
conditions for G gene amplification are detailed in Figure 4.3. 
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Figure 4.3: Comparison of (a) multiplex PCR (344 bp) and (b) RSV G primers PCR 
(fragment size 356 bp) amplification. 
a 
1000 bp 
500 bp 
b 
1000 bp 
500 bp 
lOx dilution series of Qatar IA/2000/l0 samples were used. N is a negative control. M is 
a marker with base pair sizes indicated with arrows. 
GPCR conditions were modified from mUltiplex peR condition . The primary cycle 
became as following : 94°e for 2 ruin x 1, followed by 40 cycles of: 94°e for 1 min, 
S2°e for 2 min and 72°e for 3 min. While the secondary PCR Cycle became as 
following: 94°e for 2 rnin al so for 1 minute, but followed by 40 cycles of: 94°e for 1 
min , 600 e for I min and 72°e for 1 min. The amount of 1 °product was al so increased 
from 2j.11 to 4j.11. 
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4.2.3 Sequence Analysis: 
Attempts were made to amplify all of RSV A&B positive materials, either NP A or tissue 
culture (if available) from the Qatar study children group, but after purification 
procedures only 17 RSV A & 9 RSV B samples (18 from NPA and 8 from tissue culture 
material) produced a strong signal (Figure 4.1). Because of time constraints, only isolates 
that gave a strong band were sequenced with emphasis on sequential samples from the 
same child where available. 
After the sequencing reactions had been done, only 10 & S samples of RSV A &B, 
respectively from the Qatar group produced complete sequences for the G gene. 
These sequence data were aligned with the study reference controls. AlQI 
10,13,14,16,17,19,27,29/00 isolates from the first season and AlQI 39,41101 isolates from 
the second season belonging to the RSV A sUbtype. B/Q/S,11,18,28,33/00 isolates from 
the first season only belonged to the RSV B subtype (as determined by RT-PCR). So, 
sequence analysis supported the initial RT-PCR sub typing results. 
Limited comparison of derived sequences of the second variable region of the G gene for 
AlQI 10100 obtained either directly from clinical material (NPA) or from tissue culture, 
indicated that there were no changes at the nucleotide or amino acid level following a 
single passage in Hep- 2 cells. 
To accurately define the extent of genetic variability within and between groups, the 
nucleotide sequences of the complete, partial and C-terminal end of the G protein gene 
were determined (10 of group A and S of group B) collected throughout the study period. 
The sequences determined correspond to nucleotide 1 to 900 of the A2 prototype strain 
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and to nucleotide 1 to 915 of the N2 strain (this include some areas at beginning and end 
of the gene that are covered by primers). 
There were some coding and non-coding nucleotide substitutions especially for the first 
and third nucleotide sequence (1-450 and 650 to the end) for both strains (Figure 4.4 and 
Appendix 5). No insertion, frame shift mutations or up and down stream sequence 
changes were identified in these Qatar RSV A and B strains. The middle conserved 
region (450 - 650) was identical among Qatar's RSV A strains with 8 nucleotide 
substitutions between A2 strain and Qatar strains at positions 468, 506, 515, 552, 558, 
611,639 and 644 (noncoding), whereas there were 12 nucleotide substitutions in the 
middle region ofRSV B strains at positions 470, 476, 508, 559, 573, 591,603,627,634, 
638, 643, 646 and 650 which were non synonymous. 
The nucleotide variation detected was 5% within Qatar group A isolates (complete 
sequences) and 15% between Qatar and non Qatar isolates for the partial sequences and 
4.6 & 13%, respectively for the nucleotide sequences of the C-terminal end of the G 
protein gene at the nucleotide level. 
The nucleotide variation observed within the group B isolates from Qatar was 0.8% 
(complete sequences). The mean nucleotide variation between Qatar and non-Qatar 
isolates was 10% for the partial sequences and 2.3% & 12.5%, respectively for the 
nucleotide sequences of the C-terminal end of the G protein gene at the nucleotide level. 
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Figure 4.4 (a&b): The deduced amino acid alignment by Clustal V method of Qatar RSV strains 
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(b) The deduced amino acid alignement by Clustal V method of Qatar RSV B strains, with total length of 295 amino acid for 3 viruses and 299 
for the rest.Red box indicate to the strictly conserved region in both RSV strain (A & B) viruses. 
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The deduced amino acid sequences of the Qatar group A isolates indicated that all of 
them had either a deduced G protein length of 297 or 298 amino acid due to presence of a 
ATG start codon and TAG stop codon. 
Two clusters of RSV A 1999/2000 & 2000/200 1 (with 8 for first season and 2 for the 
second season) with similar amino acid sequences within each of them were detected 
among Qatar group A strains (Figure 4.48 & 4.5.8). Sequences from these clusters 
differed by 35 to 40 amino acid over the sequenced length. 
Again two clusters of viruses with similar amino acid sequences were detected among 
group B Qatar strains (Figure 4.4.b). Sequences from these two clusters differed by 20 to 
25 amino acids over the sequenced length. 
There were some O-glycosylation sites (monosacharide-Sff) especially on the first part 
(1-160) and the third part for both RSV strain viruses. N-glycosylation sites 
(carbohydrate-N) were more localised at the C-terminal end than the first part of the G 
protein of these viruses at the following positions 85, 104, 134, 237, 251, 272 and 293 (7 
sites) for RSV A viruses and at 86, 230, 274 and 290 (4 sites) positions for RSV B 
viruses, these sites were varied between strains. In general, there were fewer non-
synymous changes in the first region than in the third part. The almost conserved middle 
nucleotide region (450-650) in both strains had a few nucleotide substitutions leading 
mainly to no-change (synonymous change) at the strictly conserved region (160-200) and 
no change in amino acid sequences of this part of the protein. 
Several phylogenetic trees were constructed using windows of different lengths and the 
longest and recent nucleotide sequences of the G protein gene already available for RSV 
isolates especially group B with particular emphasis being placed on the C-terminal end 
of this gene. 
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The phylogenetic analysis derived by the neighbour-joining method of the complete 
nucleotide sequence of Qatar isolates showed that most strains have similar amino acids 
(1-298 amino acids) Figure 4.5 a & b. Only bootstrap values (distance/parsimony) 
greater than 60% are shown. For the full length of the RSV A strains, the most significant 
bootstrapping value is that 100/99 time AlQ/39/01 & AlQ/41101 are clustered together 
from the rest of the isolates used in the analysis, AlQIl 0,27,29/00 are clustered 99/95 
times, while strains AlQ/16/191oo are grouped together 93/90 times, strains AlQ/13, 14, 17 
clustered together 84173 times. All Qatar isolate group together 80% of the time and are 
related to AlMAD/92. 
For RSV B strains full length the B/QAT/18/oo, 33, 28 are grouped together 93/94 times 
more than other. B/QAT/18/oo clusters together 93 times with B/QAT/33/00 by using 
Distance method although it clusters 62 times with B/QAT/33/00 by using Parsimony 
method. B/QAT/5/00 & B/QAT/ll100 strains grouped together 86/88 times. In general 
all Qatar B strains are close together. 
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Figure 4.5 (a & b): Phylogenetic trees of the complete sequence of the RSV G 
protein gene of Qatar strains 
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(a) Phylogenetic tree of the complete sequence of the RSV A G protein gene of Qatar 
other worldwide isolates encompassing amino acid 1 to 298 were included in the 
analysis. 
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(b) Phylogenetic tree of the complete sequence of the RSVB G protein gene of Qatar & 
one USA isolate encompassing amino acid 1 to 295 were include in analysis. 
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Comments on figure 4. 5: The phylogenetic trees of group A & group B RSV isolates 
were derived by the neighbour-joining method as determined by the PHYLIP computer 
programme. Described worldwide sequences retrieved from Gene Bank include in the 
trees for comparisons (Julyl2004). The horizontal spacing represents the number of 
nucleotide differences between branch points. Vertical lines are for spacing and label. 
The bar scale indicates nucleotide/amino acid sequence percentage divergence (xl00). 
Majority sequence was used as out-group sequences in the tree. Names of viruses 
indicate: isolate group/place of isolation/no. of isolate/year of isolation. K: Korea, MAD: 
Madrid, Moz: Mozambique, Q: Qatar, U.K: United Kingdom, URG: Uruguay, USA: 
United State of America, BM: Bone Marrow transplantation patients, HIV: Human 
Immune deficiency patients. Numbers in italic represent bootstrap proportions values 
(Distance/Parsimony method). Only bootstrapping values greater than 60% are shown. 
In an attempt to compare Qatar isolates with more worldwide isolates, shorter amino acid 
sequence alignments were obtained or constructed to compare with the available RSV 
sequences in the Gene bank. Between amino acids 20-296 of the A2 prototype strain 
(Wertz et al., 1985) and 20-293 of the B8/60 prototype strain (Sullender, 1995) a number 
of coding substitutions were identified between Qatar isolates, reference strains, and also 
between the most recently available world wide strains (Figure 4.6 a & b). 
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Figure 4.6 (a & b): The partial phylogenetic tree, Comparison between Qatar and 
worldwide isolates (July/2004) 
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(a) Phylogenetic tree of the partial sequence of the RSV A G protein gene of Qatar & 
other world wide isolates encompassing amino acids 20 to 296 were included in the 
analysis. 
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7.7 
Figure 4.&:(a & b): The partial phylogenetic tree, Comparison between Qatar and 
worldwide isolates (July/2004) 
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(b) Phylogenetic tree of the partial sequence of the RSV B G protein gene ofQatar & 
other world wide isolates encompassing amino acid 20 to 293 were include in analysis. 
Numbers in italic represent bootstrap proportions values (DistancelParsimony method). 
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The sequences from Qatar RSV A isolates were closely related, for example in 
preliminary phylogenetic analysis using nucleotide sequences, appeared as a cluster 
showing AlQI14/00 approximately 98.2% different from the nearest world wide isolate 
(AlK/98) while AlQ/lO/OO had 15.3% similarity to the most distant isolate (AlUSAl82). 
Using the sequence results from Qatar RSV B isolates for instance B/Q/5/00 was more 
closely related to the BlKor/91 strain than it was to BIUSAl90isolates, preliminary 
phylogenetic analysis using nucleotide sequences appeared as a cluster showing 
approximately 95.6 % identity & 9.3% divergence from the nearest Korean and the most 
distant USA isolates, respectively. 
To accurately define the extent of genetic variability within and between groups, the 
amino acid sequence of the C-terminal end of the G protein gene was determined. The 
sequence determined corresponds to amino acids 192 to 298 of the A2 prototype strain 
and to amino acids 184 to 299 of the B8/60 prototype strain (Figure 4. 7 a & b). The 
deduced amino acid sequence of the Qatar group A isolates indicated four clusters of 
viruses A-I, 2, 3 & 4 with similar amino acid sequences( Appendix 6: Accession 
numbers for sequences that have been derived from databases) 
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Figure 4.1:(a & b): The phylogenetic tree, Comparison between the C- terminal 
sequence of Qatar and world wide isolates (July/2004) 
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(a) Phylogenetic tree of the C-terminal sequence of the RSV A G protein gene of Qatar 
and other worldwide isolates, encompassing amino acids 192 to 296 in the analysis. 
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Figure 4.1-:(a & b): The phylogenetic tree, Comparison between the C- terminal 
sequence of Qatar and world wide isolates (July/2004) 
B/Kl93 
B/Kl95 
BIMozl99 
BIMozl99 
BIMozl99 
BIMozl99 } BIMozl99 B/KI95 B/0/5/00 B/0/33/00 
B/O/18/00 
67160 r- B/0/11/00 BIMozl99 } 
rl B/0/28/00 62162 ..--_.....!:.74:!!:/64~_.r-:=:-:------ BIUSN90-95 
'--------1 I B/KI91 
6/K195 
BlUSN98 
r..--,61U-rQl-2-0-00-----I BIUSN 95-96 
BlUSAl98 
BIUSN94-95 
65/61 BIUSN94-95 
...--------i BlUrg/HIV/2000 ~ BlUrg/HIV/2000 B/KI91 B/KI91 
BIUSN94-95 
BIUKlBM/95-96 
BIUKlBM/95-96 
BIUKlBM/95-96 
BIUKlBM/95-96 
83178 BIUKlBM/95-96 
L--------1 BIUKlBM/95-96 
BIU KlBM/95-96 9.5 ____ ...-_____ -, _____ -,-_____ -, _____ --, 
8 6 4 2 o 
Cluster 1 
Cluster 2 
(b) Phylogenetic tree of the C-terminal sequence of the RSVB G protein gene of Qatar 
other worldwide isolates encompassing amino acid 184 to 293 were include in analysis. 
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The divergence is almost the same even at the carboxyl-end of the RSV B strain between 
Qatar strains and elsewhere was higher (2.3%) than in partial phylogeny (0.8%). In 
contrast to what was observed among Qatar B isolates where they were clustered together 
67/60% of the time as assessed bootstrapping analysis. 
4.2.4 B/Q/28/00 isolate: 
The main target of the molecular work beside the analysis of strain variation was to 
select the most representative RSV B strains to perform epitope mapping by synthesis of 
peptides identified by sequence analysis of the G gene. B/Q/28/00 was chosen for various 
reasons. First of all, it was successfully grown and isolated from clinical samples, it had a 
longer nucleotide sequence than the other Qatar RSV B isolates (Figure 4.8) and 
secondly there were three sequential sera for the same infected child. Figure 4.9. shows 
the potential N and 0 -glycosylation sites along the peptide to be synthesized, from 
amino acid position 150 to 299, predicted by the ppsearch program of pro site database 
from EMBL (European Bioinformatics Institute). There are 25 potential O-glycosylation 
motifs and only two potential N-glycosylation motifs. Most of these sites are conserved 
among strains, especially the N-glycosylation sites, while O-glycosylation sites have 
some amino acid variation (mainly substitutions) compared with the amino acid 
sequences of other Qatar RSV B strains. 
Extra computer analysis was done for the whole G protein of B/Q/28/00 to predict the 
structural characteristics of this fragment. Using the Deleage & Roux modification of the 
Nishkawa & Ooi 1987 program and the DNASTAR database it was found (Table 4.3. & 
Figure 4.10) from the predicted structural class of the whole B/Q/28/00 G protein that 
the most hydrophilic and antigenic part of this protein is located from amino acid position 
150 to the C-terminal end. 
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Figure 4. 9 : C-terminal end of the G gene of Qatar RSV B isolates 
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(a & b): C-terminal end of the G gene of Qatar RSV B isolates indicating two stop 
codon (TAG) positions that lead to two nuc1eotides (a: 896 & 900) and protein lengths 
Cb: 295 and 299 amino acids). This result was obtained from a single sequence reaction 
with forward and reverse primer, which gave the same result. 
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Figure 4. 9 : C-terminal end of the G gene of Qatar RSV B isolates 
c 
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*Termination codon. E: Glutamic acid, P: Proline, S: Serine, N: Asparagine, T: 
Theronin , W: Tryptophan, R: Arginine, , K: Lysine, A: Alanine, L: Leucine, Q: 
Glutamine, Y: Tyrosine and D: Aspartic acid. 
Comparison between the G protein length of Qatar RSV B strains and elsewhere. 
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Figure 4. <f : 0 & N glycosylation sites among G-protein of B/Q128/00 
B/Q/28/00 
Red: Suggested peptide to be synthesised, from amino acid 150 to 299 position 
(Conserved and C-terminal regions). 
Blue: Potential O-glycosylation sites, Predicted with confidence by NetOGlyc 2.0). 
(Between brakets): Potential N-glycosylation sites, Predicted by ppsearch program of 
prosite database from EMBL (European Bioinformatics Institute) 
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122 
A 
A 
Figure 4.10: Structural character of B/Q/28/00 predicted with protein programme of DNAST AR database. 
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The most antigenic region among this protein localized between 150 - 290 amino acid positions. 
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• Beta, Regions - Chou-Fasman 
I!!I Turn, Regions - Garnier-Robson 
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o Coil , Regions - Garnier-Robson 
Hydrophilicity Plot - Kyte-Dooliltle 
• Alpha, Amphipathic Regions - Eisenberg 
• Beta, Amphipathic Regions - Eisenberg 
• Flexible Regions - Karplus-Schulz 
• Antigenic Index - Jameson-Wolf 
o Surface Probability Plot - Emini 
Table 43: Predict Structural Class of the Whole B/Q/28/00 G protein, with 
expected length. 
Analysis Whole protein 
Molecular Weight 33051.53 M.W. 
Length 299 aa 
1 microgram = 30.256 pMoles 
Molar Extinction coefficient 1013+/-5% 
1 A(280) = 3.26 mg/ml 
Isoelectric Point 9.97 
Charge at pH 7 25.42 
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4.3 Discussion: 
Shifts in the predominant genetic group, circulation of multiple lineages and 
emergence of new lineages have been observed in several studies of human RSV 
molecular epidemiology (Cane & Pringle, 1995b). 
In the work described in this study, primers were designed to amplify the whole G 
gene of RSV subtypes A & B. Analysis of this gene allows the differentiation and 
confirmation of isolates into strains and allows comparison of circulating strains for 
the study period. There are other published reports of primers that amplify parts of the 
RSV G gene (Sullender, 1993; Peret, 2(00), but there is no publication with a 
complete set of primers for the entire G gene. The RSV G gene is highly variable and 
therefore it is necessary to ensure that the designed primers are appropriate for the 
strains being studied. In addition, most of the published protocols require a high copy 
number, good quality samples of cultured virus material and there are no reports of 
complete sequencing directly from clinical material as attempted here. Therefore, 
although some of the previously published primers were tested they didn't work well. 
The possible reasons for failure include; firstly the sensitivity of these primers was not 
optimised or secondly that the Qatar nucleotide sequence is different from nucleotide 
sequence of these primers. To overcome this, primers were designed to amplify the 
whole G gene, which were capable of detecting virus from clinical samples or tissue 
samples with equal efficiency. 
The sequencing strategies designed were used initially to sequence an RSV A positive 
control (the study reference strain A2). 
Samples which were identified as RSV positive from the study period were 
sequenced, depending on availability of serum and virus isolate. It was clear, 
however, from initial amplification reactions that there was a lower positive rate than 
expected as the samples had been through at least one cycle of thawing and re-
freezing before being defrosted for PCR sequencing. To avoid this problem in the 
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second season, samples were prepared and stored as pellets to be ready for sequencing 
and some of them were stored as cDNA or peR primary product, which are both 
more stable than non processed clinical material. Also, to increase the positivity rate, 
the samples should have been put into tissue culture immediately, which would 
increase the yield of virus and hence provide a higher copy number but a tissue 
culture facility wasn't available at HMC. However, the study was designed to produce 
a sequencing strategy that could be used directly with clinical samples and to perform 
epitope mapping by synthesising peptides of one of the RSV B G protein sequences 
obtained during this work. 
It was apparent that the RSV G primers did not amplify as many samples as the 
multiplex primers (Figure 4.3), although the RSV G primers were shown to be as 
sensitive as the multiplex RSV primers on some isolates. It is possible that some of 
the currently circulating strains differ in sequence from those deposited in the 
Genebank Sequence Database from which the sequences were obtained for primer 
design (RSV A2 strain, isolated 1968, assigned accession number AF035006, 
(Whitehead et al., 1998). Also, the sequences deposited vary geographically and 
temporally. The other problem with sequencing is that the read-throughs for each 
sequence were only approximately 400bp so although primers were placed in the 
conserved region they were not always able to span across the whole of the variable 
region. One strategy to counteract this problem would be to use more primers in the 
sequencing reaction so that the forward and reverse primers overlap completely even 
if a shorter sequence is produced. In addition it could be that the viral load was lower 
in some samples for G primers. 
Another explanation for the differences in detection of the RSV between the 
multiplex primers and the RSV G primers is differential expression of RSV genes. For 
non-segmented negative strand RNA viruses, it has been shown that the amount of 
mRNA that is transcribed depends upon the proximity of the genes to the 3' end of the 
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genome (Wertz et al., 1998). The multiplex primers are located in the N gene close to 
the genome 3' end, whereas the G gene is distant from the 3' end. It has been shown 
that a 15 fold decrease in gene product occurs when amplifying a gene further from 
the 3' end (Wertz et al., 1998). It is not certain whether mRNA or viral RNA (vRNA) 
was detected using this methodology, but it was believed that both were detected. 
However, if it was predominantly mRNA being detected it could explain the 
differences in detection sensitivity between the two methods. Also, Fearns et al., 
(Fearns et al., 2(02) indicate that for RSV, the transcription promoter lies at the very 
3' end of the genome, irrespective of the location of the site oftranscription initiation, 
and overlaps with the replication promoter. Among the first 11 positions there was 
flexibility at position 4: the assignment of C, G, or U at this position was compatible 
with a high level of RNA synthesis, but the optimal assignment was different for 
transcription versus replication. A G residue was associated with a lower level of 
replication and a higher level of transcription than either a U or a C residue. 
The final primer set or strategy was tested on the clinical isolates obtained from Qatar. 
Seventeen RSV A samples and nine RSV B samples were amplified using the nested 
reaction with primers SH136F and FIR. The methods had to be modified when testing 
clinical material, which were of poor quality because with the original cycling 
conditions it was not possible to amplify the G gene. However, once the number of 
cycles was increased and the annealing temperature was lowered, more samples were 
amplified. Although amplification was successful, some bands were smeary and the 
correct size band was not easy to identify using long wave light. Therefore, the 
cycling conditions should be re-optimized using clinical material which has a lower 
copy number than control material. However, because of time limitations only twenty-
six isolates, which produced a strong signal, were chosen for sequencing. When the 
sequencing strategy was employed complete sequences were obtained for fifteen 
isolates. 
127 
After success with amplification of test clinical isolates, samples that were identified 
as RSV positive in children for whom there were blood samples (the Qatar study 
children) were used to attempt direct amplification and sequencing. It was clear, 
however, that it would be difficult to amplify the samples and obtain sequence 
information from all the Qatar study children. Difficulty in amplification and 
sequencing of G protein gene from clinical material may be overcome by re-designing 
the primer. Another possibility would be to further optimise the conditions for 
amplification including varying the concentration of Taq. In order to improve the 
methodology, a proof reading enzyme should be used to reduce errors. A further 
method that could be used is cloning of the selected fragment, which enables easier 
sequencing, improves accuracy and the reduction of quasispecies, which could result 
in poor quality of sequences. Cloning was not used in this study because it was not 
certain that amplification of the whole of the G gene would be possible. Also it is an 
expensive method in materials and it is labour intensive. And it is not certain whether 
the sequences obtained are representative of the majority species in the sample. 
An identical G gene sequence was found when comparing sequences derived directly 
from the original NPA samples and from RSV isolates derived from the same material 
passed in Hep 2 cells. Lack of host selection has been described elsewhere (Zambon 
et al., 200 1; Garcia et al., 1994). 
Genetic variability was analyzed for RSV isolates and viruses were characterized to 
antigenic group (group A or B) by both RT-PCR and GPCR, although viruses of both 
antigenic groups were present each year, the group A viruses were dominant for both 
years. Similar variability has been described in other studies, and overall, the group A 
viruses are more frequently identified than the group B viruses (Coggins et al., 1998; 
Anderson et al., 1991; Cane, 1997; Cane et al., 1994; Hendry et al., 1989). In a study 
performed in Finland, alternating group A and B virus dominance has been observed 
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(Waris, 1991), while in two studies performed in India and Mozambique group B 
virus was dominant for two seasons (Rajala et al., 2003; Roca et al., 2001). 
In addition to the differences in the viral groups isolated each year, sequence analysis 
showed that the group A viruses which were dominant during the two seasons were 
genetically distinct (2 clusters). Previous studies suggested that there was less 
variability among group B viruses (0.8%) than among the group A viruses (5%) 
(Coggins et al., 1998; Sullender et al., 1991). The data presented here confirm this 
observation for isolates from a period spanning two epidemics at a single location. 
However, the group B viruses have the potential for additional variability as 
evidenced, by comparisons to prototype and between Qatar isolates more (13%) than 
between Qatar isolates and elsewhere (10%) especially at the nucleotide level. 
Whether the analysis of additional group B isolates would reveal even greater 
differences remains to be determined especially with a limited number of complete 
sequences available in the GenBank. The extent to which the individual viruses vary 
locally and over time could influence the pattern of reinfections with different viral 
strains. The group A viruses may vary more extensively than the group B viruses, this 
might play a role in the studies of RSV epidemiology. 
While three different lengths (292, 295 and 299 amino acid) of the G protein gene 
have been described among B group viruses (Garcia et al., 1994; Roca et al., 2001), 3 
lengths also (295, 298 and 299 amino acid) have been found among group A isolates 
(Garcia et al., 1994). In the current study, all Qatar group A sequences had a G protein 
lengths of 297 or 298 amino acids, and two G protein lengths were observed among 
group B strains (2 isolates 299 amino acids and 3 isolates 295 amino acids). These 
results were obtained from a single sequence reaction with a primer set but the same 
result was given with the forward and reverse primer. Changes in stop codon usage 
have been associated with important anti genic variations found in RSV escape 
mutants that were selected with monoclonal antibodies recognizing strain-specific 
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epitopes (Melero et aI., 1997). In addition, assessment of the length of the protein G 
could have immunogenic implications in an RSV outbreak. 
Although a single experiment indicated longer sequences, this phenomenon has been 
observed elsewhere and consistent with other work (Roca et aI., 200 1; Venter et al. 
2001). Nucleotides addition was not a single point mutation, insertional mutation, 
duplication or read-through error but it may have arisen by a more complicated 
mechanism, perhaps due to a polymerase error, leading to addition of multiple non-
templated nucleotides. 
Others have reported this phenomenon of premature termination (by adding and 
removing last amino acids from viral genome due to insertion or deletion mutation) 
and its affect on the antigenicity of the protein, with other viruses. For instance in 
HIV, anti genic variation in multiple epitopes can lead to complicated antigenic 
oscillations, especially in CTL responses against multiple epitopes located on the 
terminal end of HIV genome (the NH2-terminal flanking region) (Nowak et al., 
1995a; Nowak et al., 1995b; Draenert et aI., 2004). 
Since there is less information about group B sequences (the complete genome) than 
about group A sequences, further analysis of group isolates of different geographical 
origin will help to clarify the uniqueness of viruses from group B. Our data obtained 
here confirm that strains of RSV circulating in a single season may be genetically 
more closely related to strains isolated in very distant places in different years than to 
co-circulating strains of the same group isolated during the same outbreak (Melero et 
al., 1997). Hence, these data reinforce the high capacity of RSV for worldwide spread 
(Garcia et al., 1994). 
Only sporadic amino acid changes were observed among sequences from the same 
cluster and most of them correspond to amino acids present in strains from the other 
cluster. These data suggest that at certain positions, and despite the sequence 
heterogeneity of RSV, the acceptance of specific amino acids was restricted. This fact 
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could have important implications in the design of broadly reactive synthetic vaccine 
candidates. 
Different patterns of putative N- and O-glycosylation sites, which may play an 
important role in the mechanisms involved in virus escape from host immune 
pressure, have been previously described in group A viruses (Cane & Pringle, 1991). 
The present results indicate the presence of 4 N-glycosylation sites among the G 
protein of group B Qatar strains. Therefore, and in agreement with the lower sequence 
heterogeneity of group B isolates, our data suggest that the potential antigenic 
variability mediated by changes in the putative N- and 0- glycosylation pattern of 
group B isolates is different from that of group A isolates (7 N-glycosylation sites). 
Whether these different patterns also have implications in the higher anti genic 
variability detected among group A isolates remains to be established. Different RSV 
virus strategies to escape from the immune response have been studied, (Palomo et 
al., 2(00) and it has been suggested that the contribution of carbohydrates to the 
antigenic structure of the G protein C-terminal third is of crucial importance, because 
this influences the expression of certain epitopes, either masking the epitope or 
contributing to antibody recognition. 
Phylogenetic analysis showed that the group A and group B viruses were placed in 
multiple lineages. Most of the major phylogenetic branches included viruses, which 
were isolated in this study, reflecting the great diversity of RS viruses, which may be 
present in a community over a period of 2 years. However, among the group A viruses 
it was also clear that viruses isolated at different times and from different places could 
be very similar to the viruses isolated from the Qatar study children. Thus, viruses 
from Spain and Korea, which were isolated several years before the viruses studied 
here, could be grouped phylogenetically with these viruses. The observation that very 
similar viruses are isolated at different times and from geographically distant sites 
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demonstrates that the virus is capable of worldwide spread (Melero, 1997; Muelenaer, 
1991). 
The study presented here was designed to assess variability in a detailed manner over 
a limited period of time. Thus, the study was not intended to address the issue of 
change over time. For the group A RS viruses, there appears to be an accumulation of 
change over time (Melero et al., 1997). This observation is also compatible with 
accumulation of changes among the group B RS viruses. However, until a greater 
number of more chronologically and geographically disperse isolates have been 
examined, this issue remains speculative for the complete genome of the G protein for 
the group B RS viruses. 
The data also shows that variability occurs among group B RSV viruses (0.8%), 
although to a lesser extent than among the group A viruses (5%). These data indicate 
that the group B RS virus G proteins, while less variable in this study, are no more 
likely to have mutations than are the group A RS virus G proteins. The high 
percentage of nucleotide changes which resulted in amino acid coding changes (Cane, 
1991; Sullender, 1991) . One possible advantage would be that such change results in 
an escape from the host immune response. This might contribute to the ability of RS 
viruses to establish infections throughout life. Also, genetic diversity permits RNA 
viruses to refine their adaptation to a constant environment, and to have a certain 
probability of finding adaptive routes in response to environmental change. 
It would be interest to study the effect of losing or adding some amino acids to the G-
protein of RSV (especially RSV B), by developing an assay to detect antibodies react 
with different RSV G-protein length either by cloning and expressing the different 
length ends of this protein (Jones et al., 2002) or by using different peptide length 
(glycosylated and non- glycosylated). 
These results confirm the variability among group A RS virus isolates which has been 
demonstrated previously and the loss of some terminal amino acids (especially in 
132 
RSV B strain) (Coggins, 1998; Cane, 1995 ; Garcia, 1994). Higher abundance of 
non synonymous (amino acid altering) mutations versus synonymous (silent) 
mutations was found in the C-terminal end and there are several reports that show the 
advantages of nonsynonymous substitutions during RNA virus evolution. One 
example is the variable secondary structural domain at the internal ribosome entry site 
of picomaviruses (Pilipenko et aI., 1989). There is evidence that secondary structure 
constraints have imposed limitations for the evolution of RNA genetic elements 
(Yamamoto & Y oshikura, 1986). Thus, mutations that alter such higher-order 
structure- irrespective of their effect on the first, second, or third base position in 
codons- must be subjected to negative-selection. Structural and regulatory elements 
within the genomic RNA are as much a part of the phenotype as are viral protein-
encoding segments. Negative-selection may act to eliminate synonymous as well as 
non-synonymous substitutions. The dominant targets of negative-selection (RNA or 
protein) may depend on the environmental condition being imposed on virus 
replication (type of cell, type of infection-acute or persistent, modulate by other 
RNAs- access of virus to antibodies and to other inhibitory molecules and so on. Such 
an evolutionary phenomenon in the absence of immuno-selection pressure, as with 
Ross River virus in a nonimmune population, was associated with a surprisingly low 
evolutionary rate of the virus (Bumess et aI., 1988). Clearly, the most powerful 
potential force directing viral evolution is the host's immunological response. Yet in 
the laboratory, neutralization escape mutants can readily be found for all viruses. 
Therefore, the paradox of high viral mutation rates and (usually) high antigenic 
stability in vivo requires explanation. In the case of influenza, the most notable 
example of viral anti genic instability, the infection is usually initiated by only a few 
infectious units (Alford et al., 1966), is short-lived, confined to the respiratory 
epithelium, and is characterized by subsequent imperfect immunity. Therefore, in 
primary infection, little opportunity for immunoselection from a large initial viral 
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population exists. Rather, such selection most effectively occurs with reinfection of, 
and passage in, partially immune hosts. These events lead to a self-propagating 
sequence of pervasive epidemics, leading to widespread partial immunity, followed 
by emergence and preponderance of viral populations best equipped to survive. In 
those infections, respiratory or otherwise, in which such viral immunoselection is not 
usually evident in nature (e.g. measles), the opposite conditions obtain; that is, 
infection is relatively protected, involves multiple viscera, and engenders more solid 
immunity, so that the opportunity for virus to flourish in the presence of antibody 
during subsequent challenge is reduced or absent as reinfection is diminished (Luoh et 
al., 1992). 
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5 Chapter 5: Analysis of specificity of anti-RSV sera using 
synthetic peptides from the G protein of RSV B 
5.1 Introduction: 
The use of vaccines is the most effective means of preventing infectious diseases. 
Table 5.1 summarizes the development of human vaccines. Besides the high cost, 
conventional vaccines have several disadvantages including lack of stability and 
requirement for refrigerated storage, which is difficult to maintain in tropical and 
developing countries (Pichichero et al., 1990). Above all, conventional vaccines 
require great attention in their preparation to avoid the risk of infection, which may 
arise with attenuated vaccines reverting to virulence. On the other hand, inactivated 
vaccines must be totally innocuous (Francis, 1990; Amon & Sela, 1985; Olszewska et 
al., 2004; Polack & Karron, 2004). For these reasons scientists have diverted their 
attention towards the development of alternative vaccine approaches. The fact that 
HBsAg (the surface antigen of hepatitis B virus), which is found in excess in the 
plasma of infected individuals, can protect against the whole virus particle has 
focused attention on the potential of subunit vaccines (Francis et al., 1986). By 
understanding the nature of the antigen-antibody interactions involved and which part 
of the virus or the microorganism is required to provide full protection, a vaccine can 
be designed from artificially engineered virus particles, viral subunits, isolated 
proteins or synthetic peptides. This can be achieved by identifying those sites 
involved in stimulating a protective immune response. Having obtained this 
information, it is then possible to design a potential vaccine, which contains only the 
important region for the induction of protective immunity. Therefore, studying the 
antigenicity and immunogenicity of a protein or antigen has become a major scientific 
activity with an increasing emphasis on the potential use of selected viral proteins as 
the basis of vaccines against a variety of diseases. 
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Table 5.1: Outline of the development of human vaccines.Adapted from Plotkin 
and Orenstein, 1999 
Live Attenuated Killed Whole Purified Protein or Genetically 
Organism polysaccharide Engineered 
Eighteenth Century 
Smallpox, 1798 
Nineteenth Century 
Rabies, 1885 Typhoid, 1896 
Cholera, 1896 
Plague, 1897 
Early Twentieth 
Century Pertussis, 1926 Diphtheria, 1923 
Tuberculosis, 1927 Influenza, Tetanus, 1927 
Yellow fever, 1935 1936 
Rickettsia, 
1938 
After World War 11 
(Cell Culture) Polio Pneumococcus Hepatitis B 
Polio (oral) (injected) Meningococcus recombinant 
Measles Rabies (new) H. influenzae PRP (Yeast- or 
Mumps Japanese Hepatitis B (plasma mammalian 
Rubella encephalitis derived) cell-derived) 
Adenovirus Hepatitis A Tick-borne 
Typhoid (Salmonella encephalitis 
Ty21 a) H. Influenza PRP-
Varicella protein (conjugated) 
Typhoid-Vi 
Acellular pertussis 
PRP, Phosphosylribitol phosphate. 
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The term antigen refers to any entity that can be specifically recognized by antibody 
molecules and the cellular components of the immune system. The antigenic 
determinant (epitope) corresponds to those parts of the antigen that are specifically 
recognized by the binding sites (paratopes) of immunoglobulin molecules (Van 
Regenmortel, 1989). Thus, epitopes are those entities that require a complementary 
paratope for their operational recognition and therefore the particular antibody 
becomes known as an antibody specific for that antigen. Antibody molecules contain 
two identical paratopes made up of six highly accessible loops of hypervariable 
sequence known as complementarity determining regions (CDRs) capable of forming 
an enormous amount of sequence variation in order to bind to myriad different 
antigens. The identity of an immunoglobulin is thus established after its 
complementary antigen has been identified. It has been postulated that the number of 
epitopes in a protein can be estimated from the total number of different mAbs that it 
is able to induce (Amit et al., 1986). 
Epitope types: The antibody response to a protein is predominantly focused to 
restricted parts of protein molecules termed B-cell epitopes, that are made up of 
amino acids. Epitopes are divided on the basis of their molecular structure into two 
main categories, sequential or continuous epitopes and conformational or 
discontinuous epitopes. The former is defined as a short linear stretch of residues 
which are located in the primary polypeptide sequence. whereas discontinuous 
epitopes consist of a group of residues that are not contiguous in the primary sequence 
but are brought together by the folding of the polypeptide chain. In general, a linear 
peptide fragment of a protein reacts less readily with antibodies raised against the 
intact protein than does the intact native antigen itself. This is partly because of the 
inability ofthe peptides to adopt the correct conformation, and secondly, the linear 
peptide may represent only a part of a larger discontinuous epitope and reacts only 
with antibodies directed to this epitope. 
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Not every residue in a linear epitope is necessarily a contact residue with the paratope 
(Geysen et al., 1988) as some of the residues in a continuous epitope can be replaced 
by any of the other 19 amino acids without impairing antigenicity. It is now widely 
believed that most of protein epitopes are conformational and very few linear 
stretches of residues are present at the surface of a protein (Leach, 1983; Chargelegue 
et al., 1997). However, most studies aimed at revealing protein antigenicity have 
focused on the cross reactivity between proteins and short linear peptides (Van 
Regenmortel et al., 1978). 
There are also three other types of epitopes, e.g.; first group of epitopes, which are 
hidden and become exposed only after fragmentation or denaturation of the antigen 
(Van Regenmortel, 1992). Second group of epitopes that are specific for the 
quaternary structure of proteins; they arise as a result of conformational changes 
induced by intersubunit bonds of residues from neighboring subunits, and are 
commonly found in viral capsids (Van Regenmortel, 1966). Third group of epitopes 
(neutralization epitopes) correspond to those epitopes of infectious agents and toxins 
that are specifically recognized by antibody able to neutralize the biological activity 
of the antigen. The identification of neutralization epitopes is important for the 
development of synthetic vaccines because it is this type of epitope that should be 
mimicked by synthetic peptides and used for eliciting protective immunity. 
Antigenicity ofRSV: Two antigenic subgroups of RSV, designated A and B, have 
been distinguished on the basis of the two anti genic and sequence dimorphisms that 
are most pronounced for the ectodomain of the G protein (as previously described in 
the Introduction), one of the two major protective antigens. Although there is 
substantial cross-reactivity between the two subgroups, they are sufficiently distinct 
that an effective RSV B-cell epitope based-vaccine will need to protect against 
infection with both. Thus a potential B- cell epitope-based vaccine to RSV should 
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contain B-ceU epitopes from both A and B sUbtypes of G protein. Most studies have 
been conducted with B-cell epitopes from RSV A isolates (Appendix 7), because 
sequence data for the G protein of subgroup B RSV strains are much more limited 
than are those of subgroup A. In addition, most work on RSV A has been performed 
with laboratory - adapted strains. Finally because most RSV B studies are widely 
separated, either geographically or chronologically, focus has been on RSV A. 
From the information in Appendix 7, it can be concluded that most of the work on B 
cell epitopes was focused on the conserved region of protein G. The exception was the 
work of (Sullender, 1990; Sullender, 1995) who used the whole G protein as 
expressed protein and in both their studies they used non-human sera. Only (Akerlind-
Stopner et al., 1990) used peptides from part of the C-terminal end (including the 
conserved region) of the G-protein with human sera. However, it was not specified if 
the sera had neutralizing activity. 
The rest of the studies have been done on the RSV A G protein and have identified 
different amino acid sequences recognized by either human sera or as protective 
epitopes (Norrby et al., 1987; Plotnicky-Gilquin et al., 1999; Power et al., 2001; 
Dagouassat et al., 2(01). Antibodies to some of these epitopes were able to confer 
protection. 
Methods used for epitope identification: The most commonly used methods to localise 
protein epitopes consist of identifying which fragments of the molecule are able to 
cross react with antibodies raised against the native protein. Several different 
strategies for identifying epitopes have been described. Some of these studies 
involved the use of the protein molecule itself such as X-ray crystallography as in the 
case of the neuraminidase of influenza virus (Col man et al., 1983). This method is 
based on structural analysis, since it is the only method that gives selective attention 
to the visual appearance of the spatial arrangements found in the antigen-antibody 
complex at a specific time. However, this method is labour intensive and requires 
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special expertise. Other approaches involve the use of fragmentation of the native 
protein, either by chemical cleavage or by controlled proteolysis. The resultant 
fragments are then screened for immunologically active domains that can bind to 
antibodies and interfere with their interaction with the intact antigen (Arnon & Sela, 
1985). These methods are based on functional analysis taking into account the results 
of binding measurements. They have been used successfully for the identification of 
complete anti genic structures of myoglobulin, hen egg white lysozyme and an almost 
complete anti genic structure of serum albumin (Atassi, 1979). The method based on 
structural analysis cannot provide direct evidence that every residue contributes to the 
binding reaction. On the other hand, binding measurements are necessarily of an 
operational nature depending on the type of probe used for assessing immunochemical 
binding: for instance. free peptide versus conjugated peptide, short peptide versus a 
more constrained long peptide, liquid versus solid-phase immunoassay, monoclonal 
versus polyclonal antibodies. These methods actually analyse cross-reactivity instead 
of anti genic reactivity; and lead to the conclusion that a much smaller number of 
residues (1 to 5) are critical for antibody binding and thus that the epitope defined in a 
functional analysis involves fewer residues than may be defined in structural terms. 
The development of solid phase peptide synthesis and methods for the testing of large 
numbers of peptides on solid supports has provided new insights into the molecular 
basis for antibody specificity and the mechanisms by which the antigen and antibody 
combine. Recently, a number of alternative approaches have been also described that 
involve the systematic synthesis and screening of large peptide libraries of defined 
structure (Arnon & Sela, 1985). 
The aim of this part of the work is to identify B-cell epitopes recognized by human 
sera obtained before and after infection using a panel of I5-mer overlapping synthetic 
peptides corresponding to the RSV G protein of a recent RSV B strain isolate. 
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A widely used approach to the identification of B-cell epitopes is the use of 
overlapping synthetic peptides that span the entire sequence of a protein antigen 
synthesized using the Fmoc procedure. This synthetic approach is much milder than 
the other peptide synthesis chemistry, tBoc chemistry, because the peptide chain is not 
subjected to acid conditions during each cycle and the final deprotection and cleavage 
steps can be achieved using Trifluoroacetic acid (TF A) rather than the much stronger 
hydrofluoric (HF) acid conditions (Amon & Sela, 1985). 
The size of the peptides chosen was 15 amino acids overlapping by five amino acids 
because B cell epitopes range between 15- 22 amino acid, in length. It has been 
reported that only three to five residues of the structural epitopes contribute 
significantly to the binding energy i.e. 3-5 a.a. are in intimate contact with the 
antibody and are therefore considered as critical amino acids; deletion of one of these 
amino acids might render the peptide not reactive. Therefore it is advisable to 
have the peptides overlapping by 5 amino acids. These peptides are then tested for 
their capacity to serve as targets for B-cell epitopes in vitro. 
In the work described in this chapter, 17 I5-mer overlapping peptides (5 amino acid 
overlap) corresponding to residues 150-299 of the G protein ofRSV B strain 
B/Q/28/00 isolate (Figure 5.1 a+b) were used (Appendix 8: amino acids 
abbreviations). This sequence represents the conserved and C-terminal region and 
avoids the trans-membrane region. This RSV isolate was chosen for this part of the 
work because it had been isolated from a child for whom 3 sequential sera were 
available and the post-infection serum had a high titre of neutralizing antibody 
(Chapter 6). The (B/Q/28/00) isolate and sequence analysis was available for this 
strain (Chapter 4) with longest C-terminal end (923 nucleotides). Melero et al (1997) 
suggested that the C-terminal of the G molecule folds back in the three -dimensional 
structure, so that the C-terminal end is in close proximity to the cysteine cluster and 
he considered that some epitopes (Figure 5.2) which afford maximal neutralization , 
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would be in close proximity to the putative receptor binding site of the G molecule 
(all this work had been performed with the laboratory adapted strains of RSV). 
Three types of epitope have been identified in the G protein by mapping using escape 
mutants the reactivity of monoclonal antibodies with a large panel of viral isolates: i) 
conserved epitopes that are present in all RSV isolates; ii) group specific epitopes 
shared by all viruses of the same anti genic group, and iii) strain-specific or variable 
epitopes that are present in certain isolates of the same anti genic group (Melero et al., 
1997). The strain-specific epitopes have been mapped within the hyper variable C-
terminal third of the G protein ectodomain (Figure 5.2). It has been shown that the C-
terminal region of the RSV G protein includes epitopes important for the 
neutralization of the virus and that loss of the terminal amino acids can allow escape 
from antibody neutralization (Cane et al., 1992). 
For the work described here, it was hypothesized that maximum peptide recognition 
by human sera could be obtained with peptides from the conserved part of G protein 
and some from the C- terminal part of this protein of RSV B as had been found with 
RSV A. In addition, the possibility exists that the pattern of peptide recognition varies 
with the group of sera (children, adult and neonatal sera) and some of these sera could 
contain high affinity antibodies. By assessing the affinity (the tightness of antibody 
binding to the anti genic determinant) of antibodies of some sera that reacting with 
these peptides it may be possible to identify if this part of the protein contains 
protective epitopes that inducing high affinity antibodies. If so, then peptides from 
this region can be used to develop a potential vaccine. The objective of this work was 
to test these hypotheses. 
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Figure 5.1 (a&b): Peptide alignments 
15 14 13 12 
16 17 
TIPSNKPKKKPTIKPTKKPTIKTTKKRDPKTPAKTLKKE 
11 
----------------- 9 
10 8 
TTTNPTEEPTPKTKERDTSTSQSTVLDTTASEHTVQQQS 
7 
6 5 4 
LHSTTPENTPNSTQTPTASEPSTLNSTQNTQSRD 
3 2 
(a) Fifteen overlapping synthetic peptides (overlapping by 5 amino acid in red letters) 
representing amino acid sequence 149-299 ofRSV G protein (B/Q/28/00). The C-
terminal region with two variable regions that is separated by the most conserved 
region in both subtypes A&B (13 a.a in box) is included but the transmembrane 
region is excluded. 
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Figure 5:1:(a&b): Peptide alignments 
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(b) The peptides are numbered 1 through 15 starting from the eOOH-terminal end of 
the protein. 
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Figure 5.1: Model of the three dimensional structure of the G protein (Melero et 
al., 1997). 
s-s 
~ 
Disulphide bond (S-S) and the N- and C- terminal ends are indicated. White 
rectangles indicate the transmembrane domain and gray rectangles the variable 
regions. Red rectangles indicate the location of epitopes that induce maximal 
neutralization activity. 
145 
c 
5.2 Results: 
5.2.1 Peptide characterization: 
The peptides were synthesized using Fmoc chemistry as described in Materials and 
Methods (section 2.13) by the Pioneer peptide synthesis system (Figure 5.3). 
summarizes the steps involved in peptide synthesis. The amino acid sequence of all 
peptides was verified by mass spectrometry and the purity is assessed by HPLC. 
Molecular weights of the synthetic peptides were determined by mass spectrometry 
performed by Peptron Inc using the HP 1100 series LCIMSD model spectrometer. 
The observed peptides molecular weights were closely matched with their expected 
theoretical masses (Table 5.2). Generally most of these peptide gave the same 
expecting molecular weight. 
Peptide purity was assessed by high performance liquid chromatography (HPLC). 
Each consisted of a single major chromatographic component (Figure 5.4). 
5.2.2 Optimisation of solid-phase ELISA with human sera: 
To determine the optimal ELlS A conditions for the previously described method for 
ELISA (Section 2.15.1), different variables were considered, including the type of 
plate (IMMULON 1,2,4 & NUNC) and the composition ofthe blocking solution 
(1 % Gelatin, 1 % BSA, 1 %FCS & 5% MILK). The lowest background OD492 reading 
was achieved with IMMULON 4 plates using 1 % BSA as blocking solution. 
5.2.3 Samples 
The following panels of sera were used to test their reactivity with peptides; (i) Qatar 
study sera taken before and after infection; (ii) Qatar neonatal samples and (iii) 
control sera from UK adults (Table 5.3) 
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Figure 5.3: Schematic diagram of peptide synthesis using Fmoc chemistry. 
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Table 5.2: Mass spectrometry analysis. 
Peptide Mass expected Mass found 
1 1262.58 1263 
2 1560.73 1562 
3 1558.71 1559 
4 1705.8 1705 
5 1615.77 1616 
6 1666.8 1667 
7 1741.85 1742 
8 1657.89 1657 
9 1712.03 1713 
10 1712.09 1713 
11 1676.03 1677 
12 1675.87 1676 
13 1638.73 1638 
14 1855.82 1857 
15 1780 1780 
16 1760.77 1762 
17 1808.84 1809 
Generally most of this peptide gave the same expecting molecular weight. 
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Figure 5.4: Representative example of HPLC analysis. 
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HPLC chromatographs of peptide 12, 13 & 14 HPLC are shown. The purity of 
peptides was: peptide 14 (87%) peptide 13 (78%) peptide 12 (65%). 
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Table 5.3: Total number of samples, Mean age of individuals, when and where the samples that used for this part of the work had been 
collected. 
Study panel No. of Mean age of Date of Location Clinical 
! 
Description subjects subjects collection Or Origin features 
Qatar study 1st season paired sera 30 1 year Nov. 1999- Samples from hospitalised *ART 
(Pre & post) QI-Q30 April 2000 patients at HMC I 
, 
Qatar study 2nd season paired sera 5 1 year Dec. 2000- Samples from hospitalised ART 
(Pre & post) Q31-Q35 April 2001 patients at HMC 
I 
Qatar neonatal sera 20 15 days Randomly Hospitalised patients from No resp. I 
neonatal care unit reasons 
Adult sera from UK 6 43 years 2002 UK Lab. Staff 
- - --
-- _._- --
-
* ART: Acute respiratory tract infection. 
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5.2.4 Screening peptide reactivity with Qatar study sera 
A panel of 35 paired sera from Qatar children before and after natural infection with 
RSV A or Band 3 neonatal sera from children admitted for non-respiratory problems 
but which were found to have high anti-RSV neutralizing antibodies (RSV -Ab+) were 
tested for their reactivity with all 17 peptides (paired sera, and subtype virus were 
summarised in Appendix 3) using solid-phase ELISA that had been previously 
optimised with human serum (section 5.2). 
In attempt to summarize the peptide reactivity, a statistical analysis was undertaken 
on results of the peptide reactivity of sera taken before infection (OD pre) and after 
infection (OD post) by showing the percentage of samples where the cut off value was 
(OD> 0.2) (using SPSS programme). 
Figure 5.5 shows the total number of sera from before and after infections that react 
or do not react with each peptide, and clearly shows that peptides 11, 12, 14, 16 and 
17 were recognised by all serum samples taken before and after infection. 
Reactivity in the each peptide was generally similar with slightly increased reactivity 
with post-infection sera (Figure 5.6). 
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Figure 5.5: Peptide reactivity, exposed as % positive cases, where OD % reading 
was> 0.2. 
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• % of sera positive (pre) 0 % of sera positive (post) 
Black columns indicate the percentage of reactivity in samples collected from 
children before infection, and white columns represent the percentage reactivity in 
samples collected after infection. 
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Figure 5.6 (a & b): The mean values of the peptide reactivity (OD) with sera before 
and after infection with (a) RSV A and (b) RSV B. 
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Peptides 14, 16 and 17 have the highest mean OD value reactivity. Peptide 2 reacts 
strongly with post-infection sera especially with children infected with RSV B. 
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Majority of sera reacted strongly (ELlS A OD in excess of 0.5 at a 1: 10 dilution) with 
5 of the 17 peptides that are mainly from the conserved area of the G protein (peptides 
11, 12, 14, 16 & 17) see Table 5.4. The results with peptides 13 and 15 were 
ambiguous because they are located in the same conserved area and share an 
important 3 amino acid sequence (VPC) with peptides 14, 16 & 17 (Figure 5.1), 
which could perhaps be explained by the conformation of the peptide on the plate. 
The remaining peptides (1-10) were weakly recognised by the sera and most of those 
that were bound were from a region of the protein that is highly variable and contains 
group and strain-specific epitopes. 
Table 5.4: Peptides recognized by sera at dilution 1110. 
Peptide OD Number of sera positive * 
Range Pre infection Post infection 
11 0.2-1.3 28 28 
12 0.2-1.6 32 30 
14 0.5-1.7 33 32 
16 0.2-1.2 33 32 
17 0.2-1.3 33 31 
* Out of 35 paired sera tested 
Peptide 14 shows the highest OD values. There was no difference between reactivity 
of sera from before and after infection, with peptides (14, 16, 17) from the conserved 
region of RSV G protein. 
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5.2.5 Screening peptide reactivity with neonatal and adult sera 
Neonatal sera: Initially, only 3 neonatal sera were used, and as shown in Table 5.5 
the neonatal sera did not react with peptides 2,3,5,7 and 9. Antibodies in neonatal sera 
(mainly maternal antibodies) are important in that they can adversely effect the 
response to vaccination (as in the case of measles). Thus those peptides that are not 
recognised by neonatal sera could potentially be used to immunise and thus avoid this 
interference effect of maternal antibodies. Peptide 2 would seem to be a particularly 
useful peptide for this purpose since it was recognized by a large number of sera from 
older children with slightly high OD values (> 0.2) (Table 5.5). To confirm this 
result, further neonatal sera (7) were tested for their reactivity with peptide 2 and also 
with peptide 14 (which was recognised by most sera from the Qatar study and the 
adult sera, with high OD values). Figure 5.7shows that peptide 2 was not recognised 
by any of these additional neonatal sera. 
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Tables 5.5 (a&b): Summary of peptide recognition by Qatar children sera and 
adult sera. 
Peptide Number of positive Qatar study sera 
2 30nO (43%) 
3 21nO (30%) 
5 25no (36%) 
7 26nO (37%) 
9 9nO (13%) 
a: Peptides recognIsed by large number of sera from older Qatar study children 
Peptide Adult Sera 
12 7/10 
13 8/10 
14 9/10 
15 7/10 
16 8/10 
17 7/10 
b: peptides recognIzed by most adult sera 
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Figure 5.7: Screening peptide 2 & 14 reactivity with neonatal sera. 
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All neonatal sera were unreactive with peptide 2, but 417 reacted significantly with 
peptide 14. 
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Adult sera: 10 adult sera (4 of which were paired sera taken before and after recent 
infection with RSV strain B), were tested for their reactivity with all 17 peptides, and 
representative data are given in Figure 5.8 A similar profile of reactivity was seen 
with the Qatar children study sera, and with the panel of adult sera, showing strong 
reactivity with peptides from the conserved region of the protein (peptides 
12,13,14,15,16 & 17) and variable reactivity with peptides from the C-terminal end of 
the protein (peptides 1,3,4-11) and none of the adult sera reacted with peptides 2 and 
11, therefore, it could be considered as a compound of a childhood vaccine since it 
would avoid maternal antibody interference. While peptide 2 reacts strongly with 
post infection sera especially from children infected with RSV B, adult post infection 
sera reacts better with peptide 16. Of course, these peptides would need to be assessed 
for their ability to induce virus-neutralising and protective antibody responses in 
model system before they could be considered as potential vaccine. 
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Figure 5.8: Screening peptide reactivity with adult sera. 
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Most of the adult sera reacted highly with peptides 12-17 but did not react with peptide 2 
and 11 and reacted weakJy with peptides 1,3 and 10. 
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5.2.6 Relationship between the peptide sequences based on B/Q/28/00 and 
other sequences of the Qatar strain B viruses. 
An attempt was made to assess the relation between the sequences of synthesized 
peptides with the five available Qatar RSV strain B sequences, by tracking any amino 
acid substitution, insertion, deletion or presence of any N or 0 -glycosylation sites (N-
glycosylation occurs when the carbohydrate is attached to the nitrogen atom in the 
side chain of asparagin (carbohydrate-N), while O-glycosylation occurs at any 
monosaccharide molecule that bind to serine or threonine (monosacharide-Sff). The 
similarity or difference between the peptide sequence (based on B/QI28/(0) and other 
the Qatar RSV strain B sequences are summarized in (Table 5.6). 
From Table 5.6 (a & b) Most peptides react with sera from a patient infected with 
B/Q/33/(0) and any sequence change, either as amino acid substitution or 
glycolysation, prevented peptide recognition. For example, in peptide 2, the amino 
acid L (leucine) had been replaced with S (serine) at the same position in the 
remaining G protein sequence of other four Qatar RSV B isolates. Also 2 substitutions 
were present in peptides 6 (lysine K & arginine R) replaced with (threonine T & 
glycine G) for isolates (B/Q/5&1l/00) and in peptide 9 (lysine K & proline P) were 
replaced by (asparagine N & leucine L) in same two isolates. One amino acid 
substitution was obtained in peptide 7 (glutamic acid E changed to lysine K) and in 
peptide 8 (proline P changed to leucine L) for two isolates (B/Q/5& 111(0). Finally 
there were 3 amino acid replacements in peptide 10 (lysine K to asparagine N, 
threonine T to proline P, isoleucine I to threonine T and lysine K to asparagine N) for 
the two same isolates (B/Q/5& 111(0). 
N- Glycosylation sites were present on peptides 1,2 & 3 and O-Glycosylation sites 
were present on peptides 2,3,4 & 5. 
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In summary, amino acid changes had occurred in peptides 1 to 10, which may account 
for the low reactivity of these peptides with the sera from the Qatar study. However, 
the low reactivity of peptides 11,12 & 13 with sera could not be explained in this way 
because these sequences were identical for allS Qatar RSV B isolates. Only two sera 
(Q28 & 33) reacted with them. It is possible that these peptides failed to react with 
antibodies in sera despite the similarity of their sequence, because antibody reactivity 
was influenced by changes in previous amino acid segments or on their three 
dimensional structure. 
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Table 5.6 (a & b): Comparison of peptide sequences of Qatar RSV B strains 
Peptides 
(a) Serum: serum from children infected with isolate. 
* Serum 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
0 O &N O &N 0 0 0 0 O &N 0 0 
B/Q/5/00 L~S K~T E~K P~L K~N K~N 
R~T P~L T~P 
I~T 
B/Q/lllOO L~S K~T E~K P~L K~N K~N , , 
R~T P~L T~P 
I~T 
B/Q/18/00 L~S 
B/QI28/00 
B/Q/33/00 L~S 
- - ----- ---- - - -
Yellow squares: serum reacts with peptide (O.D > 0.2 at a dilution of 1: 10) 
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0: O-glycolysation site (monosaccharide -S (Serine)ff (threonine) 
N: N-glycolysation site (N (asparagine)-X (amino acid)) 
0: Amino acid substitution or replacement (Leucine L, lysine K, arginine R, threonine T, glycine G, proline P, asparagine N, glutamic acid E 
and isoleucine I) 
(8) The amino acid sequence of peptides shown in bold is the same in all strains. B/Q/33/00 strain has a similar sequence to B/Q/28/00, the 
source of the synthetic peptide. They differ only in the region of peptide 2 where instead of leucine in B128 strain, the B/33strain has serine. It 
seems that the difference is not important because peptide 2 still reacts with serum from a patient infected with strain B/33. 
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(b) 
Peptide Sequences 
2 B/Q128 - QTPT ASEPSTLNSTQ 
B/Q/5 - QTPTASEPSTSNSTQ 
B/QI II - QTPT ASEPSTSNSTQ 
B/Q/18 - QTPTASEPSTSNSTQ 
B/Q/33 - QTPTASEPSTSNSTQ 
6 B/Q/28 - TKERDTSTSQSTVLD 
B/Q/5 - TIEGDTSTSQSTVLD 
B/QI 11 - TIEGDTSTSQSTVLD 
7 B/Q/28 - TNPTEEPTPKTKERD 
B/Q/5 - TNPTEKPTPKTKERD 
B/QI 11 - TNPTEKPTPKTKERD 
8 B/Q/28 - ~AKTLKKETTNPTE 
B/Q/5 - LAKTLKKETTNPTE 
B/QI 11 - LAKTLKKETTNPTE 
9 B/Q/28 - KTIKKRDPKTfAKTL 
B/Q/5 - KTINKRDPKTLAKTL 
B/QIlI - KTINKRDPKTLAKTL 
10 B/Q/28 - TIKPTKKPTIKTTKK 
B/Q/5 - TIKPTNKPPTKTTNK 
B/Qlll - TIKPTNKPPTKTTNK 
(b): Relationship of peptide sequences between the Qatar RSV strain B isolates. 
Amino acid substitutions are underlined in B/Q/28/00 and the replacement in the other 
strains are shown in red. 
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5.2.7 Assessment of aff"mity using the inhibition assay 
Previous results showed that peptides 14,16 &17 were recognised by a large number 
of Qatar children and adult sera. These peptides have similar amino acid sequences in 
the conserved region of RSV B G protein. In an attempt to analyse this peptide 
antigenicity and to determine if they might be expected to induce a good immune 
response if tested in future in animal experiments, it was decided to determine the 
affinity (the tightness of antibody binding to the antigenic determinant) of the 
antibodies in some sera that react with these peptides. Peptide 14 was chosen initially 
because it was recognized by a large number of sera with the highest OD values and 
because it is located in the conserved region of the G protein. 
The affinity of an antibody response is a factor of critical biological significance 
(Steward, 1983) because it represents the strength of binding of antigen and antibody 
complex and the potentially important epitopes will be those epitopes that can induce 
and be recognized by antibodies with high affinity. 
A number of methods are available for the determination of affinity. In each 
procedure a system is set up in which antigen and antibody are allowed to come to 
eqUilibrium: 
Ab + Ag (::) Ab-Ag. 
The quantities of free antigen and complexed antigen are then measured without 
disturbing the equilibrium. There are several ways of doing this. Some separate the 
free antigen from the bound antigen by physical methods such as dialysis, gel 
filtration, centrifugation and selective precipitation. Others use change in the 
fluorescent properties of the complexed antigen and antibody. 
Data from these systems is analysed by applying the Law of Mass Action to give the 
equilibrium (affinity) constant, K: 
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K = fAb-AgJ 
[Ab] [Ag] 
Where [Ab-Ag] is the concentration of complexed antigen, [Ag] is the concentration 
of free antigen and [Ab] is the concentration of free antigen binding sites at 
equilibrium. When halfthe binding sites are occupied by antigen, [Ab] = [Ab-Ag], so 
it follows that K = l/[Ag]. In other words, a high-affinity antibody (one with a high 
K) only requires a low antigen concentration to achieve binding of antigen to half its 
combining sites, whereas a low - affinity antibody requires a much higher 
concentration of antigen to achieve this. Inhibition EIAs have been used in this work 
to obtain estimate of antibody affinity in some sera from Qatar. Serum samples were 
titrated to determine the required inhibitor dilution and the amount of peptide to be 
used in the affinity assay was determined 
A measure of the affinities of human anti - RSV antibodies to the relevant peptide 
was determined by a solid - phase enzyme inhibition assay (Rath et al., 1988). 
Appropriate dilutions of serum in blocking buffer were preincubated with 0.5 log 10 
dilutions of inhibiting peptide at 37 QC for 1 hour. The relative antipeptide antibody 
affinity was determined as the reciprocal of the molar concentration that gave 50% 
inhibition of the binding observed in the absence of inhibiting peptide. 
Determination of affmity maturation of antibodies reactive with peptide 14: 
In order to determine if there is affinity maturation of the antibodies to peptide 14 (i.e. 
a progressive immune in affinity with them), the inhibition assay was used with 
peptide 14 as the competitor peptide, RSV Ag as positive control and peptide 9 
(weakly reactive peptide) as negative control. A panel of sera obtained before 
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infection and sera from the same individuals taken after infection was used for this 
experiment Table 5.7 and Figure 5.9. 
Table 5.7 was constructed from results of the serum neutralizing assay (see following 
chapter). The average maximum OD for each serum (without inhibitor) was 
calculated. The log nMolar concentration of free peptide was calculated, using 
information from Table 5.3. 
Because the molecular weight of RSV antigen is unknown, the antigen concentration 
in ",glml was calculated. N.B. As during the assay a 2 fold dilution of the peptide and 
antigen was made by the addition of serum, the final concentration was half that of the 
calculated concentration. 
Graphs 5.9 were plotted of the OD against the log of nMolar concentration of 
peptides. From these graphs the log nMolar concentration of peptide that caused 50% 
inhibition was calculated. The anti-log of this figure was taken and the nMolar 
concentration converted to Molar concentration. To calculate the affinity of the 
antibodies, the reciprocal of this Molar concentration was taken and the result 
expressed as liters per mole. 
Peptide 14 (from RSV B G protein) could represent an important epitope stimulating 
high affinity anti-RSV antibodies (Table 5.7). Affinity values of 2 sera after infection 
(Q28 (B) and Q37 (A) were higher than before infection (i.e. affinity maturation). 
However, serum Q20 (B) has a high neutralization titre and its affinity value against 
peptide 14 after infection is lower than before infection (i.e. no affinity maturation). 
Larger amount of RSV antigen were utilized by Q20 (B) serum collected after 
infection than serum collected before infection to prevent binding to the antigen 
coated plate. It is possible that these neutralizing antibodies were mainly directed to 
other proteins (e.g. F protein) or to a confonnational epitope. Another possibility is 
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that neutralizing antibodies were mainly produced by the primary response and other 
neutralization antibodies were produced by the secondary response (more by memory 
cells). 
These results (Figure 5.9 & Table 5.7) suggest that peptide 14 probably represents a 
dominant epitope because it inhibits RSV -anti RSV binding nearly as well as does the 
RSV antigen. 
The affinity of the RSV antigen by the serum was not calculated. Since peptide 9 did 
not inhibit the binding of the serum to RSV antigen it is unlikely that peptide 9 
represents a dominant epitope. 
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Figure 5.9: Inhibition assay by using RSV antigen, peptide 14 and peptide 9 as 
inhibitors. 
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(a) Inhibition of binding of RSV antigen by human sera with free peptide 14. (b) 
Inhibition of binding of RSV antigen by human sera with RSV antigen. (c) Inhibition 
of binding of RSV antigen by human sera with free peptide 9. 
These results suggest that peptide 14 probably represents a dominant eiptope because 
it inhibits RSV -anti RSV binding nearly as well as does the RSV antigen. 
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Table 5.7: 50% inhibition assays by using RSV antigen, peptide 14 peptide and 9 
as inhibitors. 
(a) 
Sera RSV Neutralizing. Max.OD ** *** Con. **** 
Strain Titre Average Max.OD 50% Peptide 
Age/*M Average inhibition Affinity 
2 
Q20 Pre B/4 20 0.691 0.35 5.2 0.63 x 104 
Q20 Post. 640 0.826 0.4 5.92 0.12 x 104 
Q28 Pre B/6 5 0.444 0.22 9 0.1 x Ht 
Q28 Post 1280 0.791 0.39 5.4 0.39 x 104 
Q37 Pre NW 80 0.636 0.32 4.86 1.38 x lQ4 
Q37 Post 320 0.861 0.43 4.44 3.66 x l()4 
* Months 
** This value was used for the inhibition assay 
*** Log of nMolar of free peptide 14 concentration that give 50% inhibition 
**** The reciprocal M-I 
(a) Inhibition of binding of RSV antigen by human sera with free peptide 14. 
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Table 5.7: 50% inhibition assays by using RSV antigen, peptide 14 peptide and 9 
as inhibitors. 
(b) 
Sera RSV Neutralizing. Max.OD Max.OD RSVantigen 
Strain Titre Average Average conc. (~glml) 
Age/M 2 for 50% 
inhibition 
Q20 Pre B/4 20 0.845 0.42 1.32 
Q20 Post. 640 0.886 0.44 1.48 
Q28 Pre B/6 5 0.459 0.23 1.1 
Q28 Post 1280 0.959 0.48 2.06 
Q37 Pre AlW 80 0.592 0.29 1.46 
Q37 Post 320 0.841 0.42 1.6 
(b) Inhibition of binding ofRSV antigen by human sera with RSV antigen. There is 
no Inhibition of binding of RSV antigen by human sera with free peptide 9. 
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5.3 Discussion: 
Screening of serum from children (the important target population) for reactivity to 17 
RSV B - G protein peptides showed that there were antibodies to the conserved and C 
- terminal region of this protein in the samples collected from children before and 
after infection, even when the target antigen used in the assay was a linear peptide that 
was not glycosylated. The N-terminal section of the G protein was not studied 
because this part contains all the structural information required for efficient 
membrane insertion and cell surface expression. The N-terminal 71 amino acids of the 
G protein of RSV A strain failed to induce significant levels of G-specific antibodies 
in an other study (Olmsted et al., 1989) and as shown in Figure 4.11 this part of the 
protein has a low antigenic index (as assessed by protein programme of DNASTAR 
database). The strictly conserved region of the protein was covered with 2 extra 
peptides (16 & 17). 
The results obtained from screening the serum of Qatari children collected before and 
after infection showed a similar profile of peptide recognition. Also, sera from 
children infected with strain A, can bind peptides from the G protein of strain B 
(cross-reactivity), for examples peptides 14, 16, and 17. 
The majority of serum samples from all children infected were reactive with peptides 
14, 16, 17, 12 and 11. This suggests that these peptides could represent epitopes in 
the central region of the G protein that could be important targets for the induction of 
protective antibodies. From the amino acid sequences of the 5 peptides, it can be seen 
that they share some sequences with the strictly conserved 13 amino acid sequence 
present in all RSV strains (164-176). In particular, the important 3 amino acid 
sequence (VPC) is present in peptides 14, 16 and 17, this sequence has been found to 
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be important in several studies (Simard et al., 1997) and (Akerlind-Stopner et al., 
1990). 
Peptide 2 could be a potential candidate for use in a peptide - based vaccine for 
children under 6 months of age to avoid interference with maternal antibodies 
(Munoz & Gelzen, 2003; Weisman, 2(02) because it was not recognized by any 
neonatal or adult study sera and it was recognized by 43% of serum samples from 
children over 1 month of age. 
However, because this peptide derives from the C-terminal region of the G protein of 
RSV which is highly variable (Cane et al., 1996) and this sequence in RSV B/QI 
28100 contains one amino acid substitution and N & O-glycosylation sites, it may not 
be a good vaccine choice. 
The low peptide binding reactivity of peptides 1 to 10 with human sera could be a 
result of the heterogeneity of these peptide sequences, caused by either amino acid 
substitution or glycosylation. Similarity between the sequences of peptide 14, 16 & 17 
with the sequences of the infecting type for all Qatar isolates are rise to almost the 
same antibody recognition profiles. This is consistent with the finding that the pattern 
of peptide reactivity is closely related to the infecting genotype in animal models 
(Cane, 1996; Sullender, 1999). 
Peptide 14 was strongly recognized, highlighting the potential importance of residues 
150 - 165 ofthe G protein from RSV B strain. The fact that peptides 14, 16 & 17 are 
strongly bound by sera from children may indicate that epitopes in this region of the 
protein are importance in protection against RSV. 
A relatively large proportion of antibody responses to viral proteins are possibly 
directed towards conformational rather than to linear B - cell epitopes (Cane et al., 
1996). This fact can explain the low antibody recognition of pep tides 13 & 15, which 
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share some, sequences from the conserved region of protein G that has high antibody 
binding reactivity and lack of antibody recognition of peptide 11 by adult serum. 
The responses of babies to the variable of region of the G protein appeared to be 
related to some extent to the age of the child as has been reported in relation to 
affinity maturation of the response (Murphy et al., 1986; Rath et aI., 1988; Atabani et 
al., 1997). In order to determine the antigenicity of one representative peptide from 
the conserved region of protein G of RSV B strain by inhibition assay and to 
determine if there is any affinity maturation of antibody binding peptide 14 was 
chosen because this peptide was recognized by the majority (93 %) of sera. 
There was demonstrable affinity maturation in post-infection samples Q28 and Q37 
but not Q20. However, there was evidence of a secondary response in Q20 since the 
binding levels were much higher in the post-infection sample. These data suggest that 
peptide 14 could contain important epitopes that are recognized by high affinity 
antibodies post infection which inhibit antibody binding to RSV antigen. 
However, these results with peptide 14 are only preliminary and further 
immunization studies will be necessary and other peptides should be also studied 
(e.g. peptide 16, 17 and 2) to see whether they also are recognized by antibody with 
high affinity. 
It should be emphasized that even if peptides are bound with high affinity by all anti-
RSV sera it does not necessarily follow that they will be good vaccine candidates. 
This can only be indicated after extensive studies of their immunogenicity and 
antigenicity and their ability to induce virus-neutralizing and protective response in 
animal models. 
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6 Chapter 6: Analysis of the neutralization of RSV by sera 
from Qatari children 
6.1 Introduction: 
Immune responses to RSV have been extensively investigated and the induction of 
neutralizing antibodies has been associated with development of host protection. In 
infants, the presence of higher levels of maternal antibody are associated with 
increased levels of protection (Anderson & Heilman, 1995; Melero et al., 1997), 
however, infection is still possible even in the presence of maternal antibodies. 
Serological data and evidence from nucleotide sequencing indicate that major 
anti genic and amino acid sequence differences are found in the G glycoproteins of 
group A and B viruses, while the F glycoproteins of both group are more highly 
conserved. Recurrent infections with RSV occur throughout life. The importance of 
strain variation to protective immunity is less clear. Only a limited number of amino 
acid changes are required to produce a phenotype resistant to neutralization antibodies 
(in vitro) (Cane et al., 1994). Garcia-Beato et al., (1996) have shown that infection of 
different human epithelial cell lines with RSV, following passage in cell culture, 
revealed changes in the reactivity of the G glycoprotein with anti-G monoclonal 
antibodies. These results highlight the importance of cell-type specific modifications 
for the antigenicity of RSV G glycoprotein and raise questions about the actual 
antigenic structure of this molecule when RSV replicates in the respiratory tract. 
Some of the epitopes recognized by human antibodies that developed after natural 
infection have been mapped in the G protein by testing reactivity of convalescent sera 
either with synthetic peptides (Cane. 1997) or with protein segments of the G 
molecule expressed in bacteria as a fusion protein (Cane et al.. 1996). Most of these 
experiments were performed with the laboratory-adapted RSV A strains as previously 
mentioned in Chapter 5. 
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Few data are available on the immune responses to RSV B strains, including recently 
isolated RSV B strains, and little or no information is available concerning which G 
protein epitopes are recognized. Therefore, the main purpose of this part of this thesis 
was to determine whether there was a correlation between peptide binding activity to 
RSV B peptides in vitro and the titres of neutralizing anti-RSV A and B strain 
antibodies. 
Several methodologies have been described for the detection of RSV neutralizing 
antibody that are based on pretreatment of the virus with a dilution of monoclonal or 
serum antibody followed by infection of cell monolyers. Residual RSV infectivity is 
then determined by either a plaque reduction assay or assessment of the reduction in 
RSV antigen expression. In this part of the project, a modification of the micro 
neutralization method of (Anderson et al., 1985), as described in the Materials and 
Methods section 2.24 was used. 
The objective of this part of work to: 
• Develop a neutralizing antibody assay using lab adapted and recent Qatar 
isolates. 
• Determine whether or not neutralizing antibody titre is correlated with peptide 
reactivity. 
RSV neutralization activity in serum samples was evaluated in paired sera taken 
before and after infection in young children and in neonatal sera (containing 
predominantly maternal antibodies). Neutralizing antibodies present in each serum to 
3 RSV strains, two RSV A strains (one laboratory adapted strain A2 and the other a 
recent Qatar isolate AlQ/lO/OO) and one laboratory adapted B strain N2 were tested to 
determine the influence of strain and genotype diversity on anti-RSV antibody 
activity. 
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6.2 Results: 
6.2.1 Growth of viruses: 
Virus isolates were made from clinical materials from 2 seasons of the Qatar study 
group. The growth of virus from samples was assessed using Hep 2 cells and noting 
the appearance of syncytia and cytopathic effects between 3-5 days post inoculation 
(Figure 6.1 & 6.2). Considerable variation was noted between the clinical isolates in 
their ability to fonn large syncytia and to induce giant multinucleate cells. However, 
this observation of phenotypic variation in strain growth has not been followed up. 
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Figure 6.1 (a& b): Low-power view of continuous line of hep-2 cells infected with 
AlQIlO/OO 
a 
Syncytia 
CPE 
b 
Figure 6.1.a Low -Power view of continuous line of hep-2 cells inoculated with 2% 
MEM media (no virus) as negative control after 72 hours incubation (x 40). 
Figure 6.1.b Hep-2 cells infected with RSV positive clinical sample 
(QatarIRSV N2000/1O) after 72 hours incubation, multinucleate giant cell (syncytia) 
and cytopathic effect resulting from infection with RSV (x 40). 
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Figure 6.2: Electron photograph of (RSV AlQ/lO/OO) isolated from Qatar after 72 
hours incubation and ilXed by 3% phosphate butTered gluteraldhyde. (Courtesy 
of Mr. Wagner, Northern General Hospital). 
i. Different maturation stages of RSV infectious cycle in hep2 cells (x 114,100). 
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Figure 6.2: 
ii. Budding Virion (x 555000). 
Envelope 
spikes 
(SH, G, & F) 
Lipid layer 
(Matrix M, M2) 
Viral nucleocapsid 
(N, P& L) 
181 
Infected hep-2 
cell membrane 
Figure 6.2: 
Hi. Budding of two type of virion (Longitudinal & Circular particles) (x 248,418). 
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Figure 6.2: 
iv. Virus leaving a cell by lysis or buddi 
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6.2.2 Optimization of neutralization assay: 
As described previously in the Materials and Methods, a selection of both commercial 
and non-commercial antibodies, incubation periods and fixation methods were tested 
before finalizing a micro-neutralization test for field viruses that could be used with 
study sera 
A panel of 14 primary anti RSV antibodies (monoclonal and polyclonal) was 
evaluated using the cell-based ELISA test to titrate RSV study controls (RSV A A2 & 
RSV B N2) to determine which antibody was most suitable for use as a detecting 
antibody (primary antibody) in virus neutralization tests (Table 6.1& Figure 6.3) 
It was observed that some anti-RSV antibodies gave brown foci with clear 
background with RSV A only and at a high working dilution, but not with RSV B, 
and vies versa. 
The optimum incubation period was 3 days for most RSV A & B isolates with the 
development of clear syncytia and cytopathic effects on the Hep2 cells. For all tested 
viruses the best fixation method was with methanol hydrogen peroxidase (2%) for 20 
minutes (Table 6.2). 
Unfortunately, of 10 Qatar RSV A isolates and the laboratory -adapted A2 strain 
tested, only the AlQ/I0/00 and the A2 strains were detected by the commercial 
antibodies. In addition, the commercial antibodies detected none of the 5 Qatar RSV 
B isolates and only the laboratory-adapted RSVB N2 strain was recognized using the 
antibodies available for this study. This limited the work, which could be done on 
neutralization using Qatar B strains. 
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Table 6.1: Evaluation of panel of primary anti·RSV antibodies by cell based ELISA 
1 Reactivity 2lmmunogen 3 Designation Animal Source RSVA2 RSVBN2 RSV AQ/I0/00 RSV BQ128/00 I 
4F Ib Long MAB 8581 Mouse 115000 111000 No reaction No reaction 
5G 12 A2 MAB 8582 Mouse 1/9000 No reaction 115000 No reaction 
G4 A2 MAB 8583 Mouse 111000 No reaction No reaction No reaction 
G 12 A2 MAB 8584 Mouse 119000 No reaction No reaction No reaction 
G3b A2 MAB 8585 Mouse No reaction No reaction No reaction No reaction 
G5a Long MAB 8586 Mouse 117000 No reaction 1/1000 No reaction 
G A2 MAB 8593 Mouse 1/9000 No reaction No reaction No reaction 
F A2 MAB 8594 Mouse 1/1000 No reaction No reaction No reaction 
F A2 MAB 8598 Mouse No reaction No reaction No reaction No reaction 
F A2 MAB 8599 Mouse 111000 111000 No reaction No reaction 
F,G&6P A2 MAB 858-4 Mouse No reaction 115000 No reaction No reaction 
47-46 KDAF A2 MAB 858-1 Mouse No reaction 115000 No reaction No reaction 
89,KDG A2 MAB 858-2 Mouse No reaction 1/5000 No reaction No reaction 
Polyclonal A2 AB 1128 Goat 115000 115000 112000 No reaction 
- -- ---
-~--
IRSV antigen reacts with antibodies, 2 Immunogen: The origin of the virus either RSV A Long strain or A2, 3 All antibodies from Chemicon, 4 
Fusion protein, 5Glycoprotein, 6 nuclear protein. 
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Figure 6.3: Typical micro neutralization assays. 
Sera dilution (2x) 115 1110 1140 1/80 1/160 11320 
Serum I 
Serum 2 
Serum 3 
Serum 4 
Positive control 
(No Serum) 
Negative control 
(No virus) 
The positive control is virus (NQIlO/OO, 50 pfu/well) without sera. Serum 2 has a 
neutralizing antibodies titer of 1/40, and serum 4 has titre of 1180. 
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Table 6.2: Optimal neutralization virus titration factors 
RSV A (Q/IO/OO & A2) RSV B (N2) 
Incubation period 3 days 3 days 
Fixation method Methanol1H202 (2%)/20 Methanol1H202 (2%)1 20 
minutes minutes 
Primary antibodies Mab 858-4 Mab 858-2 
6.2.3 Final RSV micro neutralization assay: 
Antiserum controls produced by inoculating rabbits with the same control strains (2 
weeks post immunization) were used as a positive neutralizing antibody control 
Figure 6.4. From this figure it can be seen that 2 fold dilutions give a range of results 
that can be easily interpreted. 
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Figure 6.4: Neutralizing of RSV by rabbit anti-RSV serum (section 2.19) and 
determination of optimal dilution of sample Ql for use in neutralization assay 
90 ·· 
80 
70 
60 . 
~ 50 
LL 
a. 40 
30 ·· 
20 ' 
10 
0 
2 3 4 5 6 7 8 9 10 11 12 
Serum dilution 
-+- 1/1 (x2) 
--- 1/2 (x2) 
---- Rabbit serum (RSV A) -.- Rabbit serum (RSV B) 
-+- Rabbit serum (No virus) 
• III serum collected before infection, 1/ 2 serum collected after one month of 
infection from same child infected with A strain. 
• (2x) 2-fold dilution. 
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A neutralization assay was developed for RSV A2 strain and RSV B N2 based on the 
cell based EIA methodology, using Mab 858-4 and 858-2 as primary antibodies for 
RSV A and B, respectively. The negative controls were culture medium without 
antibody or without virus. Results using these antisera are displayed in Figure 6.4 
Antisera were capable of neutralizing RSV A and B controls strains, Calculation of 
neutralization end points indicated that a serum dilution of 11100 provided 50% 
neutralization of RSV B, compared to a serum dilution of 1150 which gave a similar 
result against RSV A. 
6.2.4 Changes in anti·RSV titre in paired sera: 
The reactivity of 36-paired serum samples (before and following infection) with 3 
RSV viruses (RSV A Q/lO/oo (recent isolate) andA2 (lab. Adapted strain) and RSV B 
N2) was assessed (Figure 6.5 a, b, c and Table 6.3), the results of individual sera are 
shown in appendix 9. The lowest neutralizing antibody titre was observed in acute 
sera (range from 115 to 11160). In all acute sera neutralizing antibody titres were 
below 200, while most convalescent sera neutralizing antibody titres were above 320. 
From this observation it could be suggested that the cut off level for protection was 
between a neutralizing antibody titre of 200-300. 
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Figure 6.5 (a, b, c): Anti-RSV neutralization titre in paired sera from children 
either infected with strain A or B. 
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Figure 6. :(a, b, c): Anti-RSV neutralization titre in paired sera from children 
either infected with strain A or B. 
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Figure 6. 5:(a, b, c): Anti-RSV neutralization titre in paired sera from children 
either infected with strain A or B. 
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Most infections occurred in patients in who the serum neutralization titre was below 
320. 
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Table 6.3: Number of sera with titre> 200 level of neutralizing titre among acute 
and convalescent sera of Qatar study children group (a) and their GMT mean 
and P value (b). 
(a) 
Virus strain AcuteRSVA Convalescent AcuteRSVB Convalescent 
sera RSVAsera sera RSVB sera 
RSV A (A2) 0/23 12/23 0/13 3/13 
RSVA 0/23 9/23 0/13 4/13 
(QI0/00) 
RSVB (N2) 1123 11123 0/13 8/13 
(b) 
Virus Acute Convalescent P value Acute Convalescent P value 
strain RSVA RSVA sera RSVB RSVB sera 
sera sera 
RSVA 47.9 203.6 <.005 22.2 160 <.005 
(A2) 
RSVA 42.5 168.0 <.005 24.7 198.04 <.005 
(QI0/00) 
RSVB 31.7 155.2 <.005 21.1 305.49 <.005 
(N2) 
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Convalescent sera with high level of neutralizing antibodies (>200) were more often 
seen from children infected with RSV B strain than from children infected with RSV 
A strain especially when the challenge virus was RSV B (N2) strain (Table 6.3). 
Sera with high neutralizing antibody titres show cross reactivity and can neutralize 
viruses from different groups at high working dilutions. For example, serum samples 
QlO, 21 & 37 obtained from children infected with RSV A could neutralize RSV B 
N2 at dilutions of 11320, 11640 & 11320 respectively. In addition, some sera (Q2, 28, 
43) from children infected with RSV B could neutralize virus AlQ/lO/oo at a high 
titre 111280, 111280 & 11640, respectively. These results suggest that the titre of 
neutralizing antibody appears to be more important than strain diversity. Also there 
were no significant differences in neutralizing antibody reactivity when either the 
recent RSV A isolate (AlQIlO/oo) or the laboratory-adapted strain (A2) were used. 
6.2.5 The etTect of age on RSV neutralizing antibody titre in sera before and 
after infection: 
The relationship between the titre of RSV neutralizing antibody from children (before 
and after infection) to the child's age at the time of molecular-proven infection was 
studied in 36 paired sera from the Qatar study children and the neonatal group 
consisting of 20 sera from children admitted to hospital for non-respiratory symptoms 
at an age of less than one month. Most of the Qatar study children and neonatal 
children who were less than 1 month had high titres of neutralizing antibody in their 
sera (mainly maternal antibodies). This suggests that children are born with a high 
neutralizing antibody titre (above 320) and after one month the titre decreases and the 
children become susceptible to infection. Figure 6.6. a. 
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Figure 6.6:(a, b, c, d): Comparison of RSV A & B neutralization antibody titre in 
individual Qatari children acute serum samples from children challenged with 
AQI0 strain (a & c) or challenged with BN2 strain (b & d). 
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Figure 6. ~:(a, b, c, d): Comparison of RSV A & B neutralization antibody titre in 
individual Qatari children acute serum samples from children challenged with 
AQI0 strain (a & c) or challenged with BN2 strain (b & d). 
(c) BN2I RSVA sera 
Mean neut. titre 
o 100 200 300 400 500 600 
_ .•. _____ .... ____________ .. ______________________ .•. ____________________ L .. ___ ... ___________ J ______________________ .L.... _ _ . .! ... 
-
., 
3 _ 
-
·l 
~ 5
-c:: o 7 __ 
:lE 
9 
III 
11 .'-
-
o 
(d) BN2I RSVB sera 
Mean neut. titre 
100 200 300 400 500 600 
700 800 
700 800 
______________________________________________ ... _____ • _._." ____________________ L. ________ __________ •• _l .• ____ • ___________ .... 1 •••••••••• ___________ .1.__ •• __ .•.• __ J 
3 
-~ 5 • 
-c:: o 7 :lE __ 
9 
11 
Each data point represents a serum sample of Qatar children serum above 1 month of 
age while less than 1 month represent neonatal sera (N= 20), all these collected at the 
same collecting time. 
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The question arises as to whether neonatal sera with high titres of neutralizing 
antibody to RSV A also react with a high neutralizing antibody titre to RSV B. 
Results in Figure 6.6.b show that this group of children were born with slightly 
higher neutralizing antibody titres to A than B, and this explains why this group of 
sera react better with strain A. 
6.2.6 Neutralizing antibody in sequential sera samples from individual 
children: 
The titre of neutralizing antibody in serum samples taken from Qatar (at the beginning 
ofthe study, after 1 month, after 12 months and after 13 months) was determined 
(Figure 6.7). 
The following points can be drawn from these results: -
(a) In general, there is an increase in neutralizing antibody titre in convalescent 
serum (recent infection) from all children; 
(b) There is very little difference in the reactivity to the two RSV A strains; 
(c) All children, irrespective of whether they were infected with RSV A or B 
subtype, had neutralizing antibodies to A and B strains; 
A decrease in neutralizing antibody titre was observed in the convalescent serum 
samples from children Q (7, 15,28,29,32 and 33). Over the study period this could 
indicate that infecting virus was bound by the existing antibodies and eliminated but 
this did not induce a boost in antibody titre. The failure to detect virus after re-
infection may be because the shedding period is usually very short in secondary 
infections due to the presence of preexisting antibodies; and 
Samples from children Q (13, 17, 18, 19, 21 and 34) show an increase in the titre of 
neutralizing antibody over the study period, indicating a recent infection with RSV. 
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Figure 6. 1: (a, b, c): Neutralizing antibody titre in sequential samples from 
Qatar children (a) against RSV A A2; (b) RSV AlQIlO and (c) RSV B N2. 
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Figure 6. 7f: (a, b, c): Neutralizing antibody titre in sequential samples from 
Qatar children (a) against RSV A A2; (b) RSV AlQ/lO and (c) RSV B N2. 
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The neutralizing antibody dilution level as following: 
1 = 115,2 = 1/10, 3 = 1120, 4= 1140, 5= 1180, 6= 11160,7 = 11320, 8 = 11640, 9= 1/1280, 
10 = 112560. 
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6.2.7 Relationship between neutralizing antibody titre and peptide binding 
reactivity in Qatar sera: 
To determine whether there was any correlation between neutralizing antibody titre 
and serum reactivity with the peptides in acute and convalescent sera, peptide binding 
values (OD) and neutralization titres using RSV strains (A (AlQ/to/OO) & B (BIN2) 
were assessed by regression analysis. The results of this analysis are given Table 6.4. 
The results show that although there is a relationship between peptide binding activity 
(OD) and neutralizing antibody titre, the r-values were in general low, some r-values 
were negative (when one variable decreases as the other increases) and some r-values 
were positive (when one variable increases as the other increases). For example, the r-
value with BIN2 neutralization vs. peptide binding for peptide 10 was the highest 
estimated (0.4) and r-values with Alto neutralization vs. peptide binding for peptides 
16, 14, 7 were also moderate (0.25, 0.23 and 0.22). The overall conclusion to be 
drawn from these analyses is that there was only a weak correlation between 
neutralizing antibody levels and reactivity with most sera of the peptides. 
In general, the reactivity of antibodies to peptides was not correlates with serum 
neutralizing antibody. 
6.2.8 Statistical analysis 
In an attempt to do more statistical analysis on the relationship between the titre of 
neutralizing antibodies and peptide reactivity, descriptive statistical analysis was 
undertaken. The mean values of neutralizing antibody titre of serum samples were 
taken from children before and following the infection and tested with 2 RSV strains 
(RSV AlQ/10 and RSV BN2) and compared with mean values of peptide reactivity 
(OD). A comparison made between those sera had a greater rise in mean anti-RSV A 
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and B titre when collected after the infection (317 and 351) than before infection 
(54.8 and 55). Mean OD values were slightly increased in line with an increase of 
mean of neutralizing titres of A&B with peptides (2,3,10,11,13 & 14), there was a 
reverse correlation with peptide (1,7,8,12) and no difference with remaining of 
peptides (Figure 6.8). 
6.8.2. Further statistical analysis was performed using stepwise regression (taking 
peptide 14 as base line for the analysis), to study peptide reactivity in post infection 
sera (OD post). These sera have higher neutralization antibody titres than pre 
infection sera (OD pre). There is statistical evidence that an increase in neutralizing 
antibody titre is associated with increase in peptide 14 recognition by sera from 
children after infection particularly if the sera show reactivity with this peptide before 
infection (Table 6.4 and Figure 6.9 as an example). 
In general it can be concluded that there is either no correlation or a weak correlation 
between neutralization activity and peptide reactivity (peptide 14) (Figure 6.10 and 
6.11) 
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Table 6.4: Regression values (r) of peptide reactivity and neutralizing antibody 
of Qatari sera. 
r values of r values of r values of r values of 
Peptide Neut (Al10) pre Neut (Al10) post Neut (B/N2) pre Neut (B/N2) post 
1 0.085 0.17 0.169 0.111 
2 0.079 0.062 0.049 0.004 
3 0.005 0.016 0.046 0.062 
4 0.026 0.1722 0.151 0.119 
5 0.33 0.228 0.171 0.174 
6 0.14 0.096 0.194 0.17 
7 0.041 0.215 0.101 0.07 
8 0.041 0.097 0.115 0.008 
9 0.171 0.023 0.046 0.187 
10 0.205 0.168 0.075 0.404 
11 0.059 0.106 0.194 0.15 
12 0.066 0.021 0.16 0.067 
13 0.266 0.212 0.094 0.004 
14 0.126 0.228 0.126 0.056 
15 0.092 0.2 0.142 0.082 
16 0.138 0.253 0.374 0.168 
17 0.257 0.189 0.069 0.053 
Red values indicate a positive relationship when neutralizing antibody reactivity 
increases as peptide reactivity increases after infection. 
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Figure 6 .. '9'; (a & b): Statistical analysis was undertaken on data from mean 
values of peptide reactivity (OD) with Qatar children serum samples (pre & post 
infection). 
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Figure 6. 8 :(a & b): Statistical analysis was undertaken on data from mean 
values of peptide reactivity (OD) with Qatar children serum samples (pre & post 
infection). 
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(b): Relation ship of neutralization titre and peptide binding reactivity (A/Q/lO/oo). 
Comparing those that had a greater rise in mean anti-RSV titer (Mean ne ut. Post 
A&B) 317.03 & 351.721 with those that had lower mean anti-RSV titer (Mean neut. 
Pre A&B) 54.84 & 55. 
The overall level of mean OD values were slightly increased with the increase of 
mean of ne ut. Titer of A&B with peptides (2,3,10,11,13 & 14), reverse correlation 
with peptide (1,7,8,12) and no difference with rest of peptides. 
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Figure 6. q : (a& b): Relationship of neutralizing antibody titre and solid phase 
binding to peptide 14 in all sera challenged with RSV AlI0/00. 
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Figure 6 .. Cl : (a& b): Relationship of neutralizing antibody titre and solid phase 
binding to peptide 14 in all sera challenged with RSV Al10/00. 
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(a) Qatar children sera infected with RSV A strain and (b) Qatar children sera 
infected with RSV B strain. 
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Figure 6.1 0: Detection the correlation between peptide reactivity and 
neutralization titre 
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Figure 6.11:(a, b, c, d): Relationship of neutralizing antibody titre and peptide 
reactivity for all sera challenged with RSV AllO/OO (a & b) and RSV B N2 strains 
(c & d). (a & c) Qatar children sera infected with RSV A strain and (b & d) 
Qatar children sera infected with RSV B strain. 
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6.3 Discussion: 
The role of antibodies against RSV in protective immunity has not been fully 
elucidated. However, antibodies against both the F and G protein are thought to be 
necessary for the efficient neutralization of RSV infection. 
The principal considerations of this study were the strain variation of RSV and the 
localisation of some epitopes on the G protein of RSV B strain using sera of known 
neutralizing antibody titre. Despite the extensive genetic and phenotypic differences 
found in the expression of G protein epitopes among RSV isolates, there are also 
epitopes in the G protein that are conserved among viral strains (Figure 5.2). The 
relative dominance of different epitopes in humoral immune responses during a 
natural infection is unclear (Melero et al., 1997). However, some studies (Cane, 1997) 
have suggested that conserved epitopes of the G protein were usually recognised by 
convalescent sera. These studies were complicated by the use of laboratory-adapted 
strains rather than viruses matched to the infecting genotype. Therefore the present 
project involves the identification of epitopes in the C-terminal region of the G 
protein of an RSV B strain isolated in Qatar that are recognized by neutralizing 
antibodies in serum of infected Qatari children. 
A fraction of material from NPA was used for RSV isolation from 36 children from 
whom paired sera were available from 2 seasons. In all of these children, respiratory 
material was positive by EIA and PCR, indicating a reasonable potential for recovery 
of RSV. 12/36 samples (33%) yielded RSV viruses. Among the isolates some viruses 
were easy to grow, giving 80-90% CPE after 3 days (e.g. AlQ/lO/OO strain) and others 
required a longer incubation period and induced limited CPE, particularly RSV B 
strains. Others (Savon et al., 2000; Hall et al., 1990) have observed this phenomenon 
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with RSV B strain. Following multiple passage of virus through cell culture, the RSV 
B and A strains could adapt to grow in the cell culture and hence lead to an increase 
yield of virus and this has been carried out for one strain. The failure to recover the 
RSV from previously identified positive samples (25 samples) was probably due to 
the lag in time between receipt of specimen and attempts to isolate virus, which was at 
least 6 months. Ideally, upon receipt of a sample, an aliquot should immediately be 
placed in tissue culture, which should allow better recovery of the virus. 
Electron micrographs obtained of RSV indicate different maturation stages of the 
virus, from accumulation of the virus internal structure near the cell membrane to the 
complete budding of the virus from this membrane. These photographs show two 
types of budding virion (longitudinal and circular particles) as indicated in other 
studies. These structural differences among Paramyxovirinae and Pneumovirinae 
may have a bearing on the replication strategies or on their neucleocapside flexibility 
employed by each virus subfamily (Bhella et al., 2(02) and also show two ways for 
the virus to leave the infected cell (either by budding or by lysis). 
A neutralization assay was established for evaluation of paired sera from children, by 
testing a panel of 14 primary anti RSV antibodies by the cell-based ELISA test (Table 
6.1). It was found that some monoclonal antibodies were not useful for virus detection 
in the neutralization assay, e.g. monoclonal antibodies raised against the nuclear 
protein (NP) reacted well with RSV strain B in agreement with the results from 
(Waris et al., 1990) but not with those from (Saville, 1997). In contrast, polyclonal 
antibody AB 1128 goat anti RSV detected both RSV strains efficiently, an 
observation also been made by (Martinez & Melero, 1998), but it was combined with 
a lot of false positive due to cross reactivity. Positive controls were also prepared. 
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The categorization of RSV isolates into two major antigenic groups has led to interest 
in group-specific antigenic differences and their relevance to the epidemiology of 
RSV infection and illness. We examined antigenic group - specific serum antibody 
responses to 3 RS viruses (2 strains A & 1 strain B) in children who had been 
followed for 2 seasons. The aim was to pick up secondary infection but because 
secondary infections were milder, no obvious secondary infections were detected. 
Evidence for the prophylactic importance of the neutralization titre of anti RSV 
antibodies titre was demonstrated in the 1980s (Prince et aI., 1985). A serum 
neutralization titre of 1 :300 in cotton rats conferred almost complete protection. 
These data are compatible with the protective level of maternal RSV neutralizing 
antibodies in the neonatal group. This protective effect is more likely to be noted in 
the first months of life, and less so at or beyond 3 months of age, depending on the 
starting antibody concentration. Acute RSV infection in women during pregnancy is 
likely to boost maternal RSV antibody that can transmit transplacentally to the infant, 
providing protection early in life (Munoz & Glezen, 2003). Also, the presence of 
protective antibodies in the neonatal group and non protective antibodies in young 
children of Qatar study group, could be explained by that the fact that antibodies 
generated by young children after their first RSV infection are qualitatively different 
from passively-acquired maternal antibodies in an age-matched group of non-infected 
children (Roca et al., 2003). In addition, maternally-acquired antibodies are likely to 
have developed after several infections in the mothers who might be expected to have 
accumulated a cross-reactive pool of antibodies as well as more avid antibodies to 
cross-reactive epitopes. 
If a protective neutralizing antibody titre (e.g. > 1 :320) could be established, then 
screening of various target populations would provide an estimate of the number of 
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individuals at risk of infection. This information would be useful in targeting groups 
for vaccination (Falsey, 1998). 
Children who experienced primary infections with one strain A genotype made 
significant levels of antibody cross - reactive with antigens of the other A genotype 
and B strain in the virus neutralization assay and in the peptide binding assay. Also, 
most children with primary infections with group B viruses had similar antibody 
levels in the neutralization assay with A strain and similar levels of peptide reactivity. 
Muelenaer et al. (Muelenaer et al., 1991) studied the antigenic group - specific serum 
antibody responses to first and second infection. They observed significant cross -
neutralization of group B viruses by convalescent sera obtained from children who 
had experienced group A infections, but not the converse. The present study showed 
significant levels of cross reactivity in neutralizing antibodies and peptide reactivity in 
serum from children infected with group A or B viruses and there is statistical 
evidence that an increase in neutralization titre is associated with an increase of 
peptide recognition by using same serum panel from children after infection 
especially if these react with peptide before infection. 
These findings suggest that at least part of the response in children was directed to 
epitopes conserved between groups on the F and for the conserved regions of the G 
protein, it well be useful in future to measure how much of neutralizing antibodies 
against G protein and how much against F protein among these sera. Also, using 
peptides from the C-terminal of the G protein as antigens (Cane, 1997) showed that 
infant responses can recognize strain-specific epitopes, although these may be 
masked, in part, in the fully glycosylated protein (Palomo et al., 2(00). Therefore, it is 
reasonable to propose that the strain-specific element of the response is directed 
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against the G glycoprotein. That these antibodies were not detected in the 
neutralization test suggest that antibodies directed to hyper variable regions of G 
protein may have low neutralizing capacity as found in other work (Roca et aI., 2(03). 
Nevertheless, it is still less clear whether differences between strains within the same 
group affect susceptibility to infection. In animals, the titres of neutralizing antibody 
and the level of protection from virus challenge are not significantly different when 
strains from different genotype within the same group are used (Jones et aI., 2(02) 
and (Sullender et al., 1998) and this is consistent with the results presented here. On 
the other hand, the annual shift in the group or genotype of viruses causing outbreaks 
in communities suggests that differences between strains in the same group may affect 
susceptibility to infection (Cane et al., 1994; Hall et al., 1990; Peret et aI, 1998). It is 
possible that a virus from a new genotype can transmit more efficiently or be more 
pathogenic because the RSV immunity in the population is most effective against a 
recentl y circulating genotype. 
The observation that the peptide reactivity of an antiserum was not correlated with 
neutralization activity indicates that this approach is of limited value. 
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7 Chapter 7: General summary and Conclusions 
RSV is a well-recognised cause of severe respiratory illness in infancy, in the elderly 
and in immunocompromised patients (Falseyet al., 1995; Raboni et al., 2(03). Little 
is known about RSV infection in the Gulf region (Rajala et aI., 2(03). The conclusion 
of the work reported here was that RSV is responsible for high number of paediatric 
seasonal hospital admissions in Qatar (38%). This finding highlights the need for an 
effective RSV vaccine in children. Although the work presented here has revealed 
that RSV accounts for a significant proportion of illness presenting as disease of the 
respiratory system, there is still a large number of other diseases of the respiratory 
system remaining un-diagnosed. Investigation of the samples from which no virus 
was identified by peR may suggest that other significant pathogens circulate within 
the community during the winter months e.g. the new paramyxovirus (the human 
metapneumovirus hMPV (van den Hoogen et al., 2(01), that give an overlapping or 
similar clinical picture to that of RSV infection (Chen et aI., 2004). Preliminary data 
suggest that hMPV may be responsible for approximately 7-8% of viral respiratory 
tract illnesses (RTI) in children (Stockton et al., 2002; Freymouth et al., 2(03). 
Application of a multiplex PCR to detect targets other than RSV and influenza in 
these samples would thus be informative. Follow up of the patients would also be 
useful as the duration of the symptoms was not available for the work presented here. 
Several factors need to be monitored along with duration of the symptoms, including 
the measurement of cytokines, temperature, requirement for ventilation etc. It would 
only be possible, however, to conduct these types of studies volunteers or from 
patient's records after their permission or parent permission. 
No attempt to monitor the circulation of RSV beyond the winter season was made 
here. Although hospital reports of RSV within HMC are very few during the summer, 
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the collection of samples from the paediatric department for analysis using the 
sensitive method of PCR may reveal background levels of circulation sporadic cases. 
In addition, little is known about RSV infection in the general community especially 
in elderly population in Qatar and the relationship to their admission to hospital. 
Expansion of the knowledge of RSV circulation and strain distribution within the 
general community will help with any vaccine design and delivery programme in this 
part of the world. 
For studies where the samples are of poor quality and low virus copy number, the 
storage of specimens can be critical. For maximum recovery of an RNA virus the 
stability of the viral RNA in transport media may be crucial. It would be better for all 
of the samples to be analysed upon receipt, preferably with virus grown to high titre in 
tissue culture. This is not always possible, however. Obviously, the longer the time 
the virus remains in sub-optimal conditions, the lower recovery of that virus. Steps to 
improve subsequent detection of virus after specimen receipt may include preserving 
the sample into guanidinium- based buffers before long storage, by collection in 
guanidinium stabilization buffer, binding matrix glass fibre fleece (or on filter paper 
impregnated with guanidinium buffer) and elution in low volume or store the sample 
as a primary PCR product after the transcription step (cDNA genome which is more 
stable than RNA genome) (DeGraves et al., 2(03). 
It has been demonstrated in this work that RSV infection in Qatar is highly seasonal, 
positively correlated with relative humidity and rainfall and inversely correlated with 
temperature. This type of information could be helpful for healthcare workers, when 
they intend to use the available anti-viral drugs or treatments of RSV (e.g.palivizumab 
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and aerosolised ribavirin). However, with several new antiviral compounds active 
against RSV now in the early clinical stages of development, targeted treatment of 
illness might become a realistic option. New anti-RSV agents would need to be tested 
in young adults and the elderly, and targeted treatment would need appropriate tests 
for the rapid diagnosis of RSV. In children, the titre of RSV in the nasal secretions is 
high, so rapid diagnosis is easy with either the indirect fluorescent-antibody test or 
commercial EIA (Zambon et al., 2(01). 
In addition, studies of the role of other environmental factors (e.g. environmental 
pollutant; diesel engine emission etc (Harrod et al., 2(03) and their effect on the RSV 
season would be of interest, e.g. Martinez ( 2003) suggests that both genetic and 
environmental factors determine the type of immune response to the acute RSV 
infection and that this response, in turn, may affect the development of the control 
mechanisms involved in the regulation of airway tone. Factors associated with 
increased risk are considered to be mostly environmental in nature (Munoz & Glezen, 
2(03), and especially social! environmental conditions, as air quality could contribute 
to the high RSV morbidity reported by large American or European centres, mostly 
located in dense urban environment (Brandenburg et al., 1997). 
The present genetic analysis of a recent RSV season in Qatar confirms the previously 
described higher variability found among group A isolates. Large differences were 
shown between group A and B isolates when a detailed comparison of different 
genetic features was performed. These differences may play role in the varied host 
immune response induced in infected children against the different RSV group. In 
addition, most of the Qatar RSV sequences analysed were genetically closely related 
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to previously describe viruses worldwide. The results therefore provide additional 
insight into the genetic and antigenic structure of both groups of RSV co-circulating 
in Middle East region and will contribute to the overall understanding of RSV 
circulation in the world. Also, it is still important to know whether the general 
community, especially the adult community, is infected with the same viral strains as 
infants and children. This is because any vaccine, for RSV, will ultimately be aimed 
at the infant and children populations (De Vincenzo, 1997). For example, if the viral 
strains circulating in the general community are distinct from those seen in the 
hospitalised infant population, they may represent a potential pool from which infants 
and children could be re-infected, post vaccination. 
The G protein gene displays the highest capacity for differentiating between RSV 
strains (Simoes, 200 1). Extensive analysis of RSV G protein variability has been 
performed with isolates from antigenic group A (Cane & Pringle, 1991; Cane & 
Pringle, 1995a; Garcia et al., 1994; Thompson et al., 2(03). Human antibody 
responses to linear epitopes of the variable region of the group B RS virus G protein 
analysed here have been assessed. The reactivity of human antibodies with synthetic 
peptides varied with the infecting RS virus group. In addition, all of the defined linear 
epitopes involved potential N-linked glycosylation sites in some of the RSV virus 
isolates. It has been suggested that the modulation of glycosylation sites might be a 
mechanism for evasion of the host immune response by RS viruses (Anderson et al., 
1991). The variable reactivity of human antibodies against peptides from this region 
of the G protein suggests the potential importance of antigenic changes in this region 
(peptide 1 to 10). Other workers have suggested that the final 68 C-terminal amino 
acids do not contribute to the major epitopes(s) of the G protein that are involved in 
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inducing protective immunity (Olmsted et al., 1989). The work presented here has 
demonstrated a lack of correlation between peptide reactivity and neutralizing 
antibody titre for both strain A and B of RSV. 
Contrary to what was observed in group B primary RSV infection, where cross-
reactive antibodies were detected in only a minor proportion of children, antibodies 
recognizing epitopes of the G protein of group B viruses were present in children with 
group A primary RSV infection (Hendry et al., 1988). Based on the data presented 
here, and accepting that the three-dimensional structure of the G protein remains to be 
elucidated, it could be hypothesized that the different pattern and number of putative 
glycosylation sites at the C-terminal of the G molecule found among both groups of 
viruses (especially for RSV A strains) and different G protein length (or stop codon 
termination for RSV B strains) might explain previous observations, since extensive 
glycosylation of group A strains may help to mask epitopes that are also present in B 
strains, and because no information available from this work about the correct three-
dimensional structure of the cysteine cluster, the suggestive receptor binding site 
(Melero et al., 1997). Thus, the present work doesn't exclude the possibility that C-
terminal end of the RSV G-protein directly contributes to the complete version of G-
protein epitopes. 
The poor quality of antibody responses to essential viral configurations is one factor 
of a variety of factors interfere with antibodies production quality, natural infections 
sometimes elicit very poor functional antibodies responses (e.g. HIV, Ebola virus and 
Dengue virus) (Burton & Parren, 2(00). 
Early studies described a " nonneutralizable" fraction of virus, which persisted even at 
high antibody concentrations. These nonneutralizable fractions have been described 
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for hepatitis A and hepatitis C as a result of virus association with lipids or 
lipoproteins (Burton et al., 2(00). Also, some nonneutralizing antibodies arose 
because of a failure to appreciate that antibodies that bind to isolated envelope 
molecules do not necessarily, and very often do not, bind to envelope spikes. A 
classic example is HIV -1 where many antibodies have been described which bind 
with high affinity to monomeric gp 120 or unprocessed gp 160, very few of these 
however showing substantial affinity for envelope spikes (parren et aI., 1998). The 
response to HIV -1 may be somewhat more complex than indicated, whereas 
immunogenicity may be low for conserved regions of the envelope spike, it is much 
higher for the variable regions. 
Therefore, antibody neutralization and binding to envelope spike (especially epitopes 
located at C-terminal end of the RSV G protein) are very closely related, and any 
change at this part of molecule by adding, removing, glycosylation changes or even a 
single amino acid substitution may trigger a conformational changes in the envelope, 
for example, favour fusion or such change may non-specifically reduce binding 
between virion and antibody molecule. 
Testing this hypothesis could be done by using an antigen-presenting system (Buratti 
et al., 1998)that preserve epitope conformation in the investigation of their immune 
responses or by using neutralization escape mutant system (McLain et al., 200 I) and 
constructed either the whole longest G protein or different length of carboxyl ends of 
RSV G protein and clone it in a vector, then raising antibodies against these protein 
and test it for the presence of any escape mutant. 
The importance of strain variation in the induction of protective immunity is less 
clear. Only a limited number of amino acid changes are required to produce a resistant 
phenotype to neutralizing antibodies (Cane et al., 1994) or in other virus (e.g. HIV) 
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(McLain et aI., 200 1). Repeated infections are more likely to occur with a virus from 
the heterologous than homologous group, presumably because immunity is more 
effective against the homologous than against the heterologous group viruses. In 
addition, some strains may be more virulent than others (Anderson & Heilman, 1995). 
These data, plus the data indicating the existence of dual infections in the current 
study, suggest that a RSV vaccine should include strains from both groups A and B. 
An initial group of chimeric recombinant AB vaccines have been constructed 
(Whitehead et al., 1999) in which the F & G genes from wild-type (wt) strain A2 were 
removed and replaced with the F & G genes from strain B. The immunogenicity and 
efficacy of one particular AB chimeric vaccine candidate was assessed in 
chimpanzees and resulted in significantly less rhinorhea and cough than infection with 
wild-type RSV (Whitehead et al., 1999). Furthermore, in recent years, passive 
administration of anti-RSV antibodies to high-risk children has been found to 
effective in decreasing the chance of developing severe clinical disease upon RSV 
infection (Hemming et al., 1995), emphasizing the importance of neutralizing 
antibodies. 
Protective antibodies against RSV are predominantly directed to the F & G proteins. 
Antibody responses to the F glycoprotein of RSV are cross - reactive with RSV 
strains, whereas antibody responses to the G glycoprotein are largely subgroup 
specific (Hendry et al., 1988). One explanation as to why some patients may have 
'breakthrough, RSV infection while receiving palivirzumab (humanized chimeric 
monoclonal antibody directed against the conserved neutralizing epitope of the F 
glycoprotein of the RSV) is that this type of treatment lacks antibodies against the G 
protein (Weisman, 2(02). In addition, immunization work RSV B l/cp-52 indicated 
that responses to F alone were sufficient to mediate infectivity in vitro, albeit this viral 
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strain was markedly attenuated in vivo. Naturally occurring G protein deletion 
mutants have not been described and therefore it is reasonable to assume that G offers 
an advantage to the virus during infection in vivo (Feldman et aI., 2001). 
Any RSV subunit vaccine containing the G protein would require both A and B 
subgroup G protein to afford protection against viruses (Sullender et al., 1990). Using 
peptides representing antigen epitopes as sub-unit vaccines, it would be possible to 
avoid any epitope that is in any way responsible for pathology (e.g. the amino acid 
sequences of the G protein 184 - 198 that cause a typical pulmonary eosinophilia 
(Tebbey et al., 1998). Furthermore, the most immunogenic epitopes of the G protein 
from both strains can be used. 
B-cell epitopes (e.g. peptide 14, a.a 150-165) that mapped to the central conserved 
domain were recognised by the majority of human sera used «93%) in this study. 
However, other peptides from the central region that are predominantly recognised by 
human sera (e.g. peptides 16 and 17) needs to be studied further. Thus, structural 
features of the epitope, several host factors (Le., antigen presentation, genetic back 
ground of the host) need to be studied since these can influence immune 
responsiveness and affinity and specificity of the antibody response (Partidos & 
Steward, 2002). 
The variation in the G region was discussed earlier (Chapter 4) and any vaccine based 
on this region would need to take account of this variation. Vaccines based on the G 
protein of RSV are currently being developed, and any information on the extent of 
variation within this region (especially for RSV B strain) is therefore of use (Siegrist 
et al., 1999). The data presented in this study may contribute to overall understanding 
of the extent of variation in this region of the genome. 
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In addition to exposure environmental risk factors, other factors, such as serum 
neutralizing antibody titre and the individual's own immune response, may have a 
greater influence on disease severity than the nature of the infecting strain. Others 
have found that serum neutralizing antibody plays role in protecting an infant against 
RSV infection. The observation of Gelzen et al., (Glezen et aI., 1981) and passive 
immunoprophylaxis studies in humans (Groothuis et al., 1993) show that a serum 
neutralizing antibody titre of 1 :300 is sufficient to protect young infants against being 
hospitalized with RSV illness. Also, the anti-RSV antibody titre in pregnant women at 
the time of delivery was important in protecting their infants, Acute RSV infection in 
women during pregnancy is likely to boost maternal RSV antibody that can be 
transmitted transplacentally to the infant, providing protection early in life (Munoz & 
Glezen, 2(03). 
From the present study it was found that there was association between the presence 
of higher concentrations of maternal neutralizing antibodies to RSV and young age 
(>1 month), as others have found (Le Saux et al., 2003; Englund, 1994; Walsh & 
Falsey, 2004). The importance of the protection afforded by maternal antibodies is 
clearly seen in infants incapable of producing immunoglubulins are protected by 
maternal antibodies for the first 3 to 12 months after birth. Maternal IgG antibodies 
enter the fetal circulation through the placenta. Constant boosting of the immunety 
can be achieved by infections with various microbes. Examples are periodic 
reinfection by poliovirus, the persistence of low level of disabled measles virus, and 
controlled subclinical infection by persistent hepatitis B virus (HBV) (Zinkernagel, 
2001; Rehermann et al., 1996). 
Cross-reactivity of maternally transferred antibodies may be result of two different 
mechanisms, strain-specific immunity and strain-transcending immunity (or a 
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combination of both). First of all, it may be that multiple infections in the mother 
involving different virus strains results in a broad range of strain specific antibodies 
that are maternally acquired. Alternatively, the cross-reactivity of maternally 
transferred antibodies may be a consequence of high level of antibodies against 
conserved virus epitopes induced by repeated infection. There is no evidence from 
this study, however, that infants who developed RSV infection were deficient in 
strain-specific antibodies. But on the other hand, this study indicates that high levels 
of passively acquired antibodies may protect against RSV infection. It is likely, 
therefore, that boosting maternal antibodies may benefit infants during the first 
months of life. This type of data can be useful for maternal immunization programs 
against RSV. 
In general, longitudinal community-based studies of RSV variability will be necessary 
to define precisely the contribution of antigenic variation or the amount or titre of 
neutralizing antibodies in RSV reinfection. This type of information will be important 
when we are planning the designing and timing of RSV vaccines, because it is likely 
that different RSV vaccines will be needed for the various populations at risk. For 
example, if we intend to use the vaccine in the beginning of each season for the target 
population (infant, elderly, pregnant women and immunocompromised patients) thus 
antigenic variation is more important and it will be important to up date the vaccine 
(especially epitope based vaccine) with protective epitopes from both strains of recent 
circulating strains for each year, as for the influenza vaccine (Simoes, 2(03) and 
(Polack & Karron, 2004b). While if the amount and titre of the neutralizing antibodies 
are is more important, peptide based vaccine (non-replicating vaccine) that contains 
peptides from the conserved domains of both strains and both important glycoproteins 
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(F and G) for each season could be used. This would be particularly important if the 
season was characterised by high relative humidity, rainfall and low temperature. 
228 
8 References 
The PREVENT Study Group.( 1997). Reduction of respiratory syncytial virus 
hospitalization among premature infants and infants with bronchopulmonary 
dysplasia using respiratory syncytial virus immune globulin prophylaxis. 
Pediatrics 99,93-9. 
Akerlind, B., Norrby, E., Orvell, C. & Mufson, M. A. (1988). Respiratory syncytial 
virus: heterogeneity of subgroup B strains. J Gen Virol 69 ( Pt 9),2145-54. 
Akerlind-Stopner, B., Utter, G., Mufson, M. A., Orvell, C., Lemer, R. A. & Norrby, 
E. (1990). A subgroup-specific anti genic site in the G protein of respiratory 
syncytial virus forms a disulfide-bonded loop. J Virol64, 5143-8. 
Albargish, K. A. & Hasony, H. J. (1999). Respiratory syncytial virus infection among 
young children with acute respiratory tract infection in Iraq. East Mediterr 
Health J 5, 941-8. 
Alford, R. H., Kasel, J. A., Gerone, P. J. & Knight, V. (1966). Human influenza 
resulting from aerosol inhalation. Proc Soc Exp Bioi Med 122,800-4. 
Alwan, W. H., Kozlowska, W. J. & Openshaw, P. J. (1994). Distinct types of lung 
disease caused by functional subsets of antiviral T cells. J Exp Med 179, 81-9. 
Alwan, W. H., Record, F. M. & Openshaw, P. J. (1992). CD4+ T cells clear virus but 
augment disease in mice infected with respiratory syncytial virus. Comparison 
with the effects of CD8+ T cells. Clin Exp Immunol88, 527-36. 
Amit, A. G., Mariuzza, R. A., Phillips, S. E. & Poljak, R. J. (1986). Three-
dimensional structure of an antigen-antibody complex at 2.8 A resolution. 
Science 233, 747-53. 
Anderson, D. J., Stone, J., Lum, R. & Linial, M. L. (1995). The packaging phenotype 
of the SE21 Q 1 b provirus is related to high proviral expression and not trans-
acting factors. J Virol69, 7319-23. 
Anderson, L. J. & Heilman, C. A. (1995). Protective and disease-enhancing immune 
responses to respiratory syncytial virus. J Infect Dis 171, 1-7. 
Anderson, L. 1., Hendry, R. M., Pierik, L. T., Tsou, C. & McIntosh, K. (1991). 
Multicenter study of strains of respiratory syncytial virus. J Infect Dis 163, 
687-92. 
Anderson, L. J., Hierholzer, J. c., Tsou, c., Hendry, R. M., Femie, B. F., Stone, Y. & 
McIntosh, K. (1985). Antigenic characterization of respiratory syncytial virus 
strains with monoclonal antibodies. J Infect Dis 151,626-33. 
229 
Anderson, L. J., Tsou, C., Potter, c., Keyserling, H. L., Smith, T. F., Ananaba, G. & 
Bangham, C. R. (1994). Cytokine response to respiratory syncytial virus 
stimulation of human peripheral blood mononuclear cells. J Infect Dis 170, 
1201-8. 
Andersson, C., Liljestrom, P., Stabl, S. & Power, U. F. (2000). Protection against 
respiratory syncytial virus (RSV) elicited in mice by plasmid DNA 
immunisation encoding a secreted RSV G protein-derived antigen. FEMS 
Immunol Med Microbiol29, 247-53. 
Amold, R. & Konig, W. (1996). ICAM-l expression and low-molecular-weight G-
protein activation of human bronchial epithelial cells (A549) infected with 
RSV. J Leukoc Biol60, 766-71. 
Amon, R. & Sela, M. (1985). Synthetic vaccines: present and future. Ann Inst Pasteur 
Immunol136D,271-82. 
Atabani, S. F., Obeid, O. E., ChargeJegue, D., Aaby, P., Whittle, H. & Steward, M. 
W. (1997). Identification of an immunodominant neutralizing and protective 
epitope from measles virus fusion protein by using human sera from acute 
infection. J Virol71, 7240-5. 
Atassi, M. Z. (1979). The antigenic structure of myoglobin and initial consequences 
of its precise determination. CRe Crit Rev Biochem 6, 337-69. 
Atreya, P. L., Peeples, M. E. & Collins, P. L. (1998). The NS 1 protein of human 
respiratory syncytial virus is a potent inhibitor of minigenome transcription 
and RNA replication. J Virol72, 1452-61. 
Bakir, T. M., Halawani, M. & Ramia, S. (1998). Viral aetiology and epidemiology of 
acute respiratory infections in hospitalized Saudi children. J Trop Pediatr 44, 
100-3. 
Barik, S., McLean, T. & Dupuy, L. C. (1995). Phosphorylation of Ser232 directly 
regulates the transcriptional activity of the P protein of human respiratory 
syncytial virus: phosphorylation of Ser237 may play an accessory role. 
Virology 213, 405-12. 
Bdour, S. (2001). Respiratory syncytial virus subgroup A in hospitalized children in 
Zarqa, Jordan. Ann Trop Paediatr 21,253-61. 
Behera, A. K., Matsuse, H., Kumar, M., Kong, X., Lockey, R. F. & Mohapatra, S. S. 
(200 1). Blocking intercellular adhesion molecule-Ion human epithelial cells 
decreases respiratory syncytial virus infection. Biochem Biophys Res Commun 
280, 188-95. 
Belshe, R. B., Van Voris, L. P. & Mufson, M. A. (l982a). Parenteral administration 
of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis 
145,311-9. 
230 
Belshe, R. B., Van Voris, L. P., Mufson, M. A., Buynak, E. B., McLean, A. A. & 
Hilleman, M. A. (1982b). Comparison of enzyme-linked immunosorbent assay 
and neutralization techniques for measurement of antibody to respiratory 
syncytial virus: implications for parenteral immunization with live virus 
vaccine. Infect Immun 37, 160-5. 
Bendelja, K., Gagro, A., Bace, A., Lokar-Kolbas, R., Krsulovic-Hresic, V., 
Drazenovic, V., Mlinaric-Galinovic, G. & Rabatic, S. (2000). Predominant 
type-2 response in infants with respiratory syncytial virus (RSV) infection 
demonstrated by cytokine flow cytometry. Clin Exp Immunol121, 332-8. 
Bermingham, A. & Collins, P. L. (1999). The M2-2 protein of human respiratory 
syncytial virus is a regulatory factor involved in the balance between RNA 
replication and transcription. Proc Natl Acad Sci USA 96, 11259-64. 
Bhella, D., Ralph, A., Murphy, L. B. & Yeo, R. P. (2002). Significant differences in 
nucleocapsid morphology within the Paramyxoviridae. J Gen Virol 83, 1831-
9. 
Blount, R. E., Jr., Morris, J. A. & Savage, R. E. (1956). Recovery of cytopathogenic 
agent from chimpanzees with coryza. Proc Soc Exp Bioi Med 92,544-9. 
Blydt-Hansen, T., Subbarao, K., Quennec, P. & McDonald, J. (1999). Recovery of 
respiratory syncytial virus from stethoscopes by conventional viral culture and 
polymerase chain reaction. Pediatr Infect Dis} 18, 164-5. 
Bont, L., Heijnen, C. J., Kavelaars, A., van Aalderen, W. M., Brus, F., Draaisma, J. 
T., Geelen, S. M. & Kimpen, J. L. (2000). Monocyte IL-lO production during 
respiratory syncytial virus bronchiolitis is associated with recurrent wheezing 
in a one-year follow-up study. Am} Respir Crit Care Med 161,1518-23. 
Bont, L., Van Aalderen, W. M., Versteegh, J., Brus, F., Draaisma, 1. T., Pekelharing-
Berghuis, M., Van Diemen-Steenvoorde, R. A. & Kimpen, J. L. (200 1). 
Airflow limitation during respiratory syncytial virus lower respiratory tract 
infection predicts recurrent wheezing. Pediatr Infect Dis } 20, 277-82. 
Boom, R., Sol, C. J., Salimans, M. M., Jansen, C. L., Wertheim-van Dillen, P. M. & 
van der Noordaa, J. (1990). Rapid and simple method for purification of 
nucleic acids. } Clin Microbio128, 495-503. 
Borriello, S. P. (1999). Science, medicine, and the future. Near patient 
microbiological tests. BM} 319,298-301. 
Brandenburg, A. H., Jeannet, P. Y., Steensel-Moll, H. A., Ott, A., Rothbarth, P. H., 
Wunderli, W., Suter, S., Neijens, H. J., Osterhaus, A. D. & Siegrist, C. A. 
(1997). Local variability in respiratory syncytial virus disease severity. Arch 
Dis Child 77, 410-4. 
231 
Brandenburg, A H., Kleinjan, A., van Het Land, B., Moll, H. A, Timmerman, H. H., 
de Swart, R L., Neijens, H. J., Fokkens, W. & Osterhaus, A D. (2000a). Type 
I-like immune response is found in children with respiratory syncytial virus 
infection regardless of clinical severity. J Med Virol62, 267-77. 
Brandenburg, A H., Neijens, H. J. & Osterhaus, A. D. (2001). Pathogenesis of RSV 
lower respiratory tract infection: implications for vaccine development. 
Vaccine 19,2769-82. 
Brandenburg, A H., van Beek, R, Moll, H. A, Osterhaus, A D. & Claas, E. e. 
(2000b). G protein variation in respiratory syncytial virus group A does not 
correlate with clinical severity. J Clin Microbiol 38, 3849-52. 
Brandt, C. D., Kim, H. W., Arrobio, J. 0., Jeffries, B. C., Wood, S. C., Chanock, R 
M. & Parrott, R H. (1973). Epidemiology of respiratory syncytial virus 
infection in Washington, D.e. 3. Composite analysis of eleven consecutive 
yearly epidemics. Am J Epidemiol 98, 355-64. 
Bukreyev, A, Whitehead, S. S., Murphy, B. R. & Collins, P. L. (1997). Recombinant 
respiratory syncytial virus from which the entire SH gene has been deleted 
grows efficiently in cell culture and exhibits site-specific attenuation in the 
respiratory tract of the mouse. J Virol 71, 8973-82. 
Bulkow, L. R., Singleton, R J., Karron, R A & Harrison, L. H. (2002). Risk factors 
for severe respiratory syncytial virus infection among Alaska native children. 
Pediatrics 109,210-6. 
Bumess, AT., Pardoe, I., Faragher, S. G., Vrati, S. & Dalgamo, L. (1988). Genetic 
stability of Ross River virus during epidemic spread in nonimmune humans. 
Virology 167, 639-43. 
Cane, P. A (1993). Frameshifting and anti genic variation in respiratory syncytial 
virus. Trends Microbioll, 156-9. 
Cane, P. A. (1997). Analysis of linear epitopes recognised by the primary human 
antibody response to a variable region of the attachment (G) protein of 
respiratory syncytial virus. J Med Virol51, 297-304. 
Cane, P. A., Matthews, D. A & Pringle, C. R (1991). Identification of variable 
domains of the attachment (G) protein of subgroup A respiratory syncytial 
viruses. J Gen Virol 72 ( Pt 9), 2091-6. 
Cane, P. A, Matthews, D. A & Pringle, C. R (1992). Analysis of related ne ss of 
subgroup A respiratory syncytial viruses isolated worldwide. Virus Res 25, 15-
22. 
Cane, P. A., Matthews, D. A & Pringle, C. R (1994). Analysis of respiratory 
syncytial virus strain variation in successive epidemics in one city. J Clin 
Microbiol 32, 1-4. 
232 
Cane, P. A. & Pringle, C. R. (1991). Respiratory syncytial virus heterogeneity during 
an epidemic: analysis by limited nucleotide sequencing (SH gene) and 
restriction mapping (N gene). J Gen Virol72 ( Pt 2),349-57. 
Cane, P. A. & Pringle, C. R. (1995a). Evolution of subgroup A respiratory syncytial 
virus: evidence for progressive accumulation of amino acid changes in the 
attachment protein. J Virol69, 2918-25. 
Cane, P. A. & Pringle, C. R. (1995b). Molecular epidemiology of respiratory 
syncytial virus: a review of the use of reverse transcription-polymerase chain 
reaction in the analysis of genetic variability. Electrophoresis 16,329-33. 
Cane, P. A., Thomas, H. M., Simpson, A. F., Evans, J. E., Hart, C. A. & Pringle, C. R. 
(1996). Analysis of the human serological immune response to a variable 
region of the attachment (G) protein of respiratory syncytial virus during 
primary infection. J Med Viro148, 253-61. 
Cane, P. A., Weber, M., Sanneh, M., Dackour, R., Pringle, C. R. & Whittle, H. 
(1999). Molecular epidemiology of respiratory syncytial virus in The Gambia. 
Epidemiol Infect 122, 155-60. 
Carballal, G., Videla, c., Sequeira, M. D., Mistchenko, A., Requeijo, P. V. & Arbiza, 
J. (2000). Respiratory syncytial virus: changes in prevalence of subgroups A 
and B among Argentinian children, 1990-1996. J Med Virol61, 275-9. 
Casola, A., Garofalo, R. P., Haeberle, H., Elliott, T. F., Lin, R., Jamaluddin, M. & 
Brasier, A. R. (2001). Multiple cis regulatory elements control RANTES 
promoter activity in alveolar epithelial cells infected with respiratory syncytial 
virus. J Virol75, 6428-39. 
Chan, P. K., Sung, R. Y., Fung, K. S., Hui, M., Chik, K. W., Adeyemi-Doro, F. A. & 
Cheng, A. F. (1999). Epidemiology of respiratory syncytial virus infection 
among paediatric patients in Hong Kong: seasonality and disease impact. 
Epidemiol Infect 123, 257-62. 
Chan, P. W., Chew, F. T., Tan, T. N., Chua, K. B. & Hooi, P. S. (2002). Seasonal 
variation in respiratory syncytial virus chest infection in the tropics. Pediatr 
PulmonoI34,47-51. 
Chanock, R. & Finberg, L. (1957). Recovery from infants with respiratory illness of a 
virus related to chimpanzee coryza agent (CCA). 11. Epidemiologic aspects of 
infection in infants and young children. Am J Hyg 66, 291-300. 
Chargelegue, D., Obeid, O. E., Shaw, D. M., Denbury, A. N., Hobby, P., Hsu, S. C. & 
Steward, M. W. (1997). Peptide mimics of a confonnationally constrained 
protective epitopes of respiratory syncytial virus fusion protein. Immunol Lett 
57, 15-7. 
233 
Cherrie, A H., Anderson, K., Wertz, G. W. & Openshaw, P. J. (1992). Human 
cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, 
F, M, 22K, and 1 b proteins of respiratory syncytial virus. J Virol 66, 2102-10. 
Chew, F. T., Doraisingham, S., Ling, A. E., Kumarasinghe, G. & Lee, B. W. (1998). 
Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol 
Infect 121, 121-8. 
Chin, J., Magoffin, R. L., Shearer, L. A., Schieble, J. H. & Lennette, E. H. (1969). 
Field evaluation of a respiratory syncytial virus vaccine and a trivalent 
parainfluenza virus vaccine in a pediatric population. Am J Epidemiol89, 449-
63. 
Choi, E. H. & Lee, H. J. (2000). Genetic diversity and molecular epidemiology of the 
G protein of subgroups A and B of respiratory syncytial viruses isolated over 9 
consecutive epidemics in Korea. J Infect Dis 181, 1547-56. 
Coggins, W. B., Letkowitz, E. J. & Sullender, W. M. (1998). Genetic variability 
among group A and group B respiratory syncytial viruses in a children's 
hospital. J Clin Microbiol 36, 3552-7. 
Collins, C. L. & Pollard, A J. (2002). Respiratory syncytial virus infections in 
children and adults. J Infect 45, 10-7. 
Collins, P. L., Camargo, E. & Hill, M. G. (1999a). Support plasmids and support 
proteins required for recovery of recombinant respiratory syncytial virus. 
Virology 259,251-5. 
Collins, P. L., Whitehead, S. S., Bukreyev, A., Fearns, R., Teng, M. N., Juhasz, K., 
Chanock, R. M. & Murphy, B. R. (1999b). Rational design of live-attenuated 
recombinant vaccine virus for human respiratory syncytial virus by reverse 
genetics. Adv Virus Res 54, 423-51. 
Colman, P. M., Varghese, J. N. & Laver, W. G. (1983). Structure of the catalytic and 
antigenic sites in influenza virus neuraminidase. Nature 303,41-4. 
Connors, M., Collins, P. L., Firestone, C. Y., Sotnikov, A. V., Waitze, A., Davis, A 
R., Hung, P. P., Chanock, R. M. & Murphy, B. R. (1992a). Cotton rats 
previously immunized with a chimeric RSV FG glycoprotein develop 
enhanced pulmonary pathology when infected with RSV, a phenomenon not 
encountered following immunization with vaccinia--RSV recombinants or 
RSV. Vaccine 10,475-84. 
Connors, M., Giese, N. A, Kulkarni, A. B., Firestone, C. Y., Morse, H. C., 3rd & 
Murphy, B. R. (1994). Enhanced pulmonary histopathology induced by 
respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-
immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and 
IL-lO. J Virol68, 5321-5. 
234 
Connors, M., Kulkarni, A. B., Collins, P. L., Firestone, C. Y., Holmes, K. L., Morse, 
H. c., 3rd & Murphy, B. R. (1992b). Resistance to respiratory syncytial virus 
(RSV) challenge induced by infection with a vaccinia virus recombinant 
expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while 
that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J 
Virol 66, 1277-81. 
Cristina, J., Moya, A., Arbiza, J., Russi, J., Hortal, M., Albo, c., Garcia-Barreno, B., 
Garcia, 0., Melero, J. A. & Portela, A. (1991). Evolution of the G and P genes 
of human respiratory syncytial virus (subgroup A) studied by the RNase A 
mismatch cleavage method. Virology 184, 210-8. 
Crowcroft, N. S., Cutts, F. & Zambon, M. C. (1999). Respiratory syncytial virus: an 
underestimated cause of respiratory infection, with prospects for a vaccine. 
Commun Dis Public Health 2, 234-41. 
Crowe, J. E., Jr. (1995). Current approaches to the development of vaccines against 
disease caused by respiratory syncytial virus (RSV) and parainfluenza virus 
(PN). A meeting report of the WHO Programme for Vaccine Development. 
Vaccine 13,415-21. 
Dagouassat, N., Robillard, V., Haeuw, J. F., Plotnicky-Gilquin, H., Power, U. F., 
Corvaia, N., Nguyen, T., Bonnefoy, 1. Y. & Beck, A. (2001). A novel bipolar 
mode of attachment to aluminium-containing adjuvants by BBG2Na, a 
recombinant subunit hRSV vaccine. Vaccine 19,4143-52. 
Dawod, S. T. & Hussain, A. A. (1995). Childhood asthma in Qatar. Ann Allergy 
Asthma Immunol75, 360-4. 
Dayan, P., Ahmad, F., Urtecho, J., Novick, M., Dixon, P., Levine, D. & Miller, S. 
(2002). Test characteristics of the respiratory syncytial virus enzyme-linked 
immunoabsorbent assay in febrile infants < or = 60 days of age. Clin Pediatr 
(Phila) 41, 415-8. 
DeGraves, F. J., Gao, D. & Kaltenboeck, B. (2003). High-sensitivity quantitative PCR 
platform. Biotechniques 34, 106-10, 112-5. 
De Vincenzo, J. (1997). Prevention and treatment of respiratory syncytial virus 
infections (for advances in pediatric infectious diseases). Adv Pediatr Infect 
Dis 13, 1-47. 
Domachowske, J. B. & Rosenberg, H. F. (1999). Respiratory syncytial virus infection: 
immune response, immunopathogenesis, and treatment. Clin Microbiol Rev 
12,298-309. 
Draenert, R., Le Gall, S., Pfafferott, K. J., Leslie, A. J., Chetty, P., Brander, C., 
Holmes, E. C., Chang, S. C., Feeney, M. E., Addo, M. M., Ruiz, L., Ramduth, 
D., Jeena, P., Altfeld, M., Thomas, S., Tang, Y., Verrill, C. L., Dixon, C., 
235 
Prado, J. G., Kiepiela, P., Martinez-Picado, J., Walker, B. D. & Goulder, P. J. 
(2004). Immune Selection for Altered Antigen Processing Leads to Cytotoxic 
T Lymphocyte Escape in Chronic HIV-l Infection. J Exp Med 199,905-15. 
Drews, A. L., Atmar, R. L., Glezen, W. P., Baxter, B. D., Piedra, P. A. & Greenberg, 
S. B. (1997). Dual respiratory virus infections. Clin Infect Dis 25, 1421-9. 
Ellis, J. S., Fleming, D. M. & Zambon, M. C. (1997). Multiplex reverse transcription-
PCR for surveillance of influenza A and B viruses in England and Wales in 
1995 and 1996. 1 Clin Microbiol 35, 2076-82. 
Englund, J. A. (1994). Passive protection against respiratory syncytial virus disease in 
infants: the role of maternal antibody. Pediatr Infect Dis J 13, 449-53. 
Falsey, A. R. (1998). Respiratory syncytial virus infection in older persons. Vaccine 
16, 1775-8. 
Falsey, A. R., Cunningham, C. K., Barker, W. H., Kouides, R W., Yuen, J. B., 
Menegus, M., Weiner, L. B., Bonville, C. A. & Betts, R. F. (1995). 
Respiratory syncytial virus and influenza A infections in the hospitalized 
elderly. J Infect Dis 172, 389-94. 
Fearns, R., Peeples, M. E. & Collins, P. L. (2002). Mapping the transcription and 
replication promoters of respiratory syncytial virus. J Virol 76, 1663-72. 
Feldman, S. A, Crim, R L., Audet, S. A. & Beeler, J. A (2001). Human respiratory 
syncytial virus surface glycoproteins F, G and SH form an oligomeric 
complex. Arch Viro1146, 2369-83. 
Francis, D. P., Feorino, P. M., McDougal, S., Warfield, D., Getchell, J., Cabradilla, 
c., Tong, M., Miller, W. J., Schultz, L. D., Bailey, F. J. & et al. (1986). The 
safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine 
vaccine manufacture. lama 256, 869-72. 
Francis, M. J. (1990). Peptide vaccines for viral diseases. Sci Prog 74, 115-30. 
Freymouth, F., Vabret, A., Legrand, L., Eterradossi, N., Lafay-Delaire, F., Brouard, J. 
& Guillois, B. (2003). Presence of the new human metapneumovirus in French 
children with bronchiolitis. Pediatr Infect Dis J 22, 92-4. 
Fume, J. K, Springfield, 1. R, Ho, S. B. & Levitt, M. D. (2003). Simplification of the 
end-alveolar carbon monoxide technique to assess erythrocyte survival. J Lab 
ClinMed 142,52-7. 
Garcia, 0., Martin, M., Dopazo, 1., Arbiza, J., Frabasile, S., Russi, 1., Hortal, M., 
Perez-Brena, P., Martinez, I., Garcia-Barreno, B. & et al. (1994). Evolutionary 
pattern of human respiratory syncytial virus (subgroup A): cocirculating 
lineages and correlation of genetic and anti genic changes in the G 
glycoprotein. J Virol68, 5448-59. 
236 
Garcia-Barreno, B., Portela, A., Delgado, T., Lopez, J. A. & Melero, J. A. (1990). 
Frame shift mutations as a novel mechanism for the generation of 
neutralization resistant mutants of human respiratory syncytial virus. Embo J 
9,4181-7. 
Garcia-Beato, R., Martinez, I., Franci, c., Real, F. X., Garcia-Barreno, B. & Melero, 
J. A. (1996). Host cell effect upon glycosylation and antigenicity of human 
respiratory syncytial virus G glycoprotein. Virology 221,301-9. 
Garcia-Sastre, A., Egorov, A., Matassov, D., Brandt, S., Levy, D. E., Durbin, J. E., 
Palese, P. & Muster, T. (1998). Influenza A virus lacking the NSl gene 
replicates in interferon-deficient systems. Virology 252,324-30. 
Geysen, H. M., Mason, T. J. & Rodda, S. J. (1988). Cognitive features of continuous 
antigenic determinants. J Mol Recognit 1,32-41. 
Gibson, K. M., Mori, J. & Clewley, J. P. (1993). Detection of HI V-I in serum, using 
reverse transcription and the polymerase chain reaction (RT-PCR). J Virol 
Methods 43, 101-9. 
Glezen, W. P., Paredes, A., Allison, J. E., Taber, L. H. & Frank, A L. (1981). Risk of 
respiratory syncytial virus infection for infants from low-income families in 
relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 
98, 708-15. 
Goestch, L., Plotnicky-Gilquin, H., Champion, T., Beck, A, Haeuw, 1. F., Nguyen, 
T., Bonnefoy, J. Y. & Corvaia, N. (2000). Influence of live respiratory 
syncytial virus priming on the immune response generated by a recombinant 
vaccine candidate, BBG2Na. Vaccine 18,2648-55. 
Goulder, P. J., Lechner, F., Klenerman, P., McIntosh, K. & Walker, B. D. (2000). 
Characterization of a novel respiratory syncytial virus-specific human 
cytotoxic T-Iymphocyte epitope. J Viro174, 7694-7. 
Graham, B. S., Bunton, L. A, Wright, P. F. & Karzon, D. T. (1991). Role ofT 
lymphocyte subsets in the pathogenesis of primary infection and rechallenge 
with respiratory syncytial virus in mice. J Clin Invest 88, 1026-33. 
Graham, B. S., Henderson, G. S., Tang, Y. W., Lu, X., Neuzil, K. M. & Colley, D. G. 
(1993). Priming immunization determines T helper cytokine mRNA 
expression patterns in lungs of mice challenged with respiratory syncytial 
virus. J Immunol151, 2032-40. 
Groothuis, J. R., King, S. J., Hogerman, D. A., Paradiso, P. R. & Simoes, E. A. 
(1998). Safety and immunogenicity of a purified F protein respiratory 
syncytial virus (PFP-2) vaccine in seropositive children with 
bronchopulmonary dysplasia. J Infect Dis 177,467-9. 
Groothuis, J. R., Simoes, E. A. & Hemming, V. G. (1995). Respiratory syncytial virus 
(RSV) infection in preterm infants and the protective effects of RSV immune 
237 
globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study 
Group. Pediatrics 95, 463-7. 
Groothuis, J. R, Simoes, E. A., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. 
J., Arrobio, J., Meissner, H. c., Fulton, D. R, Welliver, R. C. & et al. (1993). 
Prophylactic administration of respiratory syncytial virus immune globulin to 
high-risk infants and young children. The Respiratory Syncytial Virus Immune 
Globulin Study Group. N Engl J Med 329, 1524-30. 
Grosfeld, H., Hill, M. G. & Collins, P. L. (1995). RNA replication by respiratory 
syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also 
occurs under these conditions but requires RSV superinfection for efficient 
synthesis of full-length mRNA. J Virol69, 5677-86. 
Haeberle, H. A., Kuziel, W. A., Dieterich, H. J., Casola, A., Gatalica, Z. & Garofalo, 
R P. (200 1). Inducible expression of inflammatory chemokines in respiratory 
syncytial virus-infected mice: role of MIP-lalpha in lung pathology. J Virol 
75,878-90. 
Hall, C. B., Walsh, E. E., Long, C. E. & Schnabel, K. C. (1991). Immunity to and 
frequency of reinfection with respiratory syncytial virus. J Infect Dis 163,693-
8. 
Hall, C. B., Walsh, E. E., Schnabel, K. C., Long, C. E., McConnochie, K. M., 
Hildreth, S. W. & Anderson, L. J. (1990). Occurrence of groups A and B of 
respiratory syncytial virus over 15 years: associated epidemiologic and clinical 
characteristics in hospitalized and ambulatory children. J Infect Dis 162, 1283-
90. 
Halstead, D. C. & Jenkins, S. G. (1998). Continuous non-seasonal epidemic of 
respiratory syncytial virus infection in the southeast United States. South Med 
J91,433-6. 
Hamaguchi, M., Yoshida, T., Nishikawa, K., Naruse, H. & Nagai, Y. (1983). 
Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are 
required to constitute an active complex. Virology 128, 105-17. 
Han, L. L., Alexander, J. P. & Anderson, L. J. (1999). Respiratory syncytial virus 
pneumonia among the elderly: an assessment of disease burden. J Infect Dis 
179,25-30. 
Hancock, G. E., Speelman, D. J., Heers, K., Bortell, E., Smith, J. & Cosco, c. (1996). 
Generation of atypical pulmonary inflammatory responses in BALB/c mice 
after immunization with the native attachment (G) glycoprotein of respiratory 
syncytial virus. J Virol 70, 7783-91. 
Hardy, R W. & Wertz, G. W. (1998). The product of the respiratory syncytial virus 
M2 gene ORF 1 enhances readthrough of intergenic junctions during viral 
transcription. J Virol 72, 520-6. 
238 
Harrod, K. S., Jaramillo, R. J., Rosenberger, C. L., Wang, S. Z., Berger, J. A, 
McDonald, J. D. & Reed, M. D. (2003). Increased susceptibility to RSV 
infection by exposure to inhaled diesel engine emissions. Am J Respir Cell 
Mol Bioi 28, 451-63. 
Haynes, L. M., Moore, D. D., Kurt-Jones, E. A, Finberg, R. W., Anderson, L. J. & 
Tripp, R. A (2001). Involvement of toll-like receptor 4 in innate immunity to 
respiratory syncytial virus. J Virol 75, 10730-7. 
Hemming, V. G., Prince, G. A, Groothuis, J. R. & Siber, G. R. (1995). Hyperimmune 
globulins in prevention and treatment of respiratory syncytial virus infections. 
Clin Microbiol Rev 8, 22-33. 
Henderson, F. W., Clyde, W. A., Jr., Collier, A. M., Denny, F. W., Senior, R. J., 
Sheaffer, C. I., Conley, W. G., 3rd & Christian, R. M. (1979). The etiologic 
and epidemiologic spectrum of bronchiolitis in pediatric practice. J Pediatr 95, 
183-90. 
Hendry, R. M., Bums, 1. c., Walsh, E. E., Graham, B. S., Wright, P. F., Hemming, V. 
G., Rodriguez, W. J., Kim, H. W., Prince, G. A, McIntosh, K. & et al. (1988). 
Strain-specific serum antibody responses in infants undergoing primary 
infection with respiratory syncytial virus. J Infect Dis 157, 640-7. 
Hendry, R. M., Pierik, L. T. & McIntosh, K. (1989). Prevalence of respiratory 
syncytial virus subgroups over six consecutive outbreaks: 1981-1987. J Infect 
Dis 160, 185-90. 
Hickling, T. P., Malhotra, R., Bright, H., McDowell, W., Blair, E. D. & Sim, R. B. 
(2000). Lung surfactant protein A provides a route of entry for respiratory 
syncytial virus into host cells. Virallmmunol 13, 125-35. 
Hijazi, Z., Pacsa, A, Eisa, S., el Shazli, A., Abd el-Salam, R. & el-Gharbawy, F. 
(1995). Respiratory syncytial virus infections in children in a desert country. 
Pediatr Infect Dis J 14, 322-4. 
Holberg, C. J., Wright, A L., Martinez, F. D., Ray, C. G., Taussig, L. M. & Lebowitz, 
M. D. (1991). Risk factors for respiratory syncytial virus-associated lower 
respiratory illnesses in the first year of life. Am J Epidemiol 133, 1135-51. 
Homsleth, A, Klug, B., Nir, M., Johansen, J., Hansen, K. S., Christensen, L. S. & 
Larsen, L. B. (1998). Severity of respiratory syncytial virus disease related to 
type and genotype of virus and to cytokine values in nasopharyngeal 
secretions. Pediatr Infect Dis J 17, 1114-21. 
Hussell, T., Baldwin, C. J., O'Garra, A. & Openshaw, P. J. (1997). CD8+ T cells 
control Th2-driven pathology during pulmonary respiratory syncytial virus 
infection. Eur J Immunol27, 3341-9. 
239 
Hussell, T. & Openshaw, P. J. (1998). Intracellular IFN-gamma expression in natural 
killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial 
virus infection. J Gen Virol 79 ( Pt 11), 2593-601. 
Hussell, T. & Openshaw, P. J. (2000). IL-12-activated NK cells reduce lung 
eosinophilia to the attachment protein of respiratory syncytial virus but do not 
enhance the severity of illness in CD8 T cell-immunodeficient conditions. J 
ImmunolI65,7109-15. 
Hussell, T., Spender, L. C, Georgiou, A, O'Garra, A & Openshaw, P. J. (1996). Thl 
and Th2 cytokine induction in pulmonary T cells during infection with 
respiratory syncytial virus. J Gen Virol77 ( Pt 10),2447-55. 
Isaacs, D., Bangham, C. R. & McMichael, A J. (1987). Cell-mediated cytotoxic 
response to respiratory syncytial virus in infants with bronchiolitis. Lancet 2, 
769-71. 
J ackson, M. & Scott, R. (1996). Different patterns of cytokine induction in cultures of 
respiratory syncytial (RS) virus-specific human TH cell lines following 
stimulation with RS virus and RS virus proteins. J Med Viro149, 161-9. 
Jin, H., Clarke, D., Zhou, H. Z., Cheng, X., Coelingh, K., Bryant, M. & Li, S. (1998). 
Recombinant human respiratory syncytial virus (RSV) from cDNA and 
construction of subgroup A and B chimeric RSV. Virology 251, 206-14. 
Johansen, J., Christensen, L. S., Hornsleth, A., Klug, B., Hansen, K. S. & Nir, M. 
(1997). Restriction pattern variability of respiratory syncytial virus during 
three consecutive epidemics in Denmark. Apmis 105,303-8. 
Johnson, P. R & Collins, P. L. (1989). The IB (NS2), lC (NSl) and N proteins of 
human respiratory syncytial virus (RSV) of antigenic subgroups A and B: 
sequence conservation and divergence within RSV genomic RNA J Gen Virol 
70 ( Pt 6), 1539-47. 
Johnson, P. R, Spriggs, M. K., Olmsted, R. A & Collins, P. L. (1987). The G 
glycoprotein of human respiratory syncytial viruses of subgroups A and B: 
extensive sequence divergence between antigenically related proteins. Proc 
Natl Acad Sci USA 84, 5625-9. 
Johnson, T. R., Johnson, J. E., Roberts, S. R, Wertz, G. W., Parker, RA & Graham, 
B. S. (1998). Priming with secreted glycoprotein G of respiratory syncytial 
virus (RSV) augments interleukin-5 production and tissue eosinophilia after 
RSV challenge. J Virol 72, 2871-80. 
Jones, L. P., Zheng, H. Q., Karron, R A, Peret, T. C, Tsou, C & Anderson, L. J. 
(2002). Multiplex assay for detection of strain-specific antibodies against the 
two variable regions of the G protein of respiratory syncytial virus. Clin Diagn 
Lab Immunol9, 633-8. 
240 
Kapikian, A Z., Mitchell, R. H., Chanock, R. M., Shvedoff, R. A & Stewart, C. E. 
(1969). An epidemiologic study of altered clinical reactivity to respiratory 
syncytial (RS) virus infection in children previously vaccinated with an 
inactivated RS virus vaccine. Am J Epidemiol 89, 405-21. 
Karanfil, L. V., Conlon, M., Lykens, K, Masters, C. F., Forman, M., Griffith, M. E., 
Townsend, T. R. & Perl, T. M. (1999). Reducing the rate of nosocomially 
transmitted respiratory syncytial virus. Am J Infect Control 27, 91-6. 
Karron, R. A., Buonagurio, D. A., Georgiu, A F., Whitehead, S. S., Adamus, J. E., 
Clements-Mann, M. L., Harris, D. 0., Randolph, V. B., Udem, S. A, Murphy, 
B. R. & Sidhu, M. S. (1997). Respiratory syncytial virus (RSV) SH and G 
proteins are not essential for viral replication in vitro: clinical evaluation and 
molecular characterization of a coId-passaged, attenuated RSV subgroup B 
mutant. Proc Natl Acad Sci USA 94, 13961-6. 
Kim, H. W., Arrobio, J. 0., Brandt, C. D., Jeffries, B. c., Pyles, G., Reid, J. L., 
Chanock, R. M. & Parrott, R. H. (1973a). Epidemiology of respiratory 
syncytial virus infection in Washington, D.e. I. Importance of the virus in 
different respiratory tract disease syndromes and temporal distribution of 
infection. Am J Epidemio198, 216-25. 
Kim, H. W., Arrobio, J. 0., Brandt, C. D., Wright, P., Hodes, D., Chanock, R. M. & 
Parrott, R. H. (1973b). Safety and antigenicity of temperature sensitive (TS) 
mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics 
52,56-63. 
Kim, H. W., Canchola, J. G., Brandt, C. D., PyIes, G., Chanock, R. M., Jensen, K. & 
Parrott, R. H. (1969). Respiratory syncytial virus disease in infants despite 
prior administration of antigenic inactivated vaccine. Am J Epidemiol89, 422-
34. 
Kok, T., Barancek, K & Burrell, C. J. (1990). Evaluation of the Becton Dickinson 
Directigen test for respiratory syncytial virus in nasopharyngeal aspirates. J 
Clin Microbiol28, 1458-9. 
Krusat, T. & Streckert, H. J. (1997). Heparin-dependent attachment of respiratory 
syncytial virus (RSV) to host cells. Arch Viroll42, 1247-54. 
Kurt-Jones, E. A., Popova, L., Kwinn, L., Haynes, L. M., Jones, L. P., Tripp, R. A., 
Walsh, E. E., Freeman, M. W., GoIenbock, D. T., Anderson, L. J. & Finberg, 
R. W. (2000). Pattern recognition receptors TLR4 and CD14 mediate response 
to respiratory syncytial virus. Nat Immunol I, 398-401. 
Le Saux, N., Gaboury, I. & MacDonald, N. (2003). Maternal respiratory syncytial 
virus antibody titers: season and children matter. Pediatr Infect Dis J 22, 563-
4. 
Leach, S. J. (1983). How antigenic are antigenic peptides? Biopolymers 22, 425-40. 
241 
Levin, M. J. (1994). Treatment and prevention options for respiratory syncytial virus 
infections. J Pediatr 124, S22-7. 
Levine, S., Klaiber-Franco, R. & Paradiso, P. R. (1987). Demonstration that 
glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen 
Virol 68 ( Pt 9), 2521-4. 
Li, X., Sambhara, S., Li, C. X., Ettorre, L., Switzer, I., Cates, G., James, 0., 
Parrington, M., Oomen, R., Du, R. P. & Klein, M. (2000). Plasmid DNA 
encoding the respiratory syncytial virus G protein is a promising vaccine 
candidate. Virology 269, 54-65. 
Libon, c., Corvaia, N., Haeuw, J. F., Nguyen, T. N., Stabl, S., Bonnefoy, J. Y. & 
Andreoni, C. (1999). The serum albumin-binding region of streptococcal 
protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A 
protein. Vaccine 17,406-14. 
Lina, B., Valette, M., Foray, S., Luciani, J., Stagnara, J., See, D. M. & Aymard, M. 
(1996). Surveillance of community-acquired viral infections due to respiratory 
viruses in Rhone-Alpes (France) during winter 1994 to 1995. J Clin Microbiol 
34,3007-11. 
Lopez, J. A, Bustos, R., Orvell, c., Berois, M., Arbiza, J., Garcia-Barreno, B. & 
Melero, J. A (1998). Antigenic structure of human respiratory syncytial virus 
fusion glycoprotein. J Virol 72, 6922-8. 
Loscertales, M. P., Roca, A, Ventura, P. J., Abacassamo, F., Dos Santos, F., Sitaube, 
M., Men ndez, C., Greenwood, B. M., Saiz, J. C. & Alonso, P. L. (2002). 
Epidemiology and clinical presentation of respiratory syncytial virus infection 
in a rural area of southern Mozambique. Pediatr Infect Dis J 21, 148-55. 
Luoh, S. M., McGregor, M. W. & Hinshaw, V. S. (1992). Hemagglutinin mutations 
related to antigenic variation in HI swine influenza viruses. J Virol 66, 1066-
73. 
Mackenzie, A., Hallam, N., Mitchell, E. & Beattie, T. (1999). Near patient testing for 
respiratory syncytial virus in paediatric accident and emergency: prospective 
pilot study. Bmj 319, 289-90. 
Mackie, P. L., Madge, P. J., Getty, S. & Paton, J. Y. (1991). Rapid diagnosis of 
respiratory syncytial virus infection by using Pemasal swabs. J Clin Microbiol 
29,2653-5. 
Maitreyi, R. S., Broor, S., Kabra, S. K., Ghosh, M., Seth, P., Oar, L. & Prasad, A K. 
(2000). Rapid detection of respiratory viruses by centrifugation enhanced 
cultures from children with acute lower respiratory tract infections. J CUn 
VirolI6,41-7. 
Malley, R., DeVincenzo, J., Ramilo, 0., Dennehy, P. H., Meissner, H. c., Gruber, W. 
c., Sanchez, P. J., Jafri. H., Balsley, J., Carlin. D .• Buckingham. S .• 
Vernacchio, L. & Ambrosino, D. M. (1998). Reduction of respiratory 
242 
syncytial virus (RSV) in tracheal aspirates in intubated infants by use of 
humanized monoclonal antibody to RSV F protein. J Infect Dis 178, 1555-61. 
Martinez, F. D. (2003). Respiratory syncytial virus bronchiolitis and the pathogenesis 
of childhood asthma. Pediatr Infect Dis J 22, S76-82. 
Martinez, I., Dopazo, J. & Melero, J. A. (1997). Antigenic structure of the human 
respiratory syncytial virus G glycoprotein and relevance of hypermutation 
events for the generation of antigenic variants. J Gen Virol 78 ( Pt 10), 2419-
29. 
Martinez, I. & Melero, J. A. (1998). Enhanced neutralization of human respiratory 
syncytial virus by mixtures of monoclonal antibodies to the attachment (G) 
glycoprotein. J Gen Virol79 ( Pt 9),2215-20. 
Martinez, I. & Melero, J. A. (2000). Binding of human respiratory syncytial virus to 
cells: implication of sulfated cell surface proteoglycans. J Gen Virol 81, 2715-
22. 
McConnochie, K M., Hall, C. B., Walsh, E. E. & Roghmann, K J. (1990). Variation 
in severity of respiratory syncytial virus infections with subtype. J Pediatr 
117,52-62. 
McIntosh, K., Masters, H. B., Orr, I., Chao, R. K. & Barkin, R. M. (1978). The 
immunologic response to infection with respiratory syncytial virus in infants. J 
Infect Dis 138, 24-32. 
Meissner, H. C. (1994). Economic impact of viral respiratory disease in children. J 
Pediatr 124, SI7-21. 
Meissner, H. C., Groothuis, J. R., Rodriguez, W. J., Welliver, R. c., Hogg, G., Gray, 
P. H., Loh, R., Simoes, E. A., Sly, P., Miller, A. K., Nichols, A.I., Jorkasky, 
D. K, Everitt, D. E. & Thompson, K A. (1999). Safety and pharmacokinetics 
of an intramuscular monoclonal antibody (SB 209763) against respiratory 
syncytial virus (RSV) in infants and young children at risk for severe RSV 
disease. Antimicrob Agents Chemother 43, 1183-8. 
Melero, J. A., Garcia-Barreno, B., Martinez, I., Pringle, C. R. & Cane, P. A. (1997). 
Antigenic structure, evolution and immunobiology of human respiratory 
syncytial virus attachment (G) protein. J Gen Virol 78 ( Pt 10), 2411-8. 
Mills, J. t., Van Kirk, J. E., Wright, P. F. & Chanock, R. M. (1971). Experimental 
respiratory syncytial virus infection of adults. Possible mechanisms of 
resistance to infection and illness. J Immunol107, 123-30. 
Milner, M. E., de la Monte, S. M. & Hutchins, G. M. (1985). Fatal respiratory 
syncytial virus infection in severe combined immunodeficiency syndrome. Am 
J Dis Child 139, 1111-4. 
243 
Mito, K., Chi ba, Y., Suga, K. & Nakao, T. (1984). Cellular immune response to 
infection with respiratory syncytial virus and influence of breast-feeding on 
the response. J Med Viroll4, 323-32. 
Muelenaer, P. M., Henderson, F. W., Hemming, V. G., Walsh, E. E., Anderson, L. J., 
Prince, G. A. & Murphy, B. R. (1991). Group-specific serum antibody 
responses in children with primary and recurrent respiratory syncytial virus 
infections. J Infect Dis 164, 15-21. 
Mufson, M. A., Belshe, R. B., Orvell, C. & Norrby, E. (1987). Subgroup 
characteristics of respiratory syncytial virus strains recovered from children 
with two consecutive infections. J Clin Microbiol25, 1535-9. 
Mufson, M. A., Orvell, C., Rafnar, B. & Norrby, E. (1985). Two distinct subtypes of 
human respiratory syncytial virus. J Gen Virol66 ( Pt 10),2111-24. 
Munoz, F. M. & Glezen, W. P. (2003). Why no effect of maternal respiratory 
syncytial virus-neutralizing antibody? Pediatrics Ill, 218-20; author reply 
218-20. 
Murphy, B. R., AIling, D. W., Snyder, M. H., Walsh, E. E., Prince, G. A., Chanock, 
R. M., Hemming, V. G., Rodriguez, W. J., Kim, H. W., Graham, B. S. & et al. 
(1986). Effect of age and preexisting antibody on serum antibody response of 
infants and children to the F and G glycoproteins during respiratory syncytial 
virus infection. J Clin Microbiol 24, 894-8. 
Norrby, E., Mufson, M. A., Alexander, H., Houghten, R. A. & Lemer, R. A (1987). 
Site-directed serology with synthetic peptides representing the large 
glycoprotein G of respiratory syncytial virus. Proc Natl Acad Sci USA 84, 
6572-6. 
Nowak, M. A., May, R. M., Phillips, R. E., Rowland-Jones, S., Lalloo, D. G., 
McAdam, S., Klenerman, P., Koppe, 8., Sigmund, K., Bangham, C. R. & et 
al. (1995a). Antigenic oscillations and shifting immunodominance in HIV-l 
infections. Nature 375, 606-11. 
Nowak, M. A, May, R. M. & Sigmund, K. (l995b). Immune responses against 
multiple epitopes. J Theor Bioi 175, 325-53. 
Olmsted, R. A, Murphy, B. R., Lawrence, L. A, Elango, N., Moss, B. & Collins, P. 
L. (1989). Processing, surface expression, and immunogenicity of carboxy-
terminally truncated mutants of G protein of human respiratory syncytial 
virus. J Virol63, 411-20. 
Olszewska, W., Helson, R. & Openshaw, P. J. (2004). Vaccines for the prevention of 
respiratory viral infections: problems and current status. Expert Opin Investig 
Drugs 13,681-689. 
Olszewska, W., Partidos, C. D. & Steward, M. W. (2000). Antipeptide antibody 
responses following intranasal immunization: effectiveness of mucosal 
adjuvants. Infect Immun 68, 4923-9. 
244 
Openshaw, P. J., Clarke, S. L. & Record, F. M. (1992). Pulmonary eosinophilic 
response to respiratory syncytial virus infection in mice sensitized to the major 
surface glycoprotein G.lnt Immunol4, 493-500. 
Openshaw, P. J., Culley, F. J. & Olszewska, W. (2001). Immunopathogenesis of 
vaccine-enhanced RSV disease. Vaccine 20 Suppll, S27-31. 
Palomo, e., Cane, P. A & Melero, J. A. (2000). Evaluation of the antibody 
specificities of human convalescent-phase sera against the attachment (G) 
protein of human respiratory syncytial virus: influence of strain variation and 
carbohydrate side chains. J Med Virol 60, 468-74. 
Parrott, R. H., Kim, H. W., Arrobio, J. 0., Hodes, D. S., Murphy, B. R., Brandt, e. D., 
Camargo, E. & Chanock, R. M. (1973). Epidemiology of respiratory syncytial 
virus infection in Washington, D.e. 11. Infection and disease with respect to 
age, immunologic status, race and sex. Am J Epidemiol 98, 289-300. 
Partidos, C. D. & Steward, M. W. (2002). Mimotopes of viral antigens and 
biologically important molecules as candidate vaccines and potential 
immunotherapeutics. Comb Chem High Throughput Screen 5, 15-27. 
Peret, T. c., Hall, e. B., Hammond, G. W., Piedra, P. A, Storch, G. A, Sullender, W. 
M., Tsou, e. & Anderson, L. J. (2000). Circulation patterns of group A and B 
human respiratory syncytial virus genotypes in 5 communities in North 
America. J Infect Dis 181, 1891-6. 
Peret, T. c., Hall, e. B., Schnabel, K. e., Golub, J. A & Anderson, L. J. (1998). 
Circulation patterns of genetically distinct group A and B strains of human 
respiratory syncytial virus in a community. J Gen Virol79 ( Pt 9), 2221-9. 
Pichichero, M. E., Green, J. L., Francis, A B., Marsocci, S. M. & Disney, F. A 
(1990). New vaccines and vaccination policies. Pediatr Ann 19,686-8,690-1, 
694. 
Pilipenko, E. V., Blinov, V. M., Romanova, L. I., Sinyakov, A. N., Maslova, S. V. & 
Agol, V. I. (1989). Conserved structural domains in the 5'-untranslated region 
of picomaviral genomes: an analysis of the segment controlling translation and 
neurovirulence. Virology 168, 201-9. 
Plotkin SA and Orenstein W AVaccines. 3rded. W.B. SAUNERS COMPANY. 
Plotnicky-Gilquin, H., Goetsch, L., Huss, T., Champion, T., Beck, A, Haeuw, J. F., 
Nguyen, T. N., Bonnefoy, J. Y., Corvaia, N. & Power, U. F. (1999). 
Identification of multiple protective epitopes (protectopes) in the central 
conserved domain of a prototype human respiratory syncytial virus G protein. 
J Virol73, 5637-45. 
Polack, F. P. & Karron, R. A. (2004a). The future of respiratory syncytial virus 
vaccine development. Pediatr Infect Dis J pp. S65-73. 
245 
Polack, F. P. & Karron, R. A. (2004b). The future of respiratory syncytial virus 
vaccine development. Pediatr Infect Dis J 23, S65-73. 
Ponnuraj, E. M., Hayward, A. R., Raj, A., Wilson, H. & Simoes, E. A. (2001). 
Increased replication of respiratory syncytial virus (RSV) in pulmonary 
infiltrates is associated with enhanced histopathological disease in bonnet 
monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV 
vaccine. J Gen Virol 82, 2663-74. 
Poole, E., He, 8., Lamb, R. A., Randall, R. E. & Goodboum, S. (2002). The V 
proteins of simian virus 5 and other paramyxoviruses inhibit induction of 
interferon-beta. Virology 303, 33-46. 
Power, U. F., Plotnicky-Gilquin, H., Goetsch, L., Champion, T., Beck, A., Haeuw, J. 
F., Nguyen, T. N., Bonnefoy, J. Y. & Corvaia, N. (2001). Identification and 
characterisation of multiple linear B cell protectopes in the respiratory 
syncytial virus G protein. Vaccine 19, 2345-51. 
Power, U. F., Plotnicky-Gilquin, H., Huss, T., Robert, A., Trudel, M., Stabl, S., 
Uhlen, M., Nguyen, T. N. & Binz, H. (1997). Induction of protective 
immunity in rodents by vaccination with a prokaryotic ally expressed 
recombinant fusion protein containing a respiratory syncytial virus G protein 
fragment. Virology 230, 155-66. 
Prince, G. A., Curtis, S. J., Vim, K. C. & Porter, D. D. (2001). Vaccine-enhanced 
respiratory syncytial virus disease in cotton rats following immunization with 
Lot 100 or a newly prepared reference vaccine. J Gen Viro182, 2881-8. 
Prince, G. A., Hemming, V. G., Horswood, R. L. & Chanock, R. M. (1985). 
Immunoprophylaxis and immunotherapy of respiratory syncytial virus 
infection in the cotton rat. Virus Res 3, 193-206. 
Pu, M., Thomas, J. D., Vandervoort, P. M., Stewart, W. J., Cosgrove, D. M. & 
Griffin, B. P. (2001). Comparison of quantitative and semiquantitative 
methods for assessing mitral regurgitation by transesophageal 
echocardiography. Am J Cardiol 87, 66-70. 
Raboni, S. M., Nogueira, M. B., Tsuchiya, L. R., Takabashi, G. A., Pereira, L. A., 
Pasquini, R. & Siqueira, M. M. (2003). Respiratory tract viral infections in 
bone marrow transplant patients. Transplantation 76, 142-6. 
Rajala, M. S., Sullender, W. M., Prasad, A. K., Dar, L. & Broor, S. (2003). Genetic 
variability among Group A and B respiratory syncytial virus isolates from a 
large referral hospital in New Delhi, India. J Clin Microbiol41, 2311-6. 
246 
Rath, S., Stanley, C. M. & Steward, M. W. (1988). An inhibition enzyme 
immunoassay for estimating relative antibody affinity and affinity 
heterogeneity. J Immunol Methods 106,245-9. 
Razinkov, V., Huntley, c., Ellestad, G. & Krishnamurthy, G. (2002). RSV entry 
inhibitors block F-protein mediated fusion with model membranes. Antiviral 
Res 55, 189-200. 
Rehermann, B., Ferrari, c., Pasquinelli, C. & Chisari, F. V. (1996). The hepatitis B 
virus persists for decades after patients' recovery from acute viral hepatitis 
despite active maintenance of a cytotoxic T-Iymphocyte response. Nat Med 2, 
1104-8. 
Roberts, S. R., Lichtenstein, D., Ball, L. A. & Wertz, G. W. (1994). The membrane-
associated and secreted forms of the respiratory syncytial virus attachment 
glycoprotein G are synthesized from alternative initiation codons. J Virol68, 
4538-46. 
Roca, A., Loscertales, M. P., Quinto, L., Perez-Brena, P., Vaz, N., Alonso, P. L. & 
Saiz, J. C. (200 1). Genetic variability among group A and B respiratory 
syncytial viruses in Mozambique: identification of a new cluster of group B 
isolates. J Gen Virol 82, 103-11. 
Roca, A., Quinto, L., Abacassamo, F., Loscertales, M. P., Gomez-Olive, F. X., 
Fenwick, F., Cane, P. A, Saiz, J. C., Toms, G. & Alonso, P. L. (2003). 
Antibody response after RSV infection in children younger than 1 year of age 
living in a rural area of Mozambique. J Med Virol69, 579-87. 
Roman, M., Calhoun, W. J., Hinton, K. L., Avendano, L. F., Simon, V., Escobar, A 
M., Gaggero, A & Diaz, P. V. (1997). Respiratory syncytial virus infection in 
infants is associated with predominant Th-2-like response. Am J Respir Crit 
Care Med 156, 190-5. 
Rosenberg, H. F. & Domachowske, J. B. (2001). Eosinophils, eosinophil 
ribonucleases, and their role in host defense against respiratory virus 
pathogens. J Leukoc Bioi 70, 691-8. 
Rothbarth, P. H., Hermus, M. C. & Schrijnemakers, P. (1991). Reliability of two new 
test kits for rapid diagnosis of respiratory syncytial virus infection. J Clin 
Microbiol 29, 824-6. 
Savon, c., Goyenechea, A., Valdivia, A, Chacon, D., Cancio, R., Angel-Perez, L., 
Gonzalez, G. & Gavilondo, J. (2000). Detection of respiratory syncytial virus 
in nasopharyngeal secretions by 24-well plate precentrifugation assay using a 
monoclonal antibody against F protein. Arch Med Res 31, 93-6. 
Schwarze, 1., Cieslewicz, G., Joetham, A., Ikemura, T., Hamelmann, E. & Gelfand, E. 
W. (1999a). CD8 T cells are essential in the development of respiratory 
syncytial virus-induced lung eosinophilia and airway hyperresponsiveness. J 
ImmunolI62,4207-11. 
247 
Schwarze, J., Makela, M., Cieslewicz, G., Dakhama, A, Labn, M., Ikemura, T., 
Joetham, A & Gelfand, E. W. (1999b). Transfer of the enhancing effect of 
respiratory syncytial virus infection on subsequent allergic airway 
sensitization by T lymphocytes. J Immunol163, 5729-34. 
Seo, S. H., Hoffmann, E. & Webster, R. G. (2002). Lethal H5Nl influenza viruses 
escape host anti-viral cytokine responses. Nat Med 8, 950-4. 
Sheeran, P., Jafri, H., Carubelli, c., Saavedra, J., Johnson, c., Krisher, K., Sanchez, P. 
J. & Ramilo, O. (1999). Elevated cytokine concentrations in the 
nasopharyngeal and tracheal secretions of children with respiratory syncytial 
virus disease. Pediatr Infect Dis J 18, 115-22. 
Siegrist, C. A, Plotnicky-Gilquin, H., Cordova, M., Berney, M., Bonnefoy, J. Y., 
Nguyen, T. N., Lambert, P. H. & Power, U. F. (1999). Protective efficacy 
against respiratory syncytial virus following murine neonatal immunization 
with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J 
Infect Dis 179, 1326-33. 
Sigurs, N., Bjarnason, R., Sigurbergsson, F. & Kjellman, B. (2000). Respiratory 
syncytial virus bronchiolitis in infancy is an important risk factor for asthma 
and allergy at age 7. Am J Respir Crit Care Med 161, 1501-7. 
Simard, c., Nadon, F., Seguin, c., Thien, N. N., Binz, H., Basso, J., Laliberte, J. F. & 
Trudel, M. (1997). Subgroup specific protection of mice from respiratory 
syncytial virus infection with peptides encompassing the amino acid region 
174-187 from the G glycoprotein: the role of cysteinyl residues in protection. 
Vaccine 15,423-32. 
Simoes, E. A (200 1). Overlap between respiratory syncytial virus infection and 
influenza. Lancet 358, 1382-3. 
Sims, D. G., Downham, M. A, McQuillin, J. & Gardner, P. S. (1976). Respiratory 
syncytial virus infection in north-east England. Br Med J 2, 1095-8. 
Smith, G. L., Symons, J. A, Khanna, A., Vanderplasschen, A & Alcami, A (1997). 
Vaccinia virus immune evasion. Immunol Rev 159, 137-54. 
Smyth, R. L., Fletcher, J. N., Thomas, H. M. & Hart, C. A (1997). Immunological 
responses to respiratory syncytial virus infection in infancy. Arch Dis Child 
76,210-4. 
Sparer, T. E., Matthews, S., Hussell, T., Rae, A J., Garcia-Barreno, B., Melero, J. A. 
& Openshaw, P. J. (1998). Eliminating a region of respiratory syncytial virus 
attachment protein allows induction of protective immunity without vaccine-
enhanced lung eosinophilia. J Exp Med 187, 1921-6. 
248 
Spender, L. c., Hussell, T. & Openshaw, P. J. (1998). Abundant IFN-gamma 
production by local T cells in respiratory syncytial virus-induced eosinophilic 
lung disease. J Gen Virol79 ( Pt 7), 1751-8. 
Srikiatkhachom, A. & Braciale, T. J. (1997a). Virus-specific CD8+ T lymphocytes 
downregulate T helper cell type 2 cytokine secretion and pulmonary 
eosinophilia during experimental murine respiratory syncytial virus infection. 
J Exp Med 186,421-32. 
Srikiatkhachom, A. & Braciale, T. J. (1997b). Virus-specific memory and effector T 
lymphocytes exhibit different cytokine responses to antigens during 
experimental murine respiratory syncytial virus infection. J Virol 71, 678-85. 
Stensballe, L. G., Trautner, S., Kofoed, P. E., Nante, E., Hedegaard, K., Jensen, I. P. 
& Aaby, P. (2002). Comparison of nasopharyngeal aspirate and nasal swab 
specimens for detection of respiratory syncytial virus in different settings in a 
developing country. Trop Med Int Health 7,317-21. 
Stockton, J., Ellis, J. S., Saville, M., Clewley, J. P. & Zambon, M. C. (1998). 
Multiplex PCR for typing and sUbtyping influenza and respiratory syncytial 
viruses. J Clin Microbiol 36, 2990-5. 
Stockton, J., Stephenson, I., Fleming, D. & Zambon, M. (2002). Human 
metapneumovirus as a cause of community-acquired respiratory illness. 
Emerg Infect Dis 8, 897-901. 
Stott, E. J. & Taylor, G. (1985). Respiratory syncytial virus. Brief review. Arch Virol 
84, 1-52. 
Subramanian, K. N., Weisman, L. E., Rhodes, T., Ariagno, R., Sanchez, P. J., 
Steichen, J., Givner, L. B., Jennings, T. L., Top, F. H., Jr., Carlin, D. & 
Connor, E. (1998). Safety, tolerance and pharmacokinetics of a humanized 
monoclonal antibody to respiratory syncytial virus in premature infants and 
infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr 
Infect Dis J 17, 110-5. 
Sugaya, N., Mitamura, K., Nirasawa, M. & Takahashi, K. (2000). The impact of 
winter epidemics of influenza and respiratory syncytial virus on paediatric 
admissions to an urban general hospital. J Med Virol 60, 102-6. 
Sullender, W. (1995). Antigenic analysis of chimeric and truncated G proteins of 
respiratory syncytial virus. Virology 209, 70-9. 
Sullender, W. M., Anderson, K. & Wertz, G. W. (1990). The respiratory syncytial 
virus subgroup B attachment glycoprotein: analysis of sequence, expression 
from a recombinant vector, and evaluation as an immunogen against 
homologous and heterologous subgroup virus challenge. Virology 178, 195-
203. 
249 
Sullender, W. M. & Edwards, K. G. (1999). Mutations of respiratory syncytial virus 
attachment glycoprotein G associated with resistance to neutralization by 
primate polyclonal antibodies. Virology 264, 230-6. 
Sullender, W. M., Mufson, M. A., Anderson, L. J. & Wertz, G. W. (1991). Genetic 
diversity of the attachment protein of subgroup B respiratory syncytial viruses. 
J Virol 65, 5425-34. 
Sullender, W. M., Mufson, M. A., Prince, G. A., Anderson, L. J. & Wertz, G. W. 
(1998). Antigenic and genetic diversity among the attachment proteins of 
group A respiratory syncytial viruses that have caused repeat infections in 
children. J Infect Dis 178, 925-32. 
Sullender, W. M., Sun, L. & Anderson, L. 1. (1993). Analysis of respiratory syncytial 
virus genetic variability with amplified cDNAs. J Clin Microbiol 31, 1224-31. 
Tang, Y. W. & Graham, B. S. (1997). T cell source of type 1 cytokines determines 
illness patterns in respiratory syncytial virus-infected mice. J Clin Invest 99, 
2183-91. 
Taylor, G. S., Vipond, I. B. & Caul, E. O. (2001). Molecular epidemiology of 
outbreak of respiratory syncytial virus within bone marrow transplantation 
unit. J Clin Microbiol39, 801-3. 
Tebbey, P. W., Hagen, M. & Hancock, G. E. (1998). Atypical pulmonary eosinophilia 
is mediated by a specific amino acid sequence of the attachment (G) protein of 
respiratory syncytial virus. J Exp Med 188, 1967-72. 
Tebbey, P. W., Scheuer, C. A., Peek, J. A., Zhu, D., LaPierre, N. A., Green, B. A., 
Phillips, E. D., Ibraghimov, A. R, Eldridge, J. H. & Hancock, G. E. (2000). 
Effective mucosal immunization against respiratory syncytial virus using 
purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. 
Vaccine 18,2723-34. 
Teng, M. N. & Collins, P. L. (1999). Altered growth characteristics of recombinant 
respiratory syncytial viruses which do not produce NS2 protein. J Virol 73, 
466-73. 
Teng, M. N. & Collins, P. L. (2002). The central conserved cystine noose of the 
attachment G protein of human respiratory syncytial virus is not required for 
efficient viral infection in vitro or in vivo. J Virol 76, 6164-71. 
Teng, M. N., Whitehead, S. S., Bermingham, A., St Claire, M., Elkins, W. R, 
Murphy, B. R & Collins, P. L. (2000). Recombinant respiratory syncytial 
virus that does not express the NS 1 or M2-2 protein is highly attenuated and 
immunogenic in chimpanzees. J Viro174, 9317-21. 
Teng, M. N., Whitehead, S. S. & Collins, P. L. (2001). Contribution of the respiratory 
syncytial virus G glycoprotein and its secreted and membrane-bound forms to 
virus replication in vitro and in vivo. Virology 289, 283-96. 
250 
Thomas, L. H., Wickremasinghe, M. I., Sharland, M. & Friedland, J. S. (2000). 
Synergistic upregulation of interleukin-8 secretion from pulmonary epithelial 
cells by direct and monocyte-dependent effects of respiratory syncytial virus 
infection. J Virol74, 8425-33. 
Thompson, W. W., Shay, D. K, Weintraub, E., Brammer, L., Cox, N., Anderson, L. J. 
& Fukuda, K (2003). Mortality associated with influenza and respiratory 
syncytial virus in the United States. Jama 289, 179-86. 
Tripp, R. A., Dakhama, A., Jones, L. P., Barskey, A., Gelfand, E. W. & Anderson, L. 
J. (2003). The G glycoprotein of respiratory syncytial virus depresses 
respiratory rates through the CX3C motif and substance P. J Virol77, 6580-4. 
Tripp, R. A., Jones, L. P., Haynes, L. M., Zheng, H., Murphy, P. M. & Anderson, L. 
J. (2001). CX3C chemokine mimicry by respiratory syncytial virus G 
glycoprotein. Nat Immunol 2, 732-8 
Trudel, M., Nadon, F., Seguin, c., Simard, C. & Lussier, G. (1989). Experimental 
polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human 
and bovine respiratory syncytial virus. Vaccine 7, 12-6. 
Uduman, S. A., Ijaz, M. K, Kochiyil, J., Mathew, T. & Hossam, M. K. (1996). 
Respiratory syncytial virus infection among hospitalized young children with 
acute lower respiratory illnesses in AI Ain, UAE. J Commun Dis 28, 245-52. 
Ulloa, L., Serra, R., Asenjo, A. & Villanueva, N. (1998). Interactions between cellular 
actin and human respiratory syncytial virus (HRSV). Virus Res 53, 13-25. 
van den Hoogen, B. G., de Jong, J. c., Groen, J., Kuiken, T., de Groot, R., Fouchier, 
R. A. & Osterhaus, A. D. (2001). A newly discovered human pneumovirus 
isolated from young children with respiratory tract disease. Nat Med 7, 719-
24. 
Van Regenmortel, M. H. (1966). Plant virus serology. Adv Virus Res 12,207-71. 
Van Regenmortel, M. H. (1989). The concept and operational definition of protein 
epitopes. Phi/os Trans R Soc Land B Bioi Sci 323, 451-66. 
Van Regenmortel, M. H. (1992). The conformational specificity of viral epitopes. 
FEMS Microbiol Lett 79, 483-7. 
Van Regenmortel, M. H., Gill, K. & Fazakerley, G. (1978). Trypanosoma 
equiperdum: active immunization of rabbits with actinomycin D-inactivated 
parasites. Exp Parasitol 46, 323-9. 
van Schaik, S. M., Welliver, R. C. & Kimpen, J. L. (2000). Novel pathways in the 
pathogenesis of respiratory syncytial virus disease. Pediatr Pulmonol 30, 131-
8. 
251 
Videla, c., Carballal, G., Misirlian, A. & Aguilar, M. (1998). Acute lower respiratory 
infections due to respiratory syncytial virus and adenovirus among 
hospitalized children from Argentina. Clin Diagn VirollO, 17-23. 
Wahab, A. A., Dawod, S. T. & Raman, H. M. (200 1). Clinical characteristics of 
respiratory syncytial virus infection in hospitalized healthy infants and young 
children in Qatar. J Trop Pediatr47, 363-6. 
Walsh, E. E., Falsey, A. R. & Sullender, W. M. (1998). Monoclonal antibody 
neutralization escape mutants of respiratory syncytial virus with unique 
alterations in the attachment (G) protein. J Gen Viro179 (Pt 3), 479-87. 
Walsh, E. E., Hall, C. B., Briselli, M., Brandriss, M. W. & Schlesinger, J. J. (1987). 
Immunization with glycoprotein subunits of respiratory syncytial virus to 
protect cotton rats against viral infection. J Infect Dis 155, 1198-204. 
Walsh, E. E., McConnochie, K. M., Long, C. E. & Hall, C. B. (1997). Severity of 
respiratory syncytial virus infection is related to virus strain. J Infect Dis 175, 
814-20. 
Walzl, G., Matthews, S., Kendall, S., Gutierrez-Ramos, J. C., Coyle, A. 1., Openshaw, 
P. J. & Hussell, T. (200 1). Inhibition of TlIST2 during respiratory syncytial 
virus infection prevents T helper cell type 2 (Th2)- but not Th I-driven 
immunopathology. J Exp Med 193,785-92. 
Waris, M. (1991). Pattern of respiratory syncytial virus epidemics in Finland: two-
year cycles with alternating prevalence of groups A and B. J Infect Dis 163, 
464-9. 
Waris, M., Ziegler, T., Kivivirta, M. & Ruuskanen, O. (1990). Rapid detection of 
respiratory syncytial virus and influenza A virus in cell cultures by 
immunoperoxidase staining with monoclonal antibodies. J Clin Microbiol 28, 
1159-62. 
Weber, M. W., Dackour, R., Usen, S., Schneider, G., Adegbola, R. A., Cane, P., 
Jaffar, S., Milligan, P., Greenwood, B. M., Whittle, H. & Mulholland, E. K. 
(1998a). The clinical spectrum of respiratory syncytial virus disease in The 
Gambia. Pediatr Infect Dis J 17, 224-30. 
Weber, M. W., Mulholland, E. K. & Greenwood, B. M. (l998b). Respiratory 
syncytial virus infection in tropical and developing countries. Trop Med Int 
Health 3, 268-80. 
Weinberger, M. (2003). Clinical patterns and natural history of asthma. J Pediatr 142, 
SI5-9; discussion SI9-20. 
Weisman, L. E. (2002). Current respiratory syncytial virus prevention strategies in 
high-risk infants. Pediatr Int 44,475-80. 
Weltzin, R., Traina-Dorge, V., Soike, K., Zhang, J. Y., Mack, P., Soman, G., Drabik, 
G. & Monath, T. P. (1996). Intranasal monoclonal IgA antibody to respiratory 
252 
syncytial virus protects rhesus monkeys against upper and lower respiratory 
tract infection. J Infect Dis 174, 256-61. 
Wertz, G. W., Collins, P. L., Huang, Y., Gruber, c., Levine, S. & Ball, L. A. (1985). 
Nucleotide sequence of the G protein gene of human respiratory syncytial 
virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U 
SA 82,4075-9. 
Wertz, G. W., Perepelitsa, V. P. & Ball, L. A. (1998). Gene rearrangement attenuates 
expression and lethality of a nonsegmented negative strand RNA virus. Proc 
Natl Acad Sci USA 95, 3501-6. 
Whitehead, S. S., Hill, M. G., Firestone, C. Y., St Claire, M., Elkins, W. R, Murphy, 
B. R & Collins, P. L. (1999). Replacement of the F and G proteins of 
respiratory syncytial virus (RSV) subgroup A with those of subgroup B 
generates chimeric live attenuated RSV subgroup B vaccine candidates. J 
Virol73, 9773-80. 
Whitehead, S. S., Juhasz, K., Firestone, C. Y., Collins, P. L. & Murphy, B. R (1998). 
Recombinant respiratory syncytial virus (RSV) bearing a set of mutations 
from cold-passaged RSV is attenuated in chimpanzees. J Virol72, 4467-71. 
Woolums, A R, Singer, R S., Boyle, G. A. & Gershwin, L. J. (1999). Interferon 
gamma production during bovine respiratory syncytial virus (BRSV) infection 
is diminished in calves vaccinated with formalin-inactivated BRSV. Vaccine 
17, 1293-7. 
Wright, P. F., Belshe, R B., Kim, H. W., Van Voris, L. P. & Chanock, R. M. (1982). 
Administration of a highly attenuated, live respiratory syncytial virus vaccine 
to adults and children. Infect Immun 37, 397-400. 
Wright, P. E, Karron, R A, Belshe, R. B., Thompson, J., Crowe, J. E., Jr., Boyce, T. 
G., Halburnt, L. L., Reed, G. W., Whitehead, S. S., Anderson, E. L., Wittek, 
A E., Casey, R., Eichelberger, M., Thumar, B., Randolph, V. B., Udem, S. A., 
Chanock, R. M. & Murphy, B. R. (2000). Evaluation of a live, cold-pass aged, 
temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. 
J Infect Dis 182, 1331-42. 
Wyatt, L. S., Whitehead, S. S., Venanzi, K. A, Murphy, B. R. & Moss, B. (1999). 
Priming and boosting immunity to respiratory syncytial virus by recombinant 
replication-defective vaccinia virus MV A Vaccine 18,392-7. 
Yamamoto, K. & Yoshikura, H. (1986). Relation between genomic and capsid 
structures in RNA viruses. Nucleic Acids Res 14,389-96. 
Zambon, M. & Barclay, W. (2002). Unravelling the mysteries of influenza. Lancet 
360, 1801-2. 
253 
Zambon, M. c., Stockton, J. D., Clewley, J. P. & Fleming, D. M. (2001). Contribution 
of influenza and respiratory syncytial virus to community cases of influenza-
like illness: an observational study. Lancet 358, 1410-6. 
Zhang, L., Peeples, M. E., Boucher, R. c., Collins, P. L. & Pickles, R. J. (2002). 
Respiratory syncytial virus infection of human airway epithelial cells is 
polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 
76, 5654-66. 
Zinkemagel, R. M. (2001). Maternal antibodies, childhood infections, and 
autoimmune diseases. N Eng/ J Med 345, 1331-5. 
254 
APPENDICES 
Appendix 1: Ethical Committee agreement 
HAMAO MEDICAL CORPORATION 
~earch Co11llnift ~ Tel.392440 fl~ 
lPax.392402 
AM.OO.m .2000 
~l'" 0: Dr. Asma Ai Thalli 
Fr0111: Dr. A.A. Gehani 
Chalrman, Research Conllnittee 
Dalc:02~4·99 
Subject: "Study of Respiratory Syncytial VinlS Infection m 
Healthy Children < 2 year Hospitalized in Qatar" . 
The commi~tee had discussed and approved the above research. we would 
like to have·an update of the research results. 
Please don't hesitate to contact us should you need any further information. 
Klnd regards, 
Cc. Or.Ghalia AI Thani,MB,BCh,MRCP(UK) 
Chairperson, Dept. Pediatric 
Appendix 2: Stratagen Optiprime butTers compositions 
ButTer No. Tris-HCI MgCl KCI 
1 100 mM pH 8.3 15 mM 250 mM 
2 100 mM pH 8.3 15 mM 750 mM 
3 100 mM pH 8.3 35 mM 250 mM 
4 100 mM pH 8.3 35 mM 750 mM 
5 100 mM pH 8.8 15 mM 250 mM 
6 100 mM pH 8.8 15 mM 750 mM 
7 100 mM pH 8.8 35 mM 250 mM 
8 100 mM pH 8.8 35 mM 750 mM 
9 100 mM pH 9.2 15 mM 250 mM 
10 100 mM pH 9.2 15 mM 750 mM 
11 100 mM pH 9.2 35 mM 250 mM 
12 100 mM pH 9.2 35 mM 750 mM 
Appendix 3: Qatar study samples 
Patient No. ACUTE CONV.1 
010 y Y 
017 Y Y 
021 Y Y 
026 Y Y 
07 Y Y 
013 Y Y 
014 Y Y 
05 Y Y 
018 Y Y 
019 Y Y 
020 Y Y 
023 Y Y 
024 Y Y 
Q28 Y " V';, 
029 y Y 
031 Y y !; 
032 Y Y 
033 Y " Y," 
034 Y Y 
01 Y Y 
02 Y Y 
04 Y Y 
011 Y Y 
016 Y Y 
022 Y Y 
027 Y Y 
030 Y Y 
035 Y Y 
036 Y Y 
037 Y Y 
038 Y Y 
039 Y Y 
040 Y Y 
041 Y Y 
042 Y Y 
043 Y Y 
Y = Available isolate 
Acute= at the beginning of the infection 
Convalescent 1 = 1 month after the infection 
Convalescent 2 = 1 year after the infection 
Convalescent 3 = 1 year & 1 month after the infection 
CONV.2 CONV.3 
Y Y 
Y Y 
Y Y 
Y Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
" y . ""', 
Y 
I " V ; ", -~ 
Y 
Y 
Y 
AGE/Month TYPE Isolate 
9 A A/Q/10/00 
3 A 
3 A A/Q/21/00 
1 A A/Q/26/00 
10 A 
1 A 
2 A A/Q/14/00 
3 B 
4 A 
2 A 
4 B 
2 B 
2 B 
If 3 ,,;,"'" illB:tj:t"'; 1 .... u.. ... -tJtvt 
36 A 
12 ~ p~~ B ::-;',~'} BlCWllOo 
4 B 
3 '!;~B"':' BIOIS3Ioo 
9 A 
24 A 
2 B 
2 A 
6 B BlQ/111OO 
3 A 
6 A 
11 A A/Q/27/00 
3 B 
9 B 
3 A 
10 A A/Q/37/01 
2 A 
7 A A/Q/39/01 
3 A 
3 A A/Q/41/01 
3 A 
22 B 
Qatar study samples; Age Distribution and type of RSV, Yellow rows indicate to availability of RSV 
A isolates while blue rows indicate to availability of RSV B isolates, 
Appendix 4: Neonatal samples 
Sera No. 
D: Day 
M: Month 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
AGE 
1 0 
40 
1 0 
1 0 
1 0 
20 
1 0 
40 
1 0 
20 
1 0 
1 0 
1 0 
20 
1 0 
3M 
290 
1 0 
20 
70 
1 0 
Neonatal samples (Total number of samples and Age distribution). From children admitted to 
hospital for non respiratory system illness during the RSV infection season, and most of them are 
less than one month in age. 
Appendix 5.a: The nucleotide sequence alignment of 10 Qatar RSV A strains 
A2 
11./0/10/00 I 
11./0/13/00 
11./0/14/00 
11./0/16/00 
11./0/17/00 I 
11./0/19/00 I 
A/on7/00 
A/on9/00 
11./0/39/01 
A/O/U/Ol 
A2 
11./0/10/00 
11./0/13/00 
11./0/14/00 
11./0/16/00 I 
11./0/17/00 
11./0/19/00 
A/on7/00 
A/on9/00 
11./0/39/01 
A/O/U/Ol I 
A2 
11./0/10/00 I 
11./0/13/00 
11./0/14/00 I 
11./0/16/00 I 
11./0/17/00 I 
11./0/19/00 
11./0/27/00 
A/0/29/00 I 
1./0/39/01 
A/O/U/Ol I 
10 20 30 to SO 60 70 80 90 100 110 
ATGTCCAAAAACAAGGACCAACGCACCACCAAGACACTAGAAAAGACCTGOaACACTCTCAATCATCTATTATTCATATCATCGTGCTTATACAAGTTAAATCTTAAATC 
.......... c ................ G ••••••••••••••• G •••••••••••••••••••••• T ••••••••••••••••••••••••••••••••••••••••••• 
•••••••••• c •••••••••••••••• G ••••••••••••••• G •••••••••••••••••••••• T •••••••••••••••••••••••••••••••• TT.T ••••••• 
.......... c ................ G ••••••••••••••• G •••••••••••••••••••••• T •••••••••••••••••••••••••••••••• TT.T ••••••• 
.......... c ................ G ••••••••••••••• G •••••••••••••••••••••• T •••••••••••••••••••••••••••••••• TT ••••••••• 
.......... c ................ G ••••••••••••••• G •••••••••••••••••••••• T •••••••••••••••••••••••••••••••• TT.T ••••••• 
.......... c ................ G ••••••••••••••• G •••••••••••••••••••••• T ••••••••••••••••••••••••••••••••••••••••••• 
.......... c ................ G ••••••••••••••• G •••••••••••••••••••••• T ••••••••••••••••••••••••••••••••••••••••••• 
.......... c ................ G ••••••••••••••• G •••••••••••••••••••••• T ••••••••••••••••••••••••••••••••••••••••••• 
.......... c ................ G ••••••••••••••• G •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
.......... c ................ G ••••••••••••••• G •••••••••••••••••••••• T ••••••••••••••••••••••••••••••••••••••••••• 
120 130 140 150 160 170 180 190 200 210 220 
TATAGCACAAATCACATTATCCATTCTGGCAATGATAATCTCAACTTCACTTATAATTGCAGCCATCATATTCATAGCCTCGGCAAACCACAAAGTCACACTAACAACTG 
••••••••••••••••••••• T ••• T ••••••••••••••••••••••••••••••••••••••••••••••••••••••• T •••••••••••••••••••••••••• C. 
••••••••••••••••••••• T ••• T •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
••••••••••••••••••••• T ••• T •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
..................... T ••• T ............................ G ...................................................... . 
••••••••••••••••••••• T ••• T •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
••••••••••••••••••••• T ••• T •••••••••••••••••••••••••••• G ••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
••••••••••••••••••••• T ••• T •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• C. 
••••••••••••••••••••• T ••• T ••••••••••••••••••••••••••••••••••••••••••••••••••••••• T •••••••••••••••••••••••••• C. 
••••••••••••••••••••• T ••• T ••••••••••••••••••••••••••.••.••••••.•••.••••••••••••••••••••••••••••••••••••••••••• 
••••••••••••••••••••• T ••• T •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
230 HO 250 260 270 280 290 300 310 320 330 
CAATCATACAAGATGCAACAAGCCAGATCAAGAACACAACCCCAACATACCTCACCCAGAATCCCCAGCTTGGAATCAGCTTCTCCAATCTGTCTGAAACTACATCACAA 
••••• , ••••••••••••••• 11. ••••••••••••••••••••••••••••••••••••• G •••••••••••••••••••••••••••••••••• C ••••••••••••••• 
••••••••••••••••••••• 11. ••••••••••••••••••••••••••••••••••••••••••••• 11. •••••••••••••••••••••••••• C ••••••••••••••• 
••••••••••••••••••••• 11. ••••••••••••••••••••••••••••••••••••••••••••• 11. •••••••••••••••••••••••••• C ••••••••••••••• 
..................... 11. ........................................................................ C ••••••••••••••• 
••••••••••••••••••••• 11. ••••••••••••••••••••••••••••••••••••••••••••• 11. •••••••••••••••••••••••••• C ••••••••••••••• 
••••••••••••••••••••• 11. •••••••••••••••••••••••••••••••••••••••••••••••••••.•••••••••••••••••••• C ••••••••••••••• 
..................... A ..................................... G .................................. C ••••••••••••••• 
..................... A ..................................... G .................................. C ••••••••••••••• 
..................... 11. .................. T .................................................... • C ••• • T •••••• G ••• 
••••••••••••••••••••• 11. •••••••••••••••••• T ••••••••••••••••••••••••••••••••••••••••••••••••••••• C •••• T •••••• G ••• 
HO 350 360 370 380 390 too 410 t20 HO UO 
ACCACCACCATACTAGCTTCAACAACACCAAGTGTCAAGTCAACCCTGCAATCCACAACAGTCAAGACCAAAAACACAACAACAACCAAAATACAACCCAGCAAGCCCAC 
C ••• T ••• T ••••••••••••••••••••••••• CTG ••• T ••• T.CA ••••••••••••••••••• T ••••••••••••••••••• C •••• G ••••• T ••••• 11. ••••• 
C ••••••••••••• G ••••••••••••••••••• CTG ••••••••• CA ••••••••••••••••••• T ••••••••••••••••••• C •••••••••••••••• 1. ••••• 
C ••••••••••••• G ................... CTG ......... CA ................... T ................... C ................ 1. ••••• 
A2 
1./0/10/00 
A/0/13/00 
1./0/14/00 
1./0/16/00 
A/0/17/00 
1./0/19/00 
1./0/27/00 
It./O/29/00 
A/0/39/01 
1./0/41/01 
• C ••• T ••••••••••••••••••••••••••••• CT •••••••••• CA ••••••••••••••••••• T ••••••••••••••••••• C •••• G ••••• T ••••• 1. ••••• 
C ••••••••••••• G ••••••••••••••••••• CTG ••••••••• CA ••••••••••••••••••• T ••••••••••••••••••• C •••••••••••••••• 11. ••••• 
C ••• T ••••••••••••••••••••••••••••• CT •••••••••• CA ••••••••••••••••••• T ••••••••••••••••••• C •••• G ••••• T ••••• 11. ••••• 
C ••• T ••• T ••••••••••••••••••••••••• CTG ••• T ••• T .CA ••••••••••••••••••• T ••••••••••••••••••• C •••• G ••••• T. " •• 11. ••••• 
A2 
1./0/10/00 
A/0/13/00 
A/0/14/00 
1./0/16/00 
A/0/17/00 I 
A/0/19/00 
1./0/27/00 
A/0/29/00 
11./0/39/01 I 
A/0/41/01 
C ••• T ••• T ......................... CTG ••• T ••• T.CA ................... T ................... C .... G ••••• T ••••• 11. .... . 
C ••••••••••••• G ................... CTG ......... CA ................... T ................... C .......... T ••••• 11. ••••• 
C ••••••••••••• G ••••••••••••••••••• CTG ••••••••• CA ••••••••••••••••••• T •••••••••••••••••• • C • ••••••••• T ••••• 1. ••••• 
tsO uo no no uo 500 510 520 520 stO 550 
CACAAAACAACGCCAAAACAAACCACCAAACAAACCCAATAATGATTTTCACTTTGAAGTGTTCAACTTTGTACCTTGCAGCATATGCAGCAACAATCCAACCTGCTGGG 
•••••••••••••••••••••••••• 11. ••••••••••••••••••••••••••••••••••••••• T •••••••• C •••••••••••••••••••••••••••••••••• 
•••••••••••••••••••••••••• 11. ••••••••••••••••••••••••••••••••••••••• T •••••••• C •••••••••••••••••••••••••••••••••• 
•••••••••••••••••••••••••• 11. ••••••••••••••••••••••••••••••••••••••• T •••••••• C •••••••••••••••••••••••••••••••••• 
.......................... 11. ....................................... T ........ C ................................. . 
••••••••••••.••••••••••••• 11. ••••••••••••••••••••••••••••••••••••••• T •••••••• C •••••••••••••••••••••••••••••••••• 
.......................... 11. ••••••••••••••••••••••••••••••••••••••• T •••••••• C ................................. . 
.......................... 11. ••••••••••••••••••••••••••••••••••••••• T •••••••• C ................................. . 
.......................... 1. ....................................... T ........ C ................................. . 
.......................... 1. ••••••••••••••••••••••••••••••••••••••• T •••••••• C ................................. . 
•••••••••••••••••••••••••• 11. ••••••••••••••••••••••••••••••••••••••• T •••••••• C •••••••••••••••••••••••••••••••••• 
560 570 580 590 600 610 620 630 640 650 660 
I CTATCTGTAAAAGAATACCAAACAAAAAACCTGGAAAGAAAACCACCACCAAGCCCAoa a a a a ~CCAACCATCAAGACAACCAAAAAAGATCTCAAACCTCAAACCACA A2 
1./0/10/00 
1./0/13/00 
1./0/14/00 I 
A/0/16/00 
1./0/17/00 
1./0/19/00 
1./0/27/00 
1./0/29/00 
1./0/39/01 I 
11./0/41/01 
A2 
11./0/10/00 
11./0/13/00 I 
A/O/U/OO I 
A/0/16/00 
11./0/17/00 
11./0/19/00 I 
It./O",7/00 
.C ..... C ................................................................................ G •••• C •••••••••••••••• 
.C ..... C ................................................................................ G •••• C •••••••••••••••• 
.C ••••• C •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• G ••• • C •••••••••••••••• 
.C ..... C .................................................... G ................................ C •••••••••••••••• 
.C ..... C ................................................................................ G •••• C •••••••••••••••• 
.C ..... C .................................................... G ................................ C •••••••••••••••• 
.C ..... C ................................................................................ G •••• C ............... . 
.C ..... C ................................................................................ G •••• C •••••••••••••••• 
.C ..... C ................... • ................................................................................. . 
.C ..... C ..................................................................................................... . 
670 680 690 700 710 720 730 7tO 750 760 770 
AAACCAAAGGAAGTACCTACCACCAAGCCCACAGAAAAGCCAACCATCAACACCACCAAAACAAACATCAGAACTACACTGCTCACCAACAATACCACAGGAAATCCAGA 
................ TC .................................................... 11. ................ TC ••• C ....... 1. ........ . 
................ TC ..................................................................... CC ••• C ................ . 
................ TC ..................................................................... CC ••• C ................ . 
................ TC ................... G ................................ 11. ................ CC ••• C ................ . 
............. CT.TC ..................................................................... CC ••• C ................ . 
................ TC ................... G ................................ 11. ................ TC ••• C ................ . 
•••••••••••••••• TC •••••••••••••••••••••••••••••••••••••••••••••••••••• 11. •••••••••••••••• TC ••• C ••••••• 11. ••••••••• 
A/Q/29/00 
A/Q/39/01 
A/Q/U/Ol 
A2 
A/Q/l0/00 
A/Q/13/00 
A/Q/14/00 
A/Q/16/00 
1./0/17/00 
1./0/19/00 
A/Q/27/00 
1./0/29/00 
A/Q/39/01 
1./0/41/01 
A2 
A/Q/10/00 
A/Q/13/00 
A/Q/14/00 
A/Q/16/00 
A/Q/17/00 
A/Q/19/00 
A/Q/27/00 
A/Q/29/00 
A/Q/39/01 
A/Q/U/01 
•••••••••••••••• TC •••••••••••••••••••••••••••••••••••••••••••••••••••• 1. •••••••••••••••• TC ••• C ••••••• 1. ••••••••• 
•••• • • • •• • T •• CT. TCT •••••••••••••••••••••• GT ••••••••••••••• G ••••• G •••••••••••• GA •••••••• TC ••• C ••••••••••••••••• 
•••••••••••••••• TCT •••••••••••••••••••••• GT ••••••••••••••• G ••••• G •••••••••••• GA •••••••• TC ••• C ••••••••••••••••• 
780 790 800 810 820 830 840 850 860 870 880 
ACACACAAGTCAAAAGGGAACCCTCCACTCAACCTCCTCCGATGGCAATCCAAGCCCTTCACAAGTCTATACAACATCCGAGTACCTATCACAACCTCCATCTCCATCCA 
••••••••••••••••. 1. ••.••.••••••.••• 1. •••• T •• 1. ••••••••••••••••••••••••••••••••••••••••••••••••••• T ••• T ••••••••••• 
......... c ....... 1. •••••••••••••••• 1. ••••••• 1. ••••••••••••••••••••••••••••••••••••••••••••••••••• T ••••••••••••••• 
••••••••• C ••••••• 1. •••••••••••••••• 1. •••• T •• 1. ••••••••••••••••••••••••••••••••••••••••••••••••••• T ••• T ••••••••••• 
••••••••••••••••• 1. ••••••••• T •••••• 1. ••••••• 1. ••••••••••••••••••••••••••••••••••••••••••••••••••• T ••• T ••••••••••• 
••••••••• C ••••••• 1. •••••••••••••••• 1. ••••••• 1. ••••••••••••••••••••••••••••••••••••••••••••••••••• T ••••••••••••••• 
••••••••••••••••. 1. ••••••••• T •••••• 1. ••••••• 1. ••••••••••••••••••••••••••••••••••••••••••••••••••• T ••• T ••••••••••• 
••••••••••••••••• 1. •••••••••••••••• 1. •••• T •• 1. ••••••••••••••••••••••••••••••••••••••••••••••••••• T ••• T ••••••••••• 
••••••••••••••••• 1. ......•.•....••. 1. ••••••• 1. ••••••••••••••••••••••••••••••••••••••••••••••••••• T ••• T ••••••••••• 
••••••••• C ••••••• 1. •••••••••.•••••• 1. ••••••• 1. •••••••••••••••••••••••••••••••••••••••••••• C •••••• T ••••••••••••••• 
••••••••• C ••••••• 1. •••••••••••••••• 1. ••••••• 1. ••••••••••••••••••••••••••••••••••••••••••••••••••• T ••••••••••••••• 
890 900 
ACACAACAAACCAGTAG 
•••••••••• ATGA---
•••••••••• ATGA---
•••••••••• ATGA---
•••••••••• ATGA---
•••••••• G.ATGA---
•••••••••• ATGA---
•••••••••• ATGA---
•••••••••• ATGA---
••••••••••• TG •••• 
•••••••••• ATGA---
(a) The nucleotide sequence alignment of 10 Qatar RSV A strains, the start codon (A TO) at nucleotide 
position 1 and the stop codon at position 890 and 900. 
(b): The nucleotide sequence alignment of 5 Qatar RSV B strains 
BH2 
8/0/5/00 
8/0/11/00 
8/0/18/00 
8/0/28/00 
8/0/33/00 
10 20 30 40 50 60 70 80 90 100 110 
OOGGCAAATGCAACCATGTCCAAACACAAGAATCAACOCACTGCCAQGACTCTAOAAAAGACCTGOOATACTCTCAATCA'1'CTAAT'1'G'1'AATA'1'CCTCTTG'1'TTATACAG 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• '1' •••••••••••••••••••••••••••••••••• A 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• '1' ••••••••••••••••••••••••••••••••••• 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• '1' ••••••••••••••••••••••••••••••••••• 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• T •••••••••••••••••••••••••••••••••• A 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• '1' ••••••••••••••••••••••••••••••••••• 
120 130 140 150 160 170 180 190 200 no 220 
8)f2 
8/0/5/00 
8/0/11/00 
8/0/18/00 
8/0/28/00 
8/0/33/00 
I ATTAAATTTAAAATCTATAGCACAAATAGCACTATCAGTTCTOOCAA'1'GATAATCTCAACCTCTCTCA'1'AATTGCAGCCA'1'AATA'1''1'CA'1'CA'1'CTCTGCCAATCACAAAG 
8)f2 
8/0/5/00 
8/0/11/00 
8/0/18/00 
8/0/28/00 
8/0/33/00 
•••••••••••••••••••••••••••••••••••••••• '1' ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
•••••••••••••••••••••••••••••••••••••••• '1' ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
•••••••••••••••••••••••••••••••••••••••• '1' ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
•••••••••••••••••••••••••••••••••••••••• '1' ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
•••••••••••••••••••••••••••••••••••••••• '1' ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
230 240 250 260 270 280 290 300 310 320 330 
TTACACTAACAACGGTCACAGTTCAAACAATAAAAAACCACACT~··a··ACATCACCACCTACCTTACTCAAGTCCCACCAGAAAGGGTTAGCTCATCCAAACAACCT 
••••••••••••• '1' •••••••••••••••••••••••••••••••• G •••••••••••••• '1' ••••••••••••••• '1' ••••••••••••••••• C ••••••••••••• C 
••••••••••••• '1' •••••••••••••••••••••••••••••••• G •••••••••••••• '1' ••••••••••••••• '1' ••••••••••••••••• C ••••••••••••• C 
••••••••••••• '1' ................................ G .............. '1' ............... '1' ••••••••••••••••• C ............. C 
••••••••••••• '1' ................................ G .............. '1' ............... '1' ................. C ............. C 
••••••••••••• '1' ................................ G .............. '1' ............... '1' ••••••••••••••••• C ............. C 
340 350 360 370 380 390 400 410 420 430 4400 
8)f2 
8/0/5/00 
8/0/11/00 
8/0/18/00 
8/0/28/00 
8/0/33/00 
I ACAACCACATCACCAATCCACACAAATTCAGCCACAACATCACCCAACACAAAGTCAGAAACACACCACACAACAGCACAAACCAAAGGCAGAACCACCACCTCAACACA 
BH2 
8/0/5/00 
8/0/11/00 I 
8/0/18/00 I 
8/0/28/00 
8/0/33/00 
8N:l 
8/0/5/00 
B/O/11/00 
8/0/18/00 
B/0/28/00 I 
B/0/33/00 
8)f2 
B/0/5/00 
8/0/11/00 I 
8/0/18/00 
8/0/28/00 
8/0/33/00 
BH2 
B/0/5/00 
B/0/11/00 
B/0/18/00 
8/0/28/00 I 
B/0/33/00 I 
......... C ................ C •••••••••• '1' •••••• '1' •• '1' ••••• A .............. '1' ................................ TC ••••••• 
••••••••• C •••••••••••••••• C •••••••••• T •••••• '1' •• '1' ••••• A •••••••••••••• '1' ••••••••••••••••• G •••••••••••••• TC.C ••••• 
......... C ................ C •••••••••• '1' •••••• '1' •• '1' ••••• A •••••••••••••• '1' ••••••••••••••••• G •••••••••••••• TC.C ••••• 
........ • C ............... • C .......... '1' •••••• '1' •• '1' ••••• A .............. '1' ................................ TC ••••••• 
......... C ................ C .......... '1' •••••• '1' •• '1' ••••• A •••••••••••••• '1' ••••••••••••••••• G .............. TC.C ••••• 
450 460 470 480 no 500 510 520 530 540 550 
GACCAACAAGCCGAGCACAAAACCACGCCTAAAAAATCCAC~ ••••• ACCAAAAGA'1'GA'1''1'ACCA'1''1''1'TGAAG'1'GTTCAACTTCGTTCCCTGTAGTATATGTOOCAACA 
•• A ...................... • .. ·C ••••• G ......................................................................... . 
••••••••••••••••••••••••••••• C ••••• G •••••••••••••••••••••••••••••• C ••••••••••••••••••••••••••••••••••••••••••• 
...... A ...................... C ••••• G ......................................................................... . 
•• A •••••••••••••••••••••••••• C ••••• G •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
•••••• A •••••••••••••••••••••• C ••••• G •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
560 570 580 590 600 610 620 630 640 650 660 
ATCAACTT'1'GCAAATCCA'1'CTGTAAAACAATACCAAGCAACAAACCAAAGAAGAAACCAACCA'1'CAAACCCACAAACAAACCAACCACCAAAACCACAAACAAAAGAGAC 
....... C .............. C ................. '1' ........... A .............................. C •••••••••••••••••••••••••• 
....... C .............. C ................. '1' ........... A .............................. C •••••••••••••••••••••••••• 
....... C ............................................ A ....................... A •••••••••• '1' ••• G •• A ••••• A ••••••••• 
....... C ............................................ A ....................... A .......... '1' ... G •• A ..... A ••••••••• 
....... C ............................................ A ....................... A .......... '1' ••• G •• A ..... A ••••••••• 
670 680 690 700 710 720 730 740 750 760 770 
CCAAAAACACCAGCCAAAACGACOAAAAAAGAAACTACCACCAACCCAAO·····ACCAACCCTCACGACCACAGAAAGAGACACCAGCACCTCACAA'1'CCACTG'1'GCT 
.......... '1' .......... CT ......... G .. C ............... G ............ C •• A .......... G ................... G .......... . 
•••••••••• '1' •••••••••• CT ......... G .. C ............... G ............ C •• A .......... G ................... G .......... . 
..................... CT ............ C ............... G •• G ......... C •• A ••••• AG ....................... G ••••••••••• 
..................... CT ............ C ............... G •• G ......... C •• A ..... AG ....................... G .......... . 
..................... CT ............ C ............... G •• G ......... C .. A ..... AG ....................... G .......... . 
780 790 800 810 820 830 840 850 860 870 880 
CGACACAACCACATTAGAACACACAATCCAACAGCAATCCCTCCACTCAACCACCCCCOAAAACACACCCAAC'1'CCACACAAACACCCACAGCA'1'CCGAGCCCTCTACA'1' 
•••••••••• G ••• CO •• G ..... 00 ........................... • .. • .. •• .. ••••••••• •• • .. •• .. • .. • .................... C •••• 
•••••••••• G ••• CO •• G ••••• 00 ............................ ••• ...... ••• ....................................... C •••• 
•••••••••• G ••• CO •• G ••••• 00 ............................................................................... C •••• 
•••••••••• G ••• CO •• G ..... 00 ............................................................................... C •••• 
•••••••••• G ••• CO •• G ••••• 00 ............................................................................... C •••• 
890 900 910 
BN2 CAAATTCCACCCAAAATACCCAATCACA'1'GCTTAGTT 
8/0/5/00 I ................ AC .. T.G ... '1' ........ --
B/0/11/00 •••.••....•••••• AC •• '1'.G •• ------------
8/0/18/00 I •••••••••••••••• CC •• T.G--------------
B/0/28/00 I '1' ............... C .......... G .. A ..... . 
B/0/33/00 I •••••••••••••••• C ••••••.•.• G •. A •..••• 
(b): The nucleotide sequence alignment of 5 Qatar RSV B strains, the start codon (ATG) at 
nucleotide position! and the stop codon (TAG) at position 900 for 2 viruses and at 896 for the rest, 
the strictly conserved nucleotide sequences at both strain sequences are underlined. 
Appendix 6: Accession numbers for sequences that have been derived from databases as 
following: 
A-subtypes: 
Korean's strains: AF193304, AF193305, AF193312, AF193313, AF193309, AF193320, AF193326 
and AF193327. 
USA's strains: AF065258, AF06541O, AF065407, AF065405 and AF065408. 
Spain's strains: Z33427, Z33428, Z33432, Z33431, Z33430 and Z33423. 
UK's strains: X73350and X73354. 
Uruguay's strain: AF248642 
Mozambique strains: AF309661, AF309663, AF309664, AF309659 and AF309655. 
B-subtypes: 
Korean's strains: AF193337, AF193330, AF193333, AF193334, AF193335, AF193337, and 
AF193336. 
USA's strains: AF065250, AF065251, AF233924, M73542 and M73541. 
UK's strains: AJ290201, AJ290202, AJ290203, AJ290209, AJ290214, AJ290219and AJ290222. 
Uruguay's strain: AF251555, AF249877 and AF251557. 
Mozambique strains: AF309668, AF309677, AF309679, AF309676, AF309678 and AF309684. 
A dix 7: B-cells eDit, ·dentified fl G Drotein of RSV 
- - -------- - - - ---- - -- - -- ----------- -- -- ---- - - - - - --- - - - -- . 
Regions Amino acid sequences Type of antigen Source of sera Virus Main finding & 
(Amino acid no.) References 
174 - 188 SICSNNPTCW AICKR Peptide Rabbit, Mice & A2 Identified linear B 
Human cell epitopes 
Rabbit, 
144 - 168 SKPTIKQRQNKPPSK Human 
Rabbit. 
84-98 KNITPTWLTQNPQLG 
Rabbit. 
94-108 NPQLGISPSNPSEIT 
Rabbit. 
134 - 148 KNITTIQTQPSKPTT 
Human 
184 - 198 AICKRIPDKKPGKKT (Norrby et aI., 1987) 
Rabbit. 
194 - 208 PGKKTITKPTKKPTL 
Rabbit. 
224 - 238 EVPTTKPTEEPTINT 
C-Terminal end G230 ... PTTKPG Expressed protein Rat A2 C terminal do not 
G230 ... PTTKPCKTFELPRARVNT contribute to the 
major epitopes 
(Olmsted et al., 1989) 
Whole protein CDNA placed in vaccina virus vector Expressed protein Cotton Rat B(8/60) Subunit vaccine 
requires both A&B 
subgroup G protein. 
(Sullender et al., 
1990) 
-
Regions Amino acid sequences Type of antigen Source of sera Virus Main finding & 
(Amino acid no.) References 
Peptide Rabbit & human A2 Antigenic reactivity 
174-188 KNTTTQTQPSKPTTKQRQNKPPSKPNND sera sites depends on 
FHFEVFNFVPCSICSNNPTCW AICKRIPD A disulphide bond 
KKPGKK 
(Akerlind-Stopner et 
174-188 KGRITSTQTNKPSTKSRSKNPPKKPKDD B B(CHI8537) aI., 1990) 
YHFEVFNFVPCSICGNNQLCKSICTIPSN 
KPKKK 
Peptide BALBlMice A2 Importance of the 
174-187 KNTTTQTQPSKPTTKQRQNKPPSKPNND 174-187 region for 
FHFEVFNFVPCSICSNNPTCW AICKRIPD protection and the 
KKPGK 144-159 region to 
induce neut. 
Antibodies 
(Trudel et aI., 1991) 
Restriction fragment Amino acid 1-173, 174-214 and 215-end Expressed protein Monoclonal A Each region has role 
exchanges among antibodies from Long&A2 in MAbs & neut. 
regions of A & B G Mouse B (18537) Activity. 
protein. Polyclonal 
antibodies from (Sullender, 1995) 
Rabbit 
-- -
Regions Amino acid sequences Type of antigen Source of sera Virus Main finding & 
(Amino acid no.) References 
C-terminal Variable 84-85 C-terminal Expressed protein Human Circulating Human immune 
Acute & strain response relate to 
Convalescent infecting genotype. 
(Cane et aI., 1996) 
Recombinant Mice Long Identified protective 
bacteriophage epitopes in mice. 
173-187 CS ICSNNPTCW AICK 
(Bastien et aI., 1997) 
171-178 VPCSICSNNPTCW AICK Peptide Long BALB/c mice The importance of 
174-187 SICSNNPTCWAICK A 171-187 & disulfide 
region for reactivity. 
171 -178 VPCSICGNNQLCKSICK B 8/60(B) 
174-187 SICGNNQLCKSICK (Simard et al., 1997) I 
Recombinant 
protein 125-203 Expressed protein Long 
229- 243 KPTEKPTINTIRTNI Peptide 109 sera Clinical Identified linear 
isolate epitopes that 
262- 276 KETLHSTSPEGNPSP 47 sera A strain involved in potential 
N-glycolysation sites 
280- 294 YTTEYPSQPPSPSN 1 sera 
(Cane, 1997) 
247 - 258 LLTTNTTGNPEY 2 sera 
-
Regions Amino acid sequences Type of antigen Source of sera Virus Main finding & 
(Amino acid no.) References 
Identified 3 types of 
Epitopes C793 & 021/G Expressed protein Mouse & A epitopes: conserved, 
Conserved & C- & peptide Human group-specific & 
terminal region strain specific that 
021119G & 0211G mainly at C-terminal 
end. 
(Melero et al., 1997) 
Linear B cells 152-103, 165-172, 171-187 two overlapping Peptide Human. A B-cell epitopes 
epitopes epitopes 196-204 BBG2Na Long recognized by 
human. 
(Plotnicky-Gilquin et I 
al., 1999) I 
Synthetic peptide 174-187 Peptide Mouse A Complete protection 
, 
vaccine Long & against natural 
Bovine pathogen by 
mucosaley delivered 
synthetic peptide. 
(Bastien et al., 1999) 
Vaccine antigen 174-187 Peptide Mice A Protective immunity 
produce in plant Long by epitope (174-187) 
in mice. 
(Belanger et al., 
_ .. 
2(00) 
-
Regions Amino acid sequences Type of antigen Source of sera Virus Main finding & 
(Amino acid no.) References 
Intranasal 144-159,190-203 & 171-188. Peptide Mice A Partial protection by 
immunization of long intranasal 
mice immunisation using 
three peptide from G 
protein in mice. 
(Cano et aI., 2(00) & 
(Power et aI., 1997) 
5 - linear B cells 152 - 163, 165 - 172, 171 - 187 - (2 over Peptide Human Identification multi 
epitopes lapping epitopes) & 196 - 204 B-cell epitopes. 
(Power et aI., 200 1) 
BBG2Na TVKTKN'ITI I QTQPSKPTTKQRQNKPPN Vector Exp. Mice A Importance of 
130 ... 173 ... 176 ... 18 KPNNDFHFEVFNFVPCSICSNNPTCW AIC Long BBGN2 in inducing 
2 ... 186 ... 230 KRIPNKKPGKKTTTKPTKKPTFKTTKKD protection in different 
HKPQTTKPKEVPTTKPVD population target. 
(Dagouassat et aI., 
2(01) 
CX3CC region of G 182-186 (CW AIC) PurifiedG Rbt. A(Wt) G protein interaction I 
(a. a 169-191) with CX3CRl play 
role in RSV 
infection. 
(Tril'Q et al., 2(01) 
Regions Amino acid sequences Type of antigen Source of sera Virus Main finding & 
(Amino acid no.) References 
Re~ion responsible 151 - 206 Peptide Human A2 The role of G protein 
of PBMC from in wheezing. 
patient with asthma 
(Hancock et aI., 
---- ---------- - --- -- - ----
- .. _--------------
-------
20911 
- -- --
I PBMC: Peripheral blood mononuclear cells 
Appendix 8: Amino acids abbreviations 
Amino acid Symbol Abbreviations Amino acid Symbol Abbreviations 
Alanine Ala A Leucine Leu L 
Arginine Arg R Lysine Lys K 
Asparagine Asn N Methionine Met M 
Aspartic Acid Asp D Phenylalanine Phe F 
Cysteine Cys C Proline Pro P 
Glutamine GIn Q Serine Ser S 
Glutamic Acid Glu E Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 
Isoleucine lIe L Valine Val V 
Appendix 9: Result of individual sera reaction with synthesis peptides. 
Black columns sera hefore infection & white columns sera after infection. 
peptide 1 
1.i+------------------------------------------------------
c 12 1 0 
07 [ 
~ n ~ ne I 11. In D 0.2 n 
Reactive sera 
peptide 2 
1.7 , --------------
c 1.2 T---------------
o ~:: t .. I ID I ~ I I~D ~ ~ :, I~ ,Inl~. 
Reactive sera 
peptide 3 
1.7 1- -------------
§ 1.2 I 
~:: +:-~~.-n -. -'---0 n ~, I~. III.n 
Reactive sera 
) , 
peptide 4 
1.7 I 
I c 1.2 
0 ~L 0.7 0.2 I. n OIij,nln.al.l~ ij n a 
Reactive sera 
peptide 5 
,-
1.7 1------:------------
Cl 1.2 1--------------
o 
'0.7 t-:---------------
0.2 ~l.....I.I..L-_____ ____L___L_ _ I..IL__1.II...JL.n..L._1lll..Jl....____'lll1L_ 
Reactive sera 
peptide 6 
1.7 +------------------
c 1.2 -+--------~-------­
o 
0.7 +---------.:.....-------...,,-- -
0.2 ...JLU..ILll.&....II-lI.-------__ ----IJ_....I.lI..A.IIL-_--LJ.L..'---LL-.&JI...-~ 
Reactive sera 
peptide 7 
1.7 -+-------------------
c 1.2 +-------------------
o 
0.7 -+---------f------nr _____ -:--::---
0.2 Jll1JJa......L ____ ----L-L_--Ll.l.Aa..L.-IJ.I..I.WI..U.&.I.L---LLLJL.II..LU.. __ 
Reactive sera 
peptide 8 
1.7 -r------------------
c 1.2 1-----------------
o 
0.7 -r------------.,-n-----
Reactive sera 
peptide 9 
1.7 
c 1.2 
0 
0.7 
0.2 n n In In 
)',. 
Reactive sera 
peptide 10 
1.7 4------__________ _ 
c 1.2 4-------_________ _ 
o 
0.7 ~---------------:--__1t__ 
0.2 .JIlJ...--------lL.l.L-..I.U.....JL-J...IL.JI.A11..-___ ~--LIL....&-
2.2 
1.7 
§ 1.2 
0.7 
0.2 I~ Iln 
Reactive sera 
peptide 11 
I.~I~ I1 II 
Reactive sera 
I---
r 
-
n I1 II~ II~ III 
c 
o 
1.7 
1.2 
0.7 
0.2 
-
I1 I ~I~ 
peptide 12 
1 ! I~ II~ Iln ~ !I n t 
Reactive sera 
peptide 13 
1.7 -l----------------------
c 1.2+------------------------
o 
0.7 +------------------------
. I~ ~ 0.2 ....!..--....--''''--_________________ -.&.I.L-----L.L. __ 
; ~_, 11 . 
Reactive sera 
peptide 14 
2.2 ..,.---------------------
1.7 
§ 1.2 
0.7 
0.2 
-
- I- ~ f- - r-- -
~ 
Reactive sera 
peptide 15 
1.7.+-1 ----~------
Q 1.2 
o 
O.7+-----------------------------------or----------
Reactive sera 
I 
peptide 16 
1.7 
c 1.2 
o 
0.7 
0.2 
-~ 
.I~ I1 I~ I~ 
I-- ,... 
m I~I I1 11" I1 II~ II~ i~ 
Reactive sera 
peptide 17 
1.7 -j-----------:--------
Cl 1.2 -j---------t-----".----I-
o 
O. 7 liIT11l-::";----w--rtn--t;rIiI.U .. ---1IH--::-~JlIf-~~I~-kH 
o . 2 ..J&JLA.I1.&JL&.II.~W&JLLIJ.I.LII.II...a.LI.AJJ..LII.LII.A.II..LILII......IJI.IJL1..I..II..I.U.I.J.l.I.UJllI..l11JJWI..I.I:I.IllIlJ.llllll 
:',~ 
Reactive sera 
11 
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